document incorporate reference specify portion registrant proxy statement file commission pursuant regulation connection registrant annual meeting stockholder hold incorporate reference iii report base closing price share june exclude share registrant common stock hold executive officer director stockholder ownership exceed registrant common stock outstanding june exclusion share construe indicate person possess power direct indirect direct cause direction management policy registrant person control common control registrantgilead sciences inc annual report table content item business item risk factor item b unresolved staff comment item property item legal proceeding item safety disclosure ii item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure item b information iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service iv item exhibit financial statement schedule signature right trademark copyright trade name business include follow gilead gilead sciences stribild complera eviplera truvada viread emtriva tybost sovaldi hepsera vitekta letairis ranexa cayston ambisome vistide volibris rapiscan atripla register trademark belong bristolmyer squibb gilead sciences llc lexiscan register trademark belong astella llc macugen register trademark belong eyetech inc sustiva register trademark bristolmyers squibb pharma company tamiflu register trademark belong hoffmannla roche inc report include trademark service mark trade name companiesthis annual report include section entitle management discussion analysis financial condition result operation contain forwardlooke statement future event future result subject safe harbor create security act amend securities act securities exchange act amended exchange act word expect anticipate target goal project hope intend plan believe seek estimate continue variation word similar expression intend identify forwardlooke statement addition statement statement historical fact forward look statement include statement overall trend operate cost revenue trend liquidity capital need statement expectation belief future plan strategy anticipate event trend similar expression base forwardlooke statement current expectation future event statement guarantee future performance involve risk uncertainty assumption difficult predict actual result differ materially suggest forwardlooke statement reason include identify risk factor beginning give risk uncertainty caution place undue reliance forward look statement forwardlooke statement include report date hereof require federal security law rule regulation securities exchange commission sec undertake specifically decline obligation update statement publicly announce result revision forwardlooke statement distribution report result new information future event change assumption item business overview gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery experimental drug candidate strive transform simplify care people lifethreatene illness world gilead primary area focus include human immunodeficiency virus hiv liver disease chronic hepatitis b virus hbv infection chronic hepatitis c virus hcv infection oncologyinflammation cardiovascular respiratory condition headquarter foster city california operations north south america europe asiapacific continue add exist portfolio product internal discovery clinical development program product acquisition inlicense strategy highlight past year execute strategy bring bestinclass drug market liver disease area receive approval food drug administration fda new drug application nda sovaldi sofosbuvir mg sovaldi oncedaily oral nucleotide analog polymerase inhibitor treatment hcv infection component combination antiviral treatment regimen approval sovaldi represent significant improvement treatment paradigm patient hcv shorten duration treatment reduce completely eliminate need pegylate interferon pegifn injection certain viral genotype population hiv area expand single tablet regimen product offering treatment hiv european launch stribild elvitegravir mgcobicistat mgemtricitabine mgtenofovir disoproxil fumarate mg combine medicine oncedaily single tablet regimen receive approval tybost cobicistat vitekta elvitegravir mg mg component stribild european commission oncologyinflammation area file fda european medicine agency ema marketing approval idelalisib gs investigational target oral inhibitor pik delta treatment patient refractory indolent nonhodgkin lymphoma inhl relapse chronic lymphocytic leukemia cll continue advanced research development pipeline active clinical study end phase clinical trial hiv program substantial portion revenue derive market hiv product continue forefront advance hiv treatment development new single tablet regimen longterm goal ensure hiv patient option choose single tablet regiman right single tablet regimen allow patient adhere fully suppressive course therapy easily consistently critical successful management disease continue focus development new hiv medicine coformulation launch stribild united states europe compleraeviplera emtricitabine mgrilpivirine mgtenofovir disoproxil fumarate mg atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg single tablet regimen available december receive fda ema approval compleraeviplera certain adult patient switch stable antiretroviral regimen compleraeviplera approve united states europe patient new antiretroviral therapy september receive ema approval tybost pharmacokinetic enhancer boost blood level certain hiv medicine tybost indicate boost agent hiv protease inhibitor atazanavir mg daily darunavir mg daily antiretroviral combination therapy adult hiv infection approval allow marketing tybost country european union november ema approve vitekta integrase inhibitor treatment hiv infection adult know mutation associate resistance elvitegravir active ingredient vitekta vitekta indicate use hiv treatment regimen include ritonavirbooste protease inhibitor important progress clinical development tenofovir alafenamide taf know gs phase study show taf efficacious fraction dose viread tenofovir disoproxil fumarate mg provide potential safety advantage base result commence phase trial evaluate single tablet regimen taf elvitegravir cobicistat emtricitabine treatment hiv infection treatmentnave adult agreement janssen rd ireland janssen tibotec pharmaceutical conduct phase trial evaluate single tablet regimen taf cobicistat darunavir emtricitabine treatment hiv infection quarter complete enrollment phase clinical trial compare tafbase regimen stribild patient new hiv treatment datum study available quarter liver disease hcv therapeutic market continue vastly underserve limitation available therapy small fraction individual infect hcv diagnose small fraction patient treat prior protease inhibitor approve half patient respond current standard care involve week therapy pegifnribavirin rbv contain regimen addition protease inhibitor standard care result incremental response rate patient genotype infection regimen cause substantial effect fatigue bone marrow suppression potentially debilitate rash anemia neuropsychiatric effect discontinuation rate triple therapy combination significant acquisition pharmasset inc pharmasset acquire sofosbuvir nucleotide analog act inhibit replication hcv december receive fda approval sofosbuvir brand sovaldi treatment hcv component combination antiviral treatment regiman january receive european commission approval sovaldi treatment hcv sovaldis efficacy establish patient hcv genotype infection united states europe genotype infection europe include hepatocellular carcinoma meeting milan criterion await liver transplantation hcvhiv coinfection recommend regimen treatment duration sovaldi combination therapy hcv monoinfected hcvhiv coinfecte patient follow treatment duration genotype sovaldi pegifn rbv week genotype sovaldi rbv week genotype sovaldi rbv week hepatocellular carcinoma await liver transplantation sovaldi rbv week liver transplant note table compare current standard care week sovaldi shorten duration treatment little week reduce completely eliminate need pegifn injection certain viral genotype population second generation therapy treatment hcv advance fixeddose combination ledipasvirsofosbuvir ldvsof treatment genotype patient nda fixeddose combination ldvsof support clinical trial file february study name ion evaluate fixeddose combination ldvsof rbv week treatmentnave genotype hcvinfected patient second phase study name ion evaluate fixeddose combination rbv week rbv week therapy treatment experienced genotype hcvinfecte patient study name ion evaluate fixeddose combination ldvsof rbv week rbv week noncirrhotic treatmentnave genotype hcvinfected patient japan fully enrol phase study evaluate sofosbuvir genotype hcvinfecte patient expect file regulatory approval sofosbuvir japan mid complete enrollment phase study evaluate fixeddose combination ldvsof genotype infect hcv patient sofosbuvir rbv genotype infected hcv patient base result phase study plan file regulatory approval fixeddose combination ldvsof japan fourth quarter long term goal develop oral pangenotypic oral therapy hcv patient genotype fixeddose combination sofosbuvir gs nucleotide nsb inhibitorpangenotypic nsa inhibitor currently phase clinical trial oncologyinflammation year work advance oncology franchise idelalisib pik delta inhibitor antibody know gs evaluate treatment inhl cll september file nda idelalisib treatment patient inhl refractory non responsive rituximab alkylatingagentcontaine chemotherapy fda set target review date prescription drug user fee act pdufa september december file nda idelalisib relapse cll february fda previously grant breakthrough therapy designation idelalisib cll accept nda set target review date august pdufa november marketing authorization application idelalisib inhl cll validate ema acquisition ym biosciences inc acquire momelotinib gs know cyt jak inhibitor evaluate treatment myelofibrosis advanced momelotinib phase trial product hiv stribild oral formulation dose day treatment hiv infection treatmentnaive adult stribild complete single regimen treatment hiv fixeddose combination antiretroviral medication vitekta tybost viread emtriva emtricitabine stribild approve fda august ema compleraeviplera oral formulation dose day treatment hiv infection adult product market united states complera europe eviplera second complete single tablet regimen treatment hiv fixeddose combination antiretroviral medication viread emtriva janssen nonnucleoside reverse transcriptase inhibitor edurant rilpivirine atripla oral formulation dose day treatment hiv infection adult atripla oncedaily single tablet regimen hiv intend standalone therapy combination antiretroviral fixeddose combination antiretroviral medication viread emtriva bristol myerssquibb company bms nonnucleoside reverse transcriptase inhibitor sustiva efavirenz truvada emtricitabine tenofovir disoproxil fumarate oral formulation dose day combination therapy treat hiv infection adult fixeddose combination antiretroviral medication viread emtriva fda approve truvada combination safe sex practice reduce risk sexually acquire hiv infection adult high risk strategy call preexposure prophylaxis prep viread oral formulation nucleotide analog reverse transcriptase inhibitor dose day combination therapy treat hiv infection patient year age old european commission approve use viread combination antiretroviral agent treatment hiv infect pediatric patient age year nucleoside reverse transcriptase inhibitor resistance toxicity precluding use line pediatric agent viread approve treatment chronic hbv adult emtriva oral formulation nucleoside analog reverse transcriptase inhibitor dose day combination therapy treat hiv infection adult united states europe emtriva available oral solution approve combination therapy treat hiv infection child tybost pharmacokinetic enhancer dose day boost blood level certain hiv medicine tybost indicate boost agent hiv protease inhibitor atazanavir darunavir antiretroviral combination therapy adult hiv infection receive marketing approval tybost country european union vitekta oral formulation integrase inhibitor dose day combination therapy treat hiv infection adult know mutation associate resistance elvitegravir active ingredient vitekta vitekta indicate use hiv treatment regimen include ritonavirbooste protease inhibitor receive marketing approval vitekta countries european union liver disease sovaldi oral formulation nucleotide analog polymerase inhibitor dose day treatment hcv component combination antiviral treatment regiman sovaldi approve fda december european commission january sovaldis efficacy establish patient hcv genotype infection united states europe genotype infection europe include hepatocellular carcinoma meeting milan criterion await liver transplantation hcvhiv coinfection viread oral formulation nucleotide analog reverse transcriptase inhibitor dose day treatment chronic hbv adult compensate decompensate liver disease license glaxosmithkline inc gsk right commercialize viread treatment chronic hbv china japan saudi arabia ema approve use viread treatment chronic hbv infection adolescent patient age year compensate liver disease evidence immune active disease viread approve treatment hiv infection patient year age old combination antiretroviral agent hepsera adefovir dipivoxil oral formulation nucleotide analog polymerase inhibitor dose day treat chronic hbv patient year age old license gsk right commercialize hepsera treatment chronic hbv asia pacific latin america certain territory cardiovascular letairis ambrisentan oral formulation endothelin receptor antagonist era indicate treatment pulmonary arterial hypertension pah group patients class ii iii symptom improve exercise capacity delay clinical worsen sublicense gsk right ambrisentan market gsk volibris ambrisentan pah territory outside united states ranexa ranolazine extendedrelease tablet treatment chronic angina licensed menarini international operation luxembourg sa rights ranexa territory outside united states lexiscanrapiscan regadenoson injection indicate use pharmacologic stress agent radionuclide myocardial perfusion image mpi test detect characterize coronary artery disease patient unable undergo adequate exercise stress astella llc astella exclusive right manufacture sell regadenoson lexiscan united states subject obligation pay royalty base sale lexiscan rapidscan pharma solutions inc rps hold exclusive right manufacture sell regadenoson rapiscan europe certain territory outside united states receive royalty astella rps sale territory respiratory cayston aztreonam inhalation solution inhale antibiotic treatment respiratory system cystic fibrosis cf patient seven year age old pseudomona aeruginosa p aeruginosa tamiflu oseltamivir phosphate oral antiviral available capsule form treatment prevention influenza b tamiflu approve treatment influenza child adult country include united states japan european union tamiflu approve prevention influenza child adults united states japan european union develop tamiflu f hoffmannla roche ltd hoffmannla roche inc roche roche exclusive right manufacture sell tamiflu worldwide subject obligation pay royalty base percentage net sale tamiflu ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treat invasive fungal infection cause fungal specie adult corporate partner astella pharma inc promote sell ambisome united states canada promote sell ambisome europe australia new zealand vistide cidofovir injection antiviral injection treatment cytomegalovirus retinitis adult patient aid macugen pegaptanib sodium injection intravitreal injection antiangiogenic oligonucleotide treatment neovascular agerelate macular degeneration macugen develop eyetech inc eyetech technology license promote united states valeant pharmaceuticals inc valeant acquire eyetech valeant hold exclusive right manufacture sell macugen united states pfizer inc pfizer hold exclusive right manufacture sell macugen rest world receive royalty valeant pfizer base worldwide sale macugen sale antiviral product include product hiv liver disease area describe billion billion billion represent total revenue total revenue sale product billion billion million represent total revenue item management discussion analysis include annual report information revenue commercialization distribution international commercial sale operation marketing subsidiary australia austria belgium brazil canada czech republic denmark finland france germany greece hong kong ireland italy japan netherlands new zealand norway poland portugal russia south korea spain sweden singapore switzerland turkey united kingdom united states product market commercial team andor conjunction thirdparty distributor corporate partner commercial team promote product direct field contact physician hospital clinic healthcare provider generally grant thirdparty distributor exclusive right promote product territory specify period time agreement distributor provide collaborative effort distributor gilead obtain maintain regulatory approval product specify territory sell distribute stribild complera atripla truvada viread hepsera emtriva ranexa sovaldi vistide united states exclusively wholesale channel product sale large wholesaler cardinal health inc mckesson corp amerisourcebergen corp account total revenue year end december combine basis wholesaler account approximately product sale united states approximately total worldwide revenue letairis cayston distribute exclusively specialty pharmacy specialty pharmacy dispense medication complex chronic condition require high level patient education ongoing counseling sell distribute stribild eviplera atripla truvada sovaldi viread hepsera emtriva vitekta tybost ambisome europe country outside united states product approve commercial team thirdparty distributor corporate partner patient access priority increase access medicine people benefit regardless ability pay united states patient assistance program help therapy accessible uninsured individual need financial assistance support program unable afford copayment associate health insurance program half patient take hiv medicine united states receive federal state program substantially discount price long history work state aids drug assistance program adap provide low pricing hiv medicine price freeze institute adap extend end provide important support critical program evolve change united states healthcare environment access develop world gilead access program establish certain product treatment hiv chronic hbv visceral leishmaniasis available substantially reduce price develop world gilead deliver medicine country work regional business partner distribute brandname viread truvada price base country ability pay represent little profit gilead partnership india base company expand access generic version hiv medication leastdevelope country world work closely world health organization nongovernmental organization provide ambisome treatment leishmaniasis preferential price resource limited setting support numerous clinical study investigate role ambisome treat visceral cutaneous leishmaniasis develop country collaboration organization drug neglect disease initiative mdecin san frontire support clinical research study aim identify good treatment course visceral leishmaniasis donate ambisome support clinical study assess combination therapy costeffectiveness multiple visceral leishmaniasis treatment intervention december sign partnership agreement world health organization donate vial ambisome year donation treat patient resourcelimite country support clinical study donation product help define good treatment strategy develop world country example donate tenofovir centre aids programme research south africa caprisa microbicide trial assess effectiveness safety tenofovirbase microbicide gel prevention hiv infection south african woman provide drug number innovative international study investigate viread truvada prevent hiv transmission atrisk uninfected adult hiv prevention strategy call prep fda approval prep truvada agent indicate uninfected individual reduce risk acquire hiv sex enter number collaboration relate access product develop world include pharmachem technologies grand bahama ltd pharmachem pharmachem commercial manufacturing partner establish facility bahama manufacture tenofovir disoproxil fumarate active pharmaceutical ingredient viread active pharmaceutical ingredient atripla truvada resource limited country cooperative effort pharmachem grand bahama port authority aspen pharmacare holdings ltd aspen enter nonexclusive manufacturing distribution agreement aspen provide manufacture distribution viread truvada treatment hiv infection certain develop world country include gilead access program amend agreement aspen amend agreement aspen retain right manufacture distribute viread truvada treatment hiv infection develop world country aspen right purchase viread truvada unlabeled bottle distribution country right manufacture viread truvada active pharmaceutical ingredient purchase aspen supplier approve aspen grant right manufacture distribute generic version emtricitabine tenofovir disoproxil fumarate include version tenofovir disoproxil fumarate combination emtricitabine treatment hiv infection aspen require pay royalty net sale viread truvada royaltie net sale generic version tenofovir disoproxil fumarate include version tenofovir disoproxil fumarate combination generic version emtricitabine manufacture distribute aspen license generic manufacturer enter nonexclusive license agreement indian generic manufacturer grant right produce distribute generic version tenofovir disoproxil fumarate treatment hiv infection low income country world include india low income country gilead access program agreement require generic manufacturer meet certain national international regulatory quality standard include technology transfer enable expeditious production large volume high quality generic version tenofovir disoproxil fumarate addition agreement allow manufacture commercial quantity active pharmaceutical ingredient finish product expand nonexclusive license agreement increase number country include license include right cobicistat elvitegravir include generic version combination product contain active ingredient cobicistat elvitegravir tenofovir disoproxil fumarate emtricitabine include nonexclusive license agreement ability manufacture distribute generic version tenofovir disoproxil fumarate treatment hbv country authorize sell generic version tenofovir disoproxil fumarate hiv august announce new collaboration indian partner produce distribute generic emtricitabine develop world include single tablet regimen contain emtricitabine fixeddose combination emtricitabine coformulate gilead hiv medicines merck co inc merck enter agreement affiliate merck pursuant gilead merck provide atripla substantially reduce price hiv infect patient develop country africa caribbean latin america southeast asia agreement manufacture atripla efavirenz supply merck merck handle distribution product country cover agreement enter agreement merck commercialize atripla lowmiddle income country include brazil egypt mexico international partnership microbicide ipm conrad enter agreement grant right ipm conrad cooperate agency agency international development commit improve reproductive health expand contraceptive choice woman man develop manufacture prove efficacious arrange distribution resource limited country certain formulation tenofovir use topical microbicide prevent hiv infection medicine patent pool pool enter agreement pool organization establish united nations increase global access highquality lowcost antiretroviral therapy sharing patent grant pool nonexclusive license identify generic pharmaceutical manufacturer india specialize highquality production generic medicine grant sublicense indian manufacturer manufacture distribute generic version antiretroviral develop world sublicensee pool free develop combination product pediatric formulation hiv medicine grant pool right grant sublicense generic version single tablet regimen consist elvitegravir cobicistat tenofovir disoproxil fumarate emtricitabine product candidate elvitegravir cobicistat generic pharmaceutical manufacturer india distribution develop world janssen expand agreement janssen provide distribution compleraeviplera treatment hiv develop country enable commercialization generic version product competition market product target number area include viral cardiovascular respiratory fungal disease commercially available product treatment disease company institution make substantial investment develop additional product treat disease product compete available product base primarily efficacy safety tolerability acceptance doctor ease patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing hiv product hiv landscape competitive complex treatment trend continue evolve grow number hiv drug currently sell advanced stage clinical development competition current expect competitor erode revenue receive sale hiv product brand hiv drug available united states product primarily compete fixeddose combination product nucleotidenucleoside reverse transcriptase inhibitor nrti class include combivir lamivudinezidovudine epzicomkivexa abacavirlamivudine trizivir abacavirlamivudinezidovudine sell joint venture viiv healthcare viiv establish gsk pfizer focus hiv therapy product compete stribild compleraeviplera atripla truvada tybost compete ritonavir market abbvie inc abbvie hiv product compete broadly hiv product abbvie boehringer ingelheim gmbh merck roche janssen addition tivicay dolutegravir integrase inhibitor launch fourth quarter viiv adversely impact sale hiv product face competition generic hiv product bms videx ec didanosine ddi generic hiv product united states gsk retrovir zidovudine face competition united states result launch generic zidovudine bms zerit stavudine face competition united states result launch generic stavudine epivir lamivudine market viiv competitive emtricitabine active pharmaceutical ingredient emtriva component atripla truvada compleraeviplera stribild compound patent cover epivir lamivudine expire united states generic lamivudine available united states spain portugal italy expect generic version lamivudine launch country european union generic version combivir lamivudine zidovudine approve recently launch united states addition late generic tenofovir available turkey result increase rebate viread turkey generic efavirenz active pharmaceutical ingredient sustiva component atripla available canada europe expect competition generic efavirenz united states pricing pressure hiv product liver disease product hcv product sovaldi compete janssen olysio simeprevir united states less extent directacting antiviral victreli boceprevir market merck incivek telaprevir market vertex pharmaceutical incorporate hbv product viread hepsera face significant competition exist expect therapy treat patient hbv erode revenue receive sale hbv product hbv product face competition baraclude entecavir oral nucleoside analog develop bms launch united states europe tyzekasebivo telbivudine oral nucleoside analog develop novartis pharmaceutical corporation novartis sale united states european union china hbv product compete epivirhbvzeffix lamivudine develop gsk collaboration shire plc sell major country north south america europe asia viread hepsera treatment hbv compete establish immunomodulatory therapy include introna interferon alfab sell merck major country north south america europe asia pegasys pegylate interferon alfaa injectable drug similar introna sell roche treatment hbv cardiovascular product letairis compete directly tracleer bosentan opsumit macitentan drug sell actelion pharmaceutical inc letairis compete adcirca tadalafil united therapeutics corporation ranexa compete predominantly generic compound distinct class drug treatment chronic angina united states include generic andor brand betablocker calcium channel blocker longacte nitrate addition surgical treatment intervention coronary artery bypass graft percutaneous coronary intervention option angina patient perceive healthcare practitioner prefer method treat cardiovascular disease underlie cause angina numerous market generic andor brand pharmacologic stress agent compete lexiscanrapiscan respiratory product cayston compete primarily tobi tobramycin inhalation solution inhale medication sell novartis treatment cf patient lung contain p aeruginosa bacterial infection tamiflu compete relenza zanamivir antiinfluenza drug sell gsk relenza neuraminidase inhibitor deliver orallyinhale dry powder generic competitor include amantadine rimantadine oral tablet inhibit replication influenza virus biocryst pharmaceuticals inc develop injectable formulation peramivir influenza neuraminidase inhibitor treatment influenza currently approve japan south korea product ambisome face strong competition current expect competitor ambisome face competition vfend voriconazole develop pfizer caspofungin product develop merck market cancidas united states caspofungin ambisome compete lipidbase amphotericin b product include abelcet amphotericin b lipid complex injection sell enzon pharmaceuticals inc united states canada japan zeneus pharma ltd europe amphotec amphotericin b cholesteryl sulfate complex injection sell river pharmaceutical llc worldwide anfogen amphotericin b liposomal sell genpharma sa argentina bms numerous generic manufacturer sell conventional amphotericin b compete ambisome aware lipid formulation claim similarity ambisome available outside united state include possible entry formulation taiwan formulation reduce market demand ambisome manufacture lipid formulation amphotericin b complex formulation find unsafe sale ambisome negatively impact association vistide compete number drug treat cytomegalovirus retinitis include cytovene iv cytovene ganciclovir sell intravenous oral formulation respectively roche ocular implant bausch lomb incorporate valcyte valganciclovir market roche foscavir foscarnet intravenous drug sell astrazeneca plc generic fomivirsen macugen compete primarily visudyne verteporfin injection sell novartis connection photodynamic therapy lucentis ranibizumab sell genentech inc united states novartis territory outside united states number company pursue development technology competitive research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently pharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program collaborative relationship business strategy establish collaboration company university medical research institution assist clinical development andor commercialization certain product product candidate provide support research program evaluate opportunity acquire product right product technology complementary business company university medical research institution information certain relationship include ongoing financial accounting impact business item note collaborative arrangement consolidate financial statement include annual report commercial collaboration currently number collaboration corporate partner manufacture sale distribution andor marketing product territory worldwide follow commercial collaboration significant financial statement perspective significant ongoing collaboration activity exist bms enter collaboration arrangement bms develop commercialize single tablet regimen truvada bms sustiva efavirenz united states combination approve use united states sell brand atripla bms structure collaboration joint venture operate limited liability company name bristolmyers squibb gilead sciences llc consolidate bms grant royaltyfree sublicense joint venture use respective company own technology return grant license joint venture use intellectual property result collaboration bms amend joint venture collaboration agreement allow joint venture sell atripla canadathe economic interest joint venture hold bms include share revenue outofpocket expense base portion net selling price atripla attributable efavirenz truvada net selling price truvada change time relative net selling price efavirenz bms respective economic interest joint venture vary annually start limited number activity jointly manage party long coordinate detail promotional activity united states party reduce joint promotional effort launch complera august stribild august agreement continue terminate mutual agreement party addition party terminate party participation collaboration day launch generic version party single agent product double agent product terminate party right continue sell atripla continue party obligate pay terminate party certain royalty threeyear period follow effective date termination gilead sciences limit whollyowne subsidiary ireland bms enter collaboration agreement bms commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory party form limited liability company consolidate manufacture atripla distribution european territory efavirenz purchase bms bms estimate net selling price efavirenz european territory start limited number activity jointly manage party long coordinate detail promotional activity region december efavirenz purchase bms bms estimate net selling price efavirenz european territory include inventory consolidate balance sheet agreement terminate expiration lasttoexpire patent afford market exclusivity atripla component european territory addition party terminate agreement reason termination effective calendar quarter notice termination nonterminate party right continue sell atripla continue party obligate pay terminate party certain royalty threeyear period follow effective date termination event continue party decide sell atripla effective date termination date atripla withdraw country date party assume distribution atripla whichever early janssen enter collaboration agreement janssen develop commercialize fixeddose combination truvada janssen rilpivirine combination approve united states european union sell brand complera united states eviplera european union agreement janssen grant exclusive license compleraeviplera worldwide exclude certain middle income develop world country japan party restrict combine drug drug product record million approximately million reimbursable research development rd expense incur janssen development rilpivirine december maximum reimbursable term agreement responsible manufacturing compleraeviplera lead role registration distribution commercialization product license country janssen exercise right codetail combination product country gilead sell party amend collaboration agreement include distribution compleraeviplera rest world right distribute product north america europe latin america mexico australia new zealand janssen right distribute product region include japan russia price product expect sum price truvada price rilpivirine purchase separately cost rilpivirine purchase janssen compleraeviplera approximately market price rilpivirine specified percentage major market party terminate collaboration agreement compleraeviplera withdraw market party materially breach agreement terminate agreement united states canada expiration expire patent tenofovir disoproxil fumarate united states terminate agreement country expiration expire patent tenofovir disoproxil fumarate country european union janssen terminate agreement united states canada expiration expire patent rilpivirine united states terminate agreement country expiration expire patent rilpivirine country european union japan tobacco enter licensing agreement japan tobacco japan tobacco grant exclusive right develop commercialize elvitegravir novel hiv integrase inhibitor country world exclude japan japan tobacco retain right agreement responsible seek regulatory approval territory require use diligent effort commercialize elvitegravir treatment hiv infection bear cost expense associate commercialization effort term agreement pay upfront license fee million obligate total potential milestone payment million achievement certain clinical regulatory commercial objective additionally obligate pay royalty base net sale territory market product december total milestone payment million agreement obligation pay royalty japan tobacco terminate productbyproduct basis patent provide exclusivity product expire later tenth anniversary commercial launch product terminate agreement reason case license grant japan tobacco terminate party terminate agreement response material breach party research collaboration number collaboration partner rd certain compound drug candidate research collaboration rise level significant financial statement perspective significant ongoing collaboration activity exist research development rd philosophy strategy develop bestinclass drug improve safety efficacy unmet medical need intend continue commit significant resource rd opportunity business development activity product development effort cover wide range medical condition include hivaid liver disease hbv hcv inflammationoncology cardiovascular respiratory condition research scientist foster city fremont san dimas oceanside california branford connecticut seattle washington alberta canada engage discovery development new molecule technology hope lead approval new medicine address unmet need development product candidate subject risk uncertaintie risk uncertainty include ability enroll patient clinical trial possibility unfavorable result clinical trial need modify delay clinical trial perform additional trial risk fail obtain regulatory approval result product candidate successfully commercialize drug development inherently risky product candidate fail drug development process summary key product candidate correspond current stage development additional information development pipeline visit website wwwgileadcom product candidate treatment hiv product candidate description marketing application pende cobicistat cobicistat pharmacokinetic enhancer dose day boost blood level certain hiv medicine approve component stribild september european commission approve cobicistat market tybost stand boost agent hiv protease inhibitor atazanavir darunavir antiretroviral combination therapy adult hiv infection elvitegravir elvitegravir oral integrase inhibitor dose day combination therapy treat hiv infection adult approve component stribild november european commission approve elvitegravir market vitekta treatment hiv infection adult know mutation associate resistance elvitegravir vitekta indicate use hiv treatment regimen include ritonavirbooste protease inhibitor product phase single tablet regimen taf elvitegravir single tablet regimen taf nrti elvitegravir cobicistat emtricitabine evaluate cobicistat emtricitabine treatment hiv infection treatmentnave adult product phase single tablet regimen taf darunavir agreement janssen single tablet regimen taf darunavir cobicistat emtricitabine cobicistat emtricitabine evaluate treatment hiv infection product candidate treatment liver disease product candidate description marketing application pende fixeddose combination fixeddose combination ledipasvir oral nsa inhibitor sofosbuvir take rbv ldvsof evaluation phase trial treatment hcv product phase taf taf nrti evaluation treatment hbv product phase fixeddose combination sofosbuvir gs fixeddose combination sofosbuvir gs nucleotide nsb inhibitorpangenotypic nsa inhibitor evaluate treatment hcv gs gs tarmogen cell immunity stimulator evaluation treatment hbv gs gs oral ns protease inhibitor evaluate treatment hcv gs gs nonnucleoside nsb site polymerase inhibitor evaluation treatment hcv simtuzumab gs simtuzumab monoclonal antibody evaluate treatment liver fibrosis nonalcoholic steatohepatitis primary sclerose cholangitis product phase gs gs mmp mab inhibitor evaluate treatment ulcerative colitis gs gs oral tlr agonist evaluate treatment hbv hcv product candidate treatment oncologyinflammation product candidate description marketing application pende idelalisib idelalisib pik delta inhibitor antibody treatment inhl cll september submit nda fda approval idelalisib treatment inhl fda set target review date pdufa september december submit nda fda approval idelalisib treatment cll pdufa date file august marketing authorization application idelalisib inhl cll validate ema november product phase momelotinib gscyt momelotinib gs know cyt jak inhibitor evaluate treatment myelofibrosis product phase gs gs pik delta inhibitor evaluate potential treatment lymphoid malignancy gs gs spleen tyrosine kinase syk inhibitor evaluate hematological malignancy simtuzumab simtuzumab monoclonal antibody evaluate treatment myelofibrosis colorectal pancreatic cancer product phase gs gs mmp mab inhibitor evaluate treatment solid tumor product candidate treatment cardiovascular disease product candidate description product phase ranolazine ranolazine late sodium current inhibitor approve treatment chronic angina evaluate treatment incomplete revascularization postpercutaneous coronary intervention treatment type ii diabetes product phase ranolazine ranolazine evaluate treatment paroxysmal atrial fibrillation product phase gs gs ask inhibitor evaluate treatment diabetic nephropathy gs gs late sodium current inhibitor evaluate treatment lqt syndrome hypertrophic cardiomyopathy ventricular tachycardiaventricular fibrillation product candidate treatment respiratory disease product candidate description product phase gs gs inhalable small molecule antiviral fusion inhibitor evaluate treatment respiratory syncytial virus simtuzumab simtuzumab monoclonal antibody evaluate treatment idiopathic pulmonary fibrosis total rd expense billion compare billion billion addition internal discovery clinical development program seek add portfolio product product acquisition license collaboration follow table show recent acquisition year company therapeutic area arresto biosciences inc fibrotic disease cancer calistoga pharmaceuticals inc cancer inflammatory disease pharmasset inc chronic hcv ym biosciences inc hematological immune cell disorder inflammatory disease cancer large transaction acquisition pharmasset billion pharmasset clinicalstage pharmaceutical company locate princeton new jersey commit discover develop commercialize novel drug treat viral infection pharmasset primary focus development oral therapeutic treatment hcv infection receive fda ema approval sovaldi sofosbuvir file nda fix dose combination ldvsof treatment hcvinfecte patient february patent proprietary right european patent expiration number foreign patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent follow table show estimate expiration date include patent term extension supplementary protection certificate andor pediatric exclusivity grant united states europe primary typically compound patent phase product candidate patent cover ranolazine compound active ingredient ranexa instead discover sustained release formulation ranolazine achieve therapeutic plasma level patent obtain formulation characteristic plasma level achieve product candidate single tablet regimen estimate patent expiration date provide correspond late expiring compound patent active ingredient single tablet regimen phase product candidate patent expiration product candidate treatment hiv eu single tablet regimen taf elvitegravir cobicistat emtricitabine single tablet regimen taf emtricitabine product candidate treatment liver disease single tablet regimen ldvsof treatment hcv single agent taf treatment hbv product candidate treatment oncologyinflammation idelalisib treatment cll inhl momelotinib treatment myelofibrosis product candidate treatment cardiovascular disease ranolazine treatment incomplete revascularization postpercutaneous coronary intervention treatment type ii diabetes date parenthesis reflect estimate expiration date patent issue currently pende application estimate expiration date include potential additional exclusivity eg patent term extension supplementary protection certificate pediatric exclusivity grant follow table show actual estimate expiration date include patent term extension supplementary protection certificate andor pediatric exclusivity grant united states europe primary typically compound patent market product patent cover ranolazine compound active ingredient ranexa instead discover sustained release formulation ranolazine achieve therapeutic plasma level patent obtain formulation characteristic plasma level achieve product single tablet regimen eg truvada atripla compleraeviplera stribild estimate patent expiration date provide correspond late expiring compound patent active ingredient single tablet regimen product patent expiration eu vistide hepsera ambisome macugen tamiflu letairis viread ranexa atripla cayston emtriva truvada lexiscan compleraeviplera vitekta sovaldi stribild tybost date parenthesis reflect estimate expiration date patent issue currently pende application estimate expiration date include potential additional exclusivity eg patent term extension supplementary protection certificate pediatric exclusivity grant gilead teva pharmaceutical teva reach agreement principle settle ongoing patent litigation concern patent protect tenofovir disoproxil fumarate viread truvada atripla product agreement teva allow launch generic version viread december settlement agreement file federal trade commission department justice require law gilead lupin limited lupin reach agreement settle patent litigation prior issuance court decision agreement lupin allow launch generic version ranexa february settlement agreement file federal trade commission department justice require law product approve patent protection certain challenge patent proprietary right important business properly draft enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology rely trade secret internal knowhow technological innovation agreement party develop maintain protect competitive position ability competitive depend success strategy patent cover certain active pharmaceutical ingredient stribild compleraeviplera atripla truvada emtriva hepsera letairis vistide vitekta hold party acquire exclusive right patent agreement party patent cover ranolazine compound active ingredient ranexa instead discover sustainedrelease formulation ranolazine achieve therapeutic plasma level patent obtain formulation characteristic plasma level achieve patent cover active ingredient ambisome addition patent filing china certain asian country cover form adefovir dipivoxil active ingredient hepsera asia major market therapie hbv indication hepsera develop obtain patent certain product year marketing approval obtain product patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension supplementary protection certificate country example extension patent supplementary protection certificate product grant united states number european country compensate delay obtain marketing approval similar patent term extension available product develop certain obtain country important infringe valid patent party infringe valid patent party prevent commercialize product require obtain license party able obtain alternative technology require license reasonable term fail obtain license alternative technology unable develop commercialize product example aware body patent relate operation letairis education access program leap restrict distribution program design support letairis patent application confidential period time patent issue know competitor file patent application technology cover pende application invent file application direct technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete product addition competitor file patent application cover technology participate interferencederivation proceeding litigation determine right patent litigation interferencederivation proceeding unpredictable expensive ultimately successful result operation adversely affect event patent relate pharmaceutical biopharmaceutical biotechnology product compound process cover exist compound product process likely file future provide complete adequate protection future litigation proceeding enforcement validity exist patent future patent result invalidation patent substantially reduce protection time time certain individual entity challenge patent pende patent application patent application file collaborative partner result issuance patent result patent provide adequate protection result able prevent party develop compound product closely relate developed develop addition certain country africa asia include china provide effective enforcement patent thirdparty manufacturer able sell generic version product country litigation sofosbuvir january acquire pharmasset acquisition acquire sofosbuvir know gs nucleotide analog act inhibit replication hcv december receive fda approval sofosbuvir brandname sovaldi receive number contractual intellectual property claim sofosbuvir carefully consider claim prior follow acquisition believe merit patent claim sofosbuvir chemical entity metabolite existence patent necessarily guarantee right practice patent technology commercialize patent product party obtain right patent allegedly prevent attempt prevent commercialize sofosbuvir example aware patent patent application own party allege party cover use sofosbuvir party successfully obtain valid enforceable patent successfully prove infringement patent sofosbuvir prevent sell sofosbuvir able obtain license patent license available commercially reasonable term party successful establish exclusive right sofosbuvir expect revenue earning sale sofosbuvir adversely affect contract arbitration jeremy clark march jeremy clark employee pharmasset inventor patent patent file demand arbitration lawsuit pharmasset dr raymond schinazi mr clark initially file lawsuit pharmasset dr schinazi district court northern district alabama february seek void assignment provision employment agreement assert ownership patent patent claim metabolite sofosbuvir rg december court order stay litigation pende outcome arbitration proceeding require mr clark employment agreement instead proceed arbitration mr clark file additional lawsuit september june court subsequently dismiss september mr clark file motion seek reconsideration court december order court deny december mr clark file motion appoint special prosecutor february court issue order require mr clark enter arbitration risk dismissal case mr clark file demand arbitration march arbitration panel hold hear april june arbitration panel issue decision favor pharmasset gilead dr schinazi august gilead dr schinazi file motion district court northern district alabama seek court confirm arbitration decision mr clark file motion seek vacate arbitration decision court rule motion arbitration f hoffmanla roche ltd hoffmanla roche inc collectively roche gilead successor pharmasset party october collaboration agreement roche agreement grant roche right develop psi cytidine analog prodrug treatment hcv infection collaborative research effort agreement end december roche later ask pharmasset consider roche contributed inventorship sofosbuvir pharmasset comply confidentiality provision collaboration agreement pharmasset advise carefully consider issue raise roche believe issue merit consider issue reach conclusion march roche initiate arbitration pharmasset predecessor gilead pharmasset llc collaboration agreement arbitration demand roche assert exclusive license sofosbuvir pursuant collaboration agreement sofosbuvir prodrug uridine monophosphate analog allegedly prodrug psi cytidine analog roche claim exclusive right sofosbuvir exclusive license patent cover sofosbuvir infringe patent selling offer sale product contain sofosbuvir gilead gilead pharmasset llc file response roche arbitration demand april interference proceeding litigation idenix pharmaceuticals inc february receive notice patent trademark office uspto declare interference idenix interference patent patent idenix pharmaceuticals inc idenix pende patent application interference administrative proceeding uspto design determine invent subject matter claim party patent cover metabolite sofosbuvir rg prodrug cytidine nucleoside analog pharmasset license roche idenix attempt patent class compound include metabolite purpose idenix interference determine invent compound entitle patent claim compound march uspto patent trial appeal board board determine idenix entitle benefit early application filing date patent application include application lead idenixs patent patent patent teach compound dispute board determine entitle filing date early application file patent application compound dispute senior party idenix interference january board determine pharmasset idenix invent compound dispute accordingly gilead prevail decision board hold idenix fail prove conceive compound dispute specifically idenix fail prove idenix inventor identify structure method make use dispute compound board go conclude idenix fail work diligently make testing compound dispute relevant time period idenix appeal board decision district court district delaware board decision reverse appeal court determine idenix entitle patent claim determine infringe claim require obtain license pay royalty idenix commercialize sofosbuvir rg united states decision district court appeal party court appeal federal circuit cafcwe believe claim idenix application involve idenix interference similar foreign patent claim compound metabolite invalid result file impeachment action federal court canada invalidate idenix canadian patent canadian patent correspond patent idenix patent application subject idenix interference idenix assert canadian patent correspond patent patent idenix interference invalid file similar legal action norway oslo district court seek invalidate idenix correspond norwegian patent september idenix file invalidation action norwegian proceeding norwegian patent patent correspond patent patent trial hold november court issue decision august idenix file request invalidation chinese patent office chinese patent cn zl correspond patent patent file legal action federal court australia seek invalidate idenixs australian p atent correspond patent april idenix assert commercialization sofosbuvir infringe australian patent correspond patent bring similar action country future idenix award patent compound european patent office japan china event patent issue expect challenge proceeding similar invoke canada norway australia courts hear proceeding determine idenix entitle patent claim determine infringe claim require obtain license pay royalty idenix commercialize sofosbuvir rg country december receive gilead request uspto declare interference second idenix interference pende patent application patent patent include claim direct method treat hcv nucleoside compound similar involved idenix interference second idenix interference determine invent claim method treat hcv declaration second idenix interference uspto initially designate gilead junior party base patent application filing date appear face patent february uspto issue order cause idenix second idenix interference order require idenix explain judgment enter second idenix interference favor gilead base outcome idenix interference order indicate claim patent involve second idenix interference unpatentable gilead prevail idenix interference idenix allow claim benefit filing date early file patent application believe board determination idenix interference idenix entitle benefit early application filing date include file date patent equally applicable second idenix interference correct board conclude gilead senior party second idenix interference consistent determination idenix interference light board conclusion idenix interference application lead patent teach claim compound possible board determination second idenix interference eliminate need board address invent claim method treat hcv board consider invent claim method treat hcv ultimately conclude gilead claim patent revoke board determine idenix invent entitle patent claim determine proceeding infringe claim require obtain license pay royalty idenix commercialize sofosbuvir rg determination board appeal party federal court december idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversit montpellier ii sue district court district delaware allege commercialization sofosbuvir infringe patent interference exist patent patent patent believe claim patent invalid sole right commercialize sofosbuvir court disagree view determine patent infringe require obtain license pay royalty idenix commercialize sofosbuvir decision district court appeal party cafc december idenix udsg sue district court district massachusetts allege commercialization sofosbuvir infringe patent nos patent believe idenixs patent invalid infringe commercialization sofosbuvir sole right commercialize sofosbuvir court disagree view determine patent infringe require obtain license pay royalty idenix commercialize sofosbuvir decision district court appeal party cafc expansive patent portfolio cover nsa inhibitor treatment hcv follow recent disclosure structure idenixs nsa inhibitor samatasvir know idx evaluate compound light pende claim patent application litigation merck co inc august merck co inc merck contact request pay royalty sale sofosbuvir license patent patent patent patent coown isis pharmaceuticals inc believe merck patent invalid infringe commercialization sofosbuvir sole right commercialize sofosbuvir accordingly august file lawsuit district court northern district california seek declaratory judgment merck patent invalid infringe merck patent nos patent cover compound include relate sofosbuvir patent prosecution merck amend patent application attempt cover compound relate sofosbuvir ultimately extract royalty payment sofosbuvir commercialization exclude market court determine merck patent valid infringe claim require obtain license pay royalty merck commercialize sofosbuvir party appeal decision district court cafc litigation abbvie inc abbvie abbvie recently obtain patent nos patent purport claim use combination ldvsof treatment hcv publish pende patent application direct use combination treatment hcv specifically combination ledipasvir sofosbuvir certain application file abbvie recently issue patent reason believe abbvie patent invalid accordingly december file lawsuit district court district delaware seek declaratory judgment abbvie patent invalid unenforceable relief believe abbott laboratories inc abbvie conspire eliminate competition hcv market falsely represent pto gilead invent method treat hcv combination ldvsof february abbvie respond lawsuit filing lawsuit district court district delaware allege ldvsof product infringe patent expect abbvie patent block delay commercialization combination product court determine abbvie patent valid infringe claim require obtain license pay royalties abbvie commercialize sofosbuvir combination product party appeal decision district court cafc litigation generic manufacturer approval process product fda grant new chemical entity nce exclusivity period manufacturer application approval generic version product approve generic manufacturer challenge patent protect product grant nce exclusivity year prior end nce exclusivity period generic manufacturer seek continue seek fda approval similar identical drug abbreviate new drug application anda application form typically manufacturer seek approval generic drug tenofovir disoproxil fumarate emtricitabine fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz november receive notice teva pharmaceutical teva submit anda fda request permission manufacture market generic version truvada notice teva allege patent associate emtricitabine own emory university license exclusively invalid unenforceable andor infringe teva manufacture use sale generic fixeddose combination emtricitabine tenofovir disoproxil fumarate december file lawsuit district court southern district new york teva infringement emtricitabine patent march receive notice teva submit anda fda request permission manufacture market generic fix dose combination emtricitabine tenofovir disoproxil fumarate efavirenz notice teva challenge emtricitabine patent file lawsuit district court southern district new york teva infringement emtricitabine patent lawsuit consolidated lawsuit file december january receive notice teva submit anda fda request permission manufacture market generic version viread notice teva challenge tenofovir disoproxil fumarate patent protect viread january receive notice teva amend anda relate generic version atripla truvada product notice relate teva anda generic version atripla teva challenge patent relate tenofovir disoproxil fumarate additional patent relate emtricitabine patent relate efavirenz notice relate teva anda generic version truvada teva challenge patent relate tenofovir disoproxil fumarate additional patent relate emtricitabine march file lawsuit teva infringement viread patent additional emtricitabine patent march bristolmyers squibb company merck file lawsuit teva infringement patent relate efavirenz file lawsuit requisite day period provide hatch waxman act stay prevent fda approval teva andas month district court decision adverse patent month stay teva anda expire july april teva reach agreement settle ongoing patent litigation concern patent protect tenofovir disoproxil fumarate atripla truvada viread agreement teva allow launch generic version viread december settlement agreement file federal trade commission department justice require law october court dismissal case pursuant settlement agreement party final trial lawsuit teva relate patent protect emtricitabine atripla truvada hold october february teva reach agreement principle settle ongoing patent litigation concern emtricitabine patent protect atripla truvada term settlement agreement confidential settlement agreement file federal trade commission department justice require law november receive notice teva submit abbreviate new drug submission and canadian minister health request permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate notice teva allege patent associate truvada invalid unenforceable andor infringe teva manufacture use sale generic version truvada january file lawsuit teva federal court canada seek order prohibition approval and december receive notice teva submit and canadian minister health request permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz notice teva allege patent associate atripla merck patent associate atripla invalid unenforceable andor infringe teva manufacture use sale generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz february file lawsuit teva federal court canada seek order prohibition approval and august receive notice teva submit and canadian minister health request permission manufacture market generic version viread notice teva allege patent associate tenofovir disoproxil fumarate invalid unenforceable andor infringe teva manufacture use sale generic version viread truvada atripla september file lawsuit teva federal court canada seek order prohibition approval and august teva file impeachment action federal court canada seek invalidation canadian patent associate viread currently defend impeachment action request order prohibition connection tevas and filing tevas generic version viread truvada atripla consolidated hearing consolidated request order prohibition take place september december court issue request order prohibit canadian minister health issuing notice compliance tevas generic version viread truvada atripla product expiry patent july teva appeal decision decision ultimately resolve validity challenge raise teva impeachment action teva successful invalidating patent teva able launch generic version viread truvada atripla product prior expiry patent trial impeachment action schedule january july receive notice lupin limited lupin submit anda fda request permission manufacture market generic version truvada notice lupin allege patent associate emtricitabine patent associate tenofovir disoproxil fumarate invalid unenforceable andor infringe lupin manufacture use sale generic version fixeddose combination emtricitabine tenofovir disoproxil fumarate august file lawsuit lupin district court southern district new york infringement patent anticipate trial case fourth quarter party appeal decision district court cafc lupin successful invalidate patent lupin able launch generic version truvada product prior expiry patent july receive notice cipla ltd cipla submit anda fda request permission manufacture market generic version emtriva generic version viread notice cipla allege patent associate emtricitabine invalid unenforceable andor infringe cipla manufacture use sale generic version emtricitabine patent associate tenofovir disoproxil fumarate invalid unenforceable andor infringe cipla manufacture use sale generic version tenofovir disoproxil fumarate august file lawsuit cipla district court southern district new york infringement patent anticipate trial case fourth quarter party appeal decision district court cafc cipla successful invalidate patent cipla able launch generic version viread andor emtriva product prior expiry patent october receive notice lupin submit anda fda request permission manufacture market generic version viread notice lupin allege patent associate tenofovir disoproxil fumarate invalid unenforceable andor infringe lupin manufacture use sale generic version tenofovir disoproxil fumarate october file lawsuit lupin district court southern district new york infringement patent anticipate trial case fourth quarter party appeal decision district court cafc lupin successful invalidate patent lupin able launch generic version viread product prior expiry patent ranolazine june receive notice lupin submit anda fda request permission manufacture market generic version sustain release ranolazine notice lupin allege patent associate ranexa invalid unenforceable andor infringe lupin manufacture use sale generic version ranexa july file lawsuit lupin district court district new jersey infringement patent ranexa trial take place april august party reach agreement settle patent litigation prior issuance court decision agreement lupin allow launch generic version ranexa february settlement agreement file federal trade commission department justice require law tamiflu february receive notice natco pharma ltd natco submit anda fda request permission manufacture market generic version tamiflu notice natco allege patent associate oseltamivir phosphate invalid unenforceable andor infringe natco manufacture use sale generic version tamiflu march roche file lawsuit natco district court district new jersey infringement patent associate tamiflu december court issue rule favor gilead roche patent invalid reason state natco notice letter natco appeal decision cafc hear natcos appeal take place january court issue decision appeal natco successful appeal case remand district court district new jersey trial merit predict ultimate outcome action spend significant resource enforce defend patent unsuccessful lawsuit claim patent narrow invalidated patent protection atripla truvada viread emtriva tamiflu united states atripla truvada viread canada substantially shorten patent cover product invalidate fda canadian minister health approve request manufacture generic version products united states canada respectively prior expiration date patent sale generic version product early patent expiration significant negative effect revenue result operation trade secret rely unpatented trade secret improvement unpatente internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor agreement provide confidential information develop known individual course relationship keep confidential disclose party specify circumstance case employee agreement provide invention individual employ exclusive property certain party comply confidentiality agreement adequate remedy breach trade secret know independently discover competitor rd agreement invention jointly own corporate partner case exclusive property party certain circumstance difficult determine own particular invention dispute arise invention manufacture raw material manufacturing strategy contract party manufacture majority active pharmaceutical ingredient solid dose product rely corporate partner manufacture certain product additionally lease manufacturing facility san dimas oceanside california edmonton alberta canada cork ireland manufacture certain product active pharmaceutical ingredient clinical commercial use manufacturing product contract party manufacture certain product clinical commercial purpose include stribild compleraeviplera atripla truvada viread hepsera emtriva tybost vitekta sovaldi ranexa ambisome cayston vistide generally use multiple thirdparty contract manufacturer manufacture active pharmaceutical ingredient product exclusive manufacturer ambrisentan active pharmaceutical ingredient letairis supplier qualify active pharmaceutical ingredient letairis rely thirdparty contract manufacturer manufacture tablet capsule product example use multiple thirdparty contract manufacturer tablet stribild compleraeviplera atripla truvada viread tybost vitekta sovaldi letairis hepsera ranexa emtriva encapsulation complete thirdparty contract manufacturer manufacture agreement corporate partner roche party responsible manufacturing tamiflu agreement roche joint manufacturing committee compose representative roche gilead opportunity review roche exist manufacturing capacity tamiflu global plan manufacture tamiflu astella llc corporate partner lexiscan united states responsible commercial manufacture supply product united states dependent single supplier active pharmaceutical ingredient lexiscan future product continue develop additional manufacturing capability establish additional thirdparty supplier manufacture sufficient quantity product candidate undertake clinical trial manufacture sufficient quantity product approve commercial sale unable develop manufacturing capability internally contract large scale manufacturing party acceptable term future product ability conduct large scale clinical trial meet customer demand commercial product adversely affect manufacturing facility san dimas california manufacturing facility manufacture package label solid dosage oral form product fill package solid dosage form product include stribild compleraeviplera atripla truvada viread emtriva sovaldi ranexa finish forms label hepsera facilities san dimas manufacture cayston ambisome san dimas facility depend single supplier active pharmaceutical ingredient cayston high quality cholesterol active pharmaceutical ingredient manufacture ambisome exclusive supplier ambisome event disaster include earthquake equipment failure difficulty unable replace manufacturing capacity timely manner unable manufacture ambisome meet market need utilize cork ireland facility primarily solid dose tablet manufacturing certain antiviral product product packaging activity fill package drug product stribild compleraeviplera atripla truvada viread tybost tiveka sovaldi label hepsera emtriva facilities cork ireland perform quality control testing final labeling secondary packaging cayston ambisome final release product european union facility utilize cork ireland facility primarily solid dose tablet manufacturing certain antiviral product product packaging activity distribute product european union international market dublin ireland site edmonton alberta facility canada carry process research scaleup clinical development candidate manufacture active pharmaceutical ingredient investigational commercial product conduct chemical development activity improve exist commercial manufacturing process manufacture active pharmaceutical ingredient hepsera letairis vistide exclusively edmonton site supplier qualify active pharmaceutical ingredient letairis oceanside california facility design equip produce biologic compound toxicological phase phase clinical study use facility process development manufacture simtuzumab investigational monoclonal antibody candidate development treatment certain cancer fibrotic disease antibody currently phase clinical trial thirdparty manufacturer thirdparty manufacturer corporate partner independent entity subject unique operational financial risk control thirdparty manufacturer corporate partner fail perform require impair ability deliver product timely basis receive royalty cause delay clinical trial application regulatory approval extent risk materialize affect performance obligation financial result adversely affect example unexpected delay qualify new external site expand cayston manufacturing san dimas unable supply cayston fulfill project demand february september suspend access patient new prescription cayston subject certain exception specific medical need exist result inability manufacture sufficient cayston meet demand revenue receive sale cayston reduce believe technology use manufacture product proprietary product manufacture thirdparty contract manufacturer disclose necessary aspect technology enable manufacture product agreement thirdparty manufacturer intend restrict manufacturer reveal technology certain thirdparty manufacturer comply restriction addition thirdparty manufacturer develop technology relate work perform need manufacture product require enter additional agreement thirdparty manufacturer want use technology allow manufacturer use technology thirdparty manufacturer refuse allow use technology demand term use technology acceptable regulation manufacturing process manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation thirdparty manufacturer corporate partner subject current good manufacturing practice extensive regulation govern manufacturing process stability testing record keep quality standard define fda ema similar regulation effect country manufacture operation subject routine inspection regulatory agency example april fda conduct inspection foster city facility issue form inspectional observation note deficiency documentation validation certain quality testing procedure method result observation fda deliver complete response letter notify unable approve nda elvitegravir cobicistat standalone agent midoctober fda complete sofosbuvir preapproval inspection foster city facility follow inspection fda issue additional form inspectional observation cite deficiency relate testing reconciliation stability sample test protocol test shipping sample procedure calibrate test equipment recently complete file response observation fda unable remedy deficiency cite fda inspection currently market product time regulatory approval product development adversely affect risk regulatory agency country marketing application pende undertake similar additional review apply heighten standard review delay regulatory approval product country approval product candidate include idelalisib fixeddose combination ldvsof delay production market product interrupt anticipate revenue stock price adversely affect access supply material need access certain supply product manufacture product light global economic downturn increase difficulty purchase certain raw material manufacturing process unable purchase sufficient quantity material find suitable alternate material timely manner development effort product candidate delay ability manufacture product limit limit ability generate revenue example significant portion raw material intermediate manufacture hiv liver disease product stribild compleraeviplera atripla truvada viread emtriva tybost vitekta sovaldi supply chinesebased company result international trade dispute china united states action chinese government limit prevent chinese company supply material adversely affect ability manufacture supply hiv product meet market need material adverse effect operating result seasonal operation backlog worldwide product sale reflect significant degree seasonality royalty revenue represent approximately total revenue include tamiflu royalty affect seasonality royalty revenue recognize roche sale tamiflu impact severity flu season product delivery response influenza pandemic operate market characterize short lead time absence significant backlog believe backlog information material business government regulation operation activity subject extensive regulation numerous government authority united states countries united states drug subject rigorous fda regulation federal food drug cosmetic act federal state statute regulation govern testing manufacture safety efficacy labeling storage record keeping approval advertising promotion product result regulation product development product approval process expensive time consume fda approve drug sell united states general process approval follow preclinical testing test drug candidate human study drug laboratory experiment animal generate datum support drug candidate potential benefit safety submit datum fda investigational new drug ind application seek approval test compound human clinical trial fda accept ind drug candidate study human clinical trial determine drug candidate safe effective clinical trial involve separate phase overlap year expensive phase subject considerable regulation follow phase drug candidate give small number healthy human control subject patient suffer indicate disease test safety dose tolerance pharmacokinetic metabolism distribution excretion phase drug candidate give limited patient population determine effect drug candidate treat disease good dose drug candidate possible effect safety risk drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous phase clinical trial phase drug candidate appear effective safe phase clinical trial phase clinical trial commence confirm result phase clinical trial conduct long term involve significantly large population conduct numerous site different geographic region carefully design provide reliable conclusive datum safety benefit drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous extensive phase clinical trial fda approval process believe datum phase clinical trial adequate level safety efficacy submit appropriate filing usually form nda supplemental nda fda seek approval sell drug candidate particular use fda hold public hear independent advisory committee expert advisor ask additional question make recommendation drug candidate committee make recommendation fda binding generally follow fda fda agree compound meet require level safety efficacy particular use allow sell drug candidate united states use unusual fda reject application believe drug candidate safe efficacious believe datum submit reliable conclusive point process development drug candidate stop number reason include safety concern lack treatment benefit certain clinical trial currently conduct conduct future complete successfully specified time period choose fda require delay suspend clinical trial time appear patient expose unacceptable health risk drug candidate appear sufficient treatment benefit fda require phase nonregistrational study explore scientific question characterize safety efficacy commercial use drug fda require provide additional data information improve manufacturing process procedure facility require extensive surveillance monitor safety benefit product candidate determine file contain adequate evidence safety benefit drug addition fda approve drug limit use drug fda withdraw approval believe comply regulatory standard problem uncover occur approval addition obtain fda approval drug obtain fda approval manufacturing facility drug sell include company manufacture drug facility subject periodic inspection fda fda approve foreign establishment manufacture product sell united states facility subject periodic regulatory inspection manufacturing facility locate california include oceanside san dimas facility license state california compliance local regulatory requirement manufacture facility locate canada include edmonton alberta facility facility locate near dublin cork ireland obtain local license permit compliance local regulatory requirement drug treat life threaten disease condition adequately address exist drug development program design address unmet medical need designate fast track candidate fda eligible accelerate priority review drug treatment hiv infection designate use president emergency plan aid relief qualify expedite priority review atripla truvada viread complera sovaldi receive accelerate approval priority review drug receive accelerated approval monitor postmarkete clinical trial order confirm safety benefit drug drug subject extensive regulation outside united states european union centralize approval procedure authorize marketing product country european union include major country europe centralize approval procedure approval country european union obtain approval country european union simplified application process mutual recognition procedure decentralize procedure rely principle mutual recognition receive regulatory approval european registration procedure separate pricing reimbursement approval require country european union requirement approval manufacturing facility product approve sale european regulatory authority price reimbursement successful commercialization product depend availability governmental thirdparty payer reimbursement cost product relate treatment government health administration authority private health insurer organization generally provide reimbursement united states european union significant potentially significant market product product candidate government authority thirdparty payer increasingly attempt limit regulate price medical product service particularly new innovative product therapy result low average selling price significant portion sale majority product subject significant discount list price rebate obligations united states state adap purchase significant portion hiv product rely federal supplemental federal state funding help fund purchase product give current economic downturn experience shift payer mix patient previously cover private insurance public reimbursement program require rebate discount patient previously cover public reimbursement program public reimbursement program require great rebate discount result shift revenue growth lower prescription growth effective march automatic reduction federal spending sequestration effect sequestration acrosstheboard cut implement reduce federal state fund support adap federal state fund available amount sufficient support number patient rely adap sale hiv product negatively impact reduce revenue example quarter state budget crisis florida lead temporary movement patient previously cover florida adap industrysupporte patient assistance program prior quarter insufficiency federal state fund state reduce eligibility criterion see increase number patient state adap wait list similar increase future period result reduction federal state adap support result sequestration patient enrol adap generally receive product industrysupporte patient assistance program unable access treatment increase emphasis manage healthcare united states country regional pricing reimbursement control european union additional pressure product pricing reimbursement usage adversely affect product sale profitability pressure arise rule practice manage care group judicial decision governmental law regulation relate medicare medicaid healthcare reform pharmaceutical reimbursement policy price general country outside united states success commercialize product product candidate develop depend largely obtain maintain government reimbursement country patient unlikely use prescription drug reimburse government addition negotiate price certain governmental authority delay commercialization month reimbursement policy adversely affect ability sell product profitable basis international market government control price prescription pharmaceutical include implementation reference pricing price cut rebate revenuerelate taxis tender profit control expect price prescription pharmaceutical decline life product volume increase recently country european union increase discount require product effort continue country attempt manage healthcare expenditure especially light severe fiscal debt crisis experience country european union example june spain impose incremental discount brand drug august germany increase rebate prescription pharmaceutical freeze price prescription pharmaceutical generic drug come market face price decrease product country european union cost containment pressure european union especially southern europe lead delay treatment patient delay pricing approval negatively impact commercialization new product government agency issue regulation guideline directly applicable product addition time time professional society practice management group private healthscience foundation organization publish guideline recommendation direct certain health care patient community recommendation guideline relate matter product usage dosage route administration use related compete therapy consequently result increase decrease usage product example recent hiv treatment guideline united states abroad endorse early diagnosis treatment united states healthcare reform legislative regulatory change government prescription drug procurement reimbursement program occur relatively frequently united states foreign jurisdiction march healthcare reform legislation adopt united states result require rebate discount product reimburse pay public payer include medicaid entity eligible purchase discount product b drug pricing program public health service act adap result legislation discount rebate fee impact include minimum base rebate owe medicaid product reimburse medicaid increase discount rebate owe adap public health service entity reimburse purchase product increase require extend rebate patient receive product medicaid manage care organization require provide discount product sell patient medicare donut hole pharmaceutical manufacturer brand drug product require pay portion new industry fee know pharmaceutical excise tax billion calculate base select government sale calendar year percentage total industry government sale industry fee impose pharmaceutical industry increase billion billion additional increase year peak billion year decrease billion industry fee increase product sale increase drug patent expire major drug company expect portion pharmaceutical excise tax increase estimate portion pharmaceutical excise tax approximately million compare approximately million approximately million pharmaceutical excise tax tax deductible address healthcare reform legislation discussion continue federal level legislation allow require federal government directly negotiate price concession pharmaceutical manufacturer set minimum requirement medicare pricing addition state medicaid program request additional supplemental rebate product result increase federal base medicaid rebate private insurer use enactment increase rebate exert pricing pressure product extent private insurer manage care program follow medicaid coverage payment development adverse effect magnify private insurer adopt low payment schedule health care fraud abuse law antibribery law subject federal state law pertain health care fraud abuse include antikickback law false claim law antikickback law illegal prescription drug manufacturer solicit offer receive pay remuneration exchange induce referral business include purchase prescription particular drug breadth statutory provision increase attention give law enforcement authority possible certain practice challenge antikickback similar law false claim law generally prohibit knowingly present cause present false fraudulent claim payment federal certain state payer include medicare medicaid knowingly make cause false record statement material false fraudulent claim sale marketing medical activity subject scrutiny law addition foreign corrupt practice act similar worldwide antibribery law generally prohibit company intermediary make improper payment purpose obtain retain business policy mandate compliance antibribery law operate part world experience governmental corruption degree certain circumstance strict compliance antibribery law conflict local custom practice require interact doctor hospital state control manner different local custom despite train compliance program internal control policy procedure protect reckless criminal act commit employee agent violation fraud abuse law antibribery law punishable criminal andor civil sanction include fine civil monetary penalty possibility exclusion federal health care program include medicare medicaid violation lead imposition corporate integrity agreement similar government oversight program government allege convict violate law disruption business material adverse effect result operation compulsory license number develop country government official interested group suggest pharmaceutical company drug hiv infection available low cost alternatively government develop country require grant compulsory license allow competitor manufacture sell version product reduce product sale example past certain office government brazil express concern affordability hiv product declare consider issue compulsory license permit manufacture patent product hiv infection include viread july brazilian patent authority reject patent application tenofovir disoproxil fumarate active pharmaceutical ingredient viread high level appeal available brazilian patent authority currently patent brazil brazilian government purchase supply tenofovir disoproxil fumarate generic manufacturer addition concern cost availability tamiflu relate potential avian flu pandemic hn influenza generate international discussion compulsory licensing tamiflu patent example canadian government consider allow canadian manufacturer manufacture export active ingredient tamiflu eligible develop develop country canada access medicine regime furthermore roche issue voluntary license permit thirdparty manufacturing tamiflu example roche grant sublicense shanghai pharmaceutical group co ltd china sublicense india hetero drug limited india certain develop country compulsory license issue permit generic manufacturing override tamiflu patent roche issue additional voluntary license permit thirdparty manufacturing tamiflu development reduce royalty receive roche sale tamiflu certain country permit enforcement patent thirdparty manufacturer able sell generic version product country compulsory license sale generic version product significantly reduce sale adversely affect result operation particularly generic version product import territory exist commercial sale employee january approximately fulltime employee believe good relation employee environment health safety evaluate current level environmental impact identify way reduce energy consumption factor contribute environmental impact include greenhouse gas emission produce employee commute energy water consume facility use hazardous material chemical viruse radioactive compound rd facility pursuant evaluation take initial measure address impact example establish employee commuter program evaluate energy efficiency building instal lowflow water fixture implement proactive program minimize occurrence hazardous material incident reduce risk accidental environmental contamination worker injury subject number law regulation require compliance federal state local regulation workplace safety protection environment anticipate additional regulation near future law regulation implement consideration mitigate effect climate change mainly cause greenhouse gas emission business energy intensive anticipate subject cap trade system mitigation measure materially impact capital expenditure operation competitive position base current information subject finalization propose regulation believe primary risk relate climate change increase energy cost use hazardous material chemical viruse radioactive compound rd activity eliminate risk accidental contamination injury material misuse accident involve hazardous material lead significant litigation fine penalty information subject information requirement exchange act file periodic report proxy statement information sec report proxy statement information obtain visit public reference room sec f street ne washington dc call sec sec send electronic message sec publicinfosecgov send fax sec addition sec maintain website wwwsecgov contain report proxy information statement information issuer file electronically mail address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors section website sec filings financial information section available follow filing soon reasonably practicable electronically file furnished sec annual report quarterly report form q current report form k amendment report file furnish pursuant section exchange act filing available free charge request transaction iran transaction iran require disclosure item risk factor evaluate business carefully consider follow risk addition information annual report manifestation follow risk materially adversely affect business result operation financial condition note factor investor permit private security litigation reform act possible predict identify factor consider follow risk complete statement potential risk uncertainty face substantial portion revenue derive sale hiv product particularly atripla truvada stribild compleraeviplera unable maintain continue increase sale product result operation adversely affect currently depend sale product treatment human immunodeficiency virus hiv infection particularly atripla truvada stribild compleraeviplera support exist operation hiv product contain tenofovir disoproxil fumarate andor emtricitabine belong nucleoside class antiviral therapeutic treatment paradigm hiv change cause nucleosidebased therapeutic fall favor unable maintain continue increase hiv product sale result operation likely suffer likely need scale operation include spend research development rd effort year end december atripla truvada stribild compleraeviplera product sale billion total revenue able sustain increase growth rate sale hiv product especially stribild compleraeviplera atripla truvada tybost number reason include limited follow hiv product long period time patient combination product additional study conduct new issue respect safety resistance interaction drug arise cause provide additional warning contraindication label narrow approve indication halt sale product reduce revenue hiv product mature private insurer government payer reduce reimburse patient product increase pressure reduce price large market hiv product consist patient take hiv drug successful encourage physician change patient regimen include hiv product sale hiv product limit generic hiv product introduce major market ability maintain pricing market share affect example generic version sustiva efavirenz component atripla available canada europe expect competition generic efavirenz united states increase pricing pressure hiv product tivicay dolutegravir integrase inhibitor launch fourth quarter viiv healthcare viiv impact sale hiv product fail commercialize new product expand indication exist product prospect future revenue adversely affect introduce new product market increase sale exist product able increase maintain total revenue continue expand rd effort drug development inherently risky product candidate fail drug development process example april announce decision terminate phase clinical trial aztreonam inhalation solution treatment bronchiectasis february file new drug application nda food drug administration fda approval fixeddose combination ledipasvirsofosbuvir ldvsof genotype patient represent majority patient infect chronic hepatitis c virus hcv infection united states europe approve ldvsof likely require genotype hcv patient pill day week ribavirin rbv pegylate interferon pegifn pegifn expect file approval ldvsof europe quarter file marketing application idelalisib treatment patient indolent nonhodgkin lymphoma inhl chronic lymphocytic leukemia cll mark application approve fda european medicine agency ema foreign regulatory authority timely basis marketing approval grant product significant limitation use unable file marketing application new product inability accurately estimate demand product uptake new product time fluctuation inventory maintain customer make difficult accurately forecast sale cause revenue earning fluctuate adversely affect financial result stock price unable accurately estimate demand product include uptake new product demand dependent number factor example hcv product sovaldi ldvsof approve represent significant change treatment paradigm hcv infected patient shorten duration treatment reduction elimination need pegifn injection rbv product new therapeutic area patient demand dependent number factor revenue product difficult investor estimate sovaldi recently approve clear ldvsof ultimately approve demand product depend coverage private public insurance programs united states ability obtain maintain government reimbursement country outside united states addition doctor choose wait treat genotype hcv infected patient later anticipate approval availability ldvsof competitor alloral regimen treatment genotype hcvinfecte patient hcv product represent significant change treatment paradigm hcv infection highly anticipate medical patient community sale level prescription growth rate early launch indicative future result hcvrelate revenue difficult predict investor widely vary expectation materially higher low actual revenue extent sovaldi revenue exceed fall short expectation stock price experience significant volatility approximately product sale united states wholesaler cardinal health inc mckesson corp amerisourcebergen corp wholesaler enter inventory management agreement estimate determine end user demand completely effective match inventory level actual end user demand result change inventory level hold wholesaler cause operating result fluctuate unexpectedly sale wholesaler match end user demand addition inventory hold retail pharmacy nonwholesaler location inventory management agreement control buy pattern adverse change economic condition factor cause retail pharmacy reduce inventory product reduce order wholesaler consequently wholesaler order end user demand change example fourth quarter strong wholesaler sub wholesaler purchase result inventory drawdown wholesaler subwholesaler quarter inventory distribution channel fluctuate quarter quarter continue fluctuation earning mismatch prescription demand product revenue addition nonretail sector united states include government institution include state aids drug assistance program adap correctional facility large health maintenance organization tend consistent term buy pattern cause quarter quarter fluctuation necessarily mirror patient demand federal state budget pressure include sequestration annual grant cycle federal state adap fund cause adap purchasing pattern reflect patient demand example quarter certain prior year observe large nonretail purchase number state adap exceed patient demand believe purchase drive grant cycle federal adap fund expect continue experience fluctuation purchase pattern nonretail customer result fluctuation product sale revenue earning future light global economic downturn budget crisis face european country observe variation purchase pattern induce cost containment measure europe believe measure cause government agency purchaser reduce inventory product distribution channel decrease revenue cause fluctuation product sale earning continue trend future result operation adversely affect current potential future healthcare reform legislative regulatory change government prescription drug procurement reimbursement program occur relatively frequently united states foreign jurisdiction march healthcare reform legislation adopt united states result require rebate discount product reimburse pay public payer include medicaid entity eligible purchase discount product b drug pricing program public health service act adap result legislation discount rebate fee impact include minimum base rebate owe medicaid product reimburse medicaid increase discount rebate owe adap public health service entity reimburse purchase product increase require extend rebate patient receive product medicaid manage care organization require provide discount product sell patient medicare donut hole pharmaceutical manufacturer brand drug product require pay portion new industry fee know pharmaceutical excise tax billion calculate base select government sale calendar year percentage total industry government sale industry fee impose pharmaceutical industry increase billion billion additional increase year peak billion year decrease billion industry fee increase product sale increase drug patent expire major drug company expect portion pharmaceutical excise tax increase estimate portion pharmaceutical excise tax approximately million compare approximately million approximately million pharmaceutical excise tax tax deductible address healthcare reform legislation discussion continue federal level legislation allow require federal government directly negotiate price concession pharmaceutical manufacturer set minimum requirement medicare pricing addition state medicaid program request additional supplemental rebate product result increase federal base medicaid rebate private insurer use enactment increase rebate exert pricing pressure product extent private insurer manage care program follow medicaid coverage payment development adverse effect magnify private insurer adopt low payment schedule exist product subject reimbursement government agency party pharmaceutical pricing reimbursement pressure reduce profitability successful commercialization product depend availability governmental thirdparty payer reimbursement cost product relate treatment government health administration authority private health insurer organization generally provide reimbursement united states european union significant potentially significant market product product candidate government authority thirdparty payer increasingly attempt limit regulate price medical product service particularly new innovative product therapy result low average selling price significant portion sale majority product subject significant discount list price rebate obligations united states state adap purchase significant portion hiv product rely federal supplemental federal state funding help fund purchase product give current economic downturn experience shift payer mix patient previously cover private insurance public reimbursement program require rebate discount patient previously cover public reimbursement program public reimbursement program require great rebate discount result shift revenue growth lower prescription growth effective march automatic reduction federal spending sequestration effect sequestration acrosstheboard cut implement reduce federal state fund support adap federal state fund available amount sufficient support number patient rely adap sale hiv product negatively impact reduce revenue example quarter state budget crisis florida lead temporary movement patient previously cover florida adap industrysupporte patient assistance program prior quarter insufficiency federal state fund state reduce eligibility criterion see increase number patient state adap wait list similar increase future period result reduction federal state adap support result sequestration patient enrol adap generally receive product industrysupporte patient assistance program unable access treatment increase emphasis manage healthcare united states country regional pricing reimbursement control european union additional pressure product pricing reimbursement usage adversely affect product sale profitability pressure arise rule practice manage care group judicial decision governmental law regulation relate medicare medicaid healthcare reform pharmaceutical reimbursement policy price general country outside united states success commercialize product product candidate develop depend largely obtain maintain government reimbursement country patient unlikely use prescription drug reimburse government addition negotiate price certain governmental authority delay commercialization month reimbursement policy adversely affect ability sell product profitable basis international market government control price prescription pharmaceutical include implementation reference pricing price cut rebate revenuerelate taxis tender profit control expect price prescription pharmaceutical decline life product volume increase recently country european union increase discount require product effort continue country attempt manage healthcare expenditure especially light severe fiscal debt crisis experience country european union example june spain impose incremental discount brand drug august germany increase rebate prescription pharmaceutical freeze price prescription pharmaceutical generic drug come market face price decrease product country european union cost containment pressure european union especially southern europe lead delay treatment patient delay pricing approval negatively impact commercialization new product government agency issue regulation guideline directly applicable product addition time time professional society practice management group private healthscience foundation organization publish guideline recommendation direct certain health care patient community recommendation guideline relate matter product usage dosage route administration use related compete therapy consequently result increase decrease usage product approximately product sale occur outside united states currency fluctuation hedging expense cause earning fluctuate adversely affect stock price significant percentage product sale denominate foreign currency primarily euro face exposure adverse movement foreign currency exchange rate dollar strengthen foreign currency relative value sale respective foreign currency decrease conversely dollar weaken currency relative value sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business use foreign currency exchange forward option contract hedge percentage forecast international sale primarily denominate euro hedge certain monetary asset liability denominate foreign currency reduce eliminate exposure currency fluctuation date transaction record date cash collect pay predict future fluctuation foreign currency exchange rate dollar dollar appreciate significantly certain currency hedge program sufficiently offset effect appreciation result operation adversely affect stock price decline additionally expense recognize relation hedging activity cause earning fluctuate level hedging expense recognize particular period impact change interest rate spread foreign currency hedge dollar face significant competition face significant competition large pharmaceutical biotechnology company substantially great resource addition competitor product operate field compete long hiv product compete primarily product joint venture establish glaxosmithkline incgsk pfizer inc pfizer viiv healthcare viiv market fixeddose combination product compete stribild compleraeviplera atripla truvada example lamivudine market joint venture competitive emtricitabine active pharmaceutical ingredient emtriva component compleraeviplera atripla truvada tybost compete ritonavir market abbvie inc abbvie addition tivicay dolutegravir integrase inhibitor launch fourth quarter viiv adversely impact sale hiv product face competition generic hiv product compound patent cover epivir lamivudine expire united states generic lamivudine available united states spain portugal italy expect generic version lamivudine launch country european union generic version combivir lamivudine zidovudine approve recently launch united states addition late generic tenofovir available turkey result increase rebate viread turkey generic version sustiva efavirenz component atripla available canada europe expect competition generic efavirenz united states increase pricing pressure hiv product hcv product sovaldi competes janssen rd ireland olysio simeprevir united states less extent directacting antiviral victreli boceprevir market merck co inc merck incivek telaprevir market vertex pharmaceutical incorporate viread hepsera treatment chronic hepatitis b virus hbv infection compete primarily product produce gsk bristolmyer squibb company bms novartis pharmaceutical corporation novartis united states european union china ambisome compete primarily product produce merck pfizer addition aware lipid formulation claim similarity ambisome available outside united state include possible entry formulation taiwan formulation reduce market demand ambisome furthermore manufacture lipid formulation amphotericin b complex formulation find unsafe sale ambisome negatively impact association letairis compete directly product produce actelion pharmaceutical inc indirectly pulmonary arterial hypertension product united therapeutics corporation pfizer ranexa compete predominantly generic compound distinct class drug betablocker calcium channel blocker longacte nitrate treatment chronic angina united states cayston competes product market novartis tamiflu compete product sell gsk generic competitor addition number company pursue development technology competitive exist product research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently pharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program competitor gain market share product adversely affect result operation stock price significant safety issue arise market product product candidate future sale reduce adversely affect result operation datum support marketing approval product form basis safety warning product label obtain control clinical trial limit duration case postapproval use product long period time patient underlie health problem take numerous medicine expect continue find new issue safety resistance drug interaction issue require provide additional warning contraindication label narrow approve indication reduce market acceptance product product letairis approve fda june member class compound call endothelin receptor antagonist pose specific risk include risk birth defect risk letairis available letairis education access program leap restrict distribution program intend help physician patient learn risk associate product assure appropriate use product product additional patient discover new risk associate letairis result change distribution program additional restriction use letairis decrease demand product regulatory authority move active transparent pharmacovigilance make great amount standalone safety information directly available public website mean eg periodic safety update report summarie risk management plan summarie adverse event datum safety information appropriate context expertise misinterpret lead misperception legal action potentially cause product sale stock price decline safety resistance drug interaction issue arise market product sale product limit halt regulatory authority result operation adversely affect operation depend compliance complex fda comparable international regulation failure obtain broad approval timely basis maintain compliance delay halt commercialization product product develop approve marketing sale regulatory authority approve subject extensive regulation fda ema comparable regulatory agency country continue clinical trial stribild compleraeviplera atripla truvada viread emtriva tybost vitekta sovaldi hepsera letairis ranexa ambisome cayston currently approve additional use anticipate file marketing approval additional country additional indication product year product fail receive marketing approval timely basis market product manufacture sell product subject extensive regulation review discovery previously unknown problem market product problem manufacture promotional activity result restriction product include withdrawal product market fail comply applicable regulatory requirement include related promotion manufacturing subject penalty include fine suspension regulatory approval product recall seizure product criminal prosecution example fda rule require conduct postapproval clinical study assess know risk signal risk identify unexpected risk implement risk evaluation mitigation strategy product include medication guide patient package insert communication plan healthcare provider element fda deem necessary assure safe use drug include impose certain restriction distribution use product failure comply requirement impose sponsor fda result significant civil monetary penalty operating result adversely affect result anticipate timeline clinical trial uncertain support continue development product pipeline adversely affect prospect future revenue growth require demonstrate safety efficacy product develop intend use extensive preclinical study clinical trial result preclinical early clinical study accurately predict result later largescale clinical trial successfully complete largescale clinical trial result marketable product product candidate fails achieve primary endpoint clinical trial safety issue arise result clinical trial inadequate support regulatory approval product candidate commercialization product candidate delay halt example april announce decision terminate phase clinical trial aztreonam inhalation solution treatment bronchiectasis addition face challenge clinical trial protocol design clinical trial product candidate pipeline delay terminate prospect future revenue growth adversely impact example face numerous risk uncertaintie product candidate include ranolazine treatment incomplete revascularization postpercutaneous coronary intervention type ii diabetes single tablet regimen tenofovir alafenamideelvitegravircobicistatemtricitabine currently phase clinical trial prevent completion development product candidate risk include ability enroll patient clinical trial possibility unfavorable result clinical trial need modify delay clinical trial perform additional trial risk fail obtain fda regulatory body approval result product candidate successfully commercialize strategic decision discontinue development product candidate example believe commercialization difficult relative opportunity pipeline program pipeline complete timely basis prospect future revenue growth adversely impact addition clinical trial involve commercial product raise new safety issue exist product turn decrease revenue harm business reliance thirdparty contract research organization conduct clinical trial unable directly control timing conduct expense quality clinical trial extensively outsource clinical trial activity usually perform small portion startup activity inhouse rely independent party contract research organization cro perform clinical study include document preparation site identification screen preparation prestudy visit training program management bioanalytical analysis important aspect service perform cros direct control dispute disruption relationship cro clinical trial delay regulatory submission rely quality validity clinical work perform thirdparty cro cro process methodology result determine invalid inadequate clinical data result relate regulatory approval adversely impact expense associate clinical trial cause earning fluctuate adversely affect stock price clinical trial require regulatory approval product clinical trial require conduct approval expensive difficult accurately predict control timing expense quarter quarter fda andor regulatory agency require clinical testing originally anticipate uneven unexpected spending program include clinical trial necessary advance product candidate cause operating result fluctuate quarter quarter volatility stock price depend relationship company sale marketing performance development commercialization product candidate revenue failure maintain relationship poor performance company dispute company negatively impact business rely number significant collaborative relationship major pharmaceutical company sale marketing performance certain territory include collaboration bms atripla united states europe canada f hoffmannla roche ltd hoffmannla roche inc roche tamiflu worldwide gsk ambrisentan territory outside united states country rely international distributor sale truvada viread hepsera emtriva ambisome relationship involve clinical development product partner reliance collaborative relationship pose number risk include risk unable control resource corporate partner devote program product dispute arise respect ownership right technology develop corporate partner disagreement corporate partner cause delay termination research development commercialization product candidate result litigation arbitration contract corporate partner fail provide significant protection fail effectively enforce partner fails perform corporate partner considerable discretion elect pursue development additional product pursue alternative technology product collaboration competitor corporate partner marketing right choose pursue compete technology devote few resource marketing product product development distributor corporate partner unable pay particularly light current economic condition give risk great deal uncertainty success current future collaborative effort effort fail product development commercialization new product delay revenue product decline april licensing agreement gsk give gsk right control clinical regulatory development commercialization hepsera territories asia africa latin america include major market hepsera china japan taiwan south korea november enter agreement gsk provide gsk exclusive commercialization right registration responsibility viread treatment chronic hbv china october grant similar right gsk japan saudi arabia success hepsera viread treatment chronic hbv territory depend entirely effort gsk regard gsk promote epivirhbvzeffix product compete hepsera viread treatment chronic hbv consequently gsk marketing strategy hepsera viread treatment chronic hbv influence promotion epivirhbvzeffix receive royalty gsk equal percentage gsk net sale hepsera viread treatment chronic hbv net sale gsk epivirhbvzeffix gsk fail devote sufficient resource succeed develop commercialize hepsera viread treatment chronic hbv territory potential revenue territory substantially reduce addition cayston letairis distribute thirdparty specialty pharmacy pharmacie specialize dispense medication complex chronic condition require high level patient education ongoing counseling use specialty pharmacy require significant coordination sale marketing medical affair regulatory affair legal finance organization involve risk include limited risk specialty pharmacy provide accurate timely information inventory patient data safety complaint effectively sell support cayston letairis devote resource necessary sell cayston letairis volume time frame expect able satisfy financial obligation cease operation rely party administer leap restrict distribution program design support letairis party provide information education prescriber patient risk letairis confirm insurance coverage investigate alternative source reimbursement assistance ensure fulfillment risk management requirement mandate letairis fda coordinates control dispense patient party specialty pharmacy failure party specialty pharmacy distribute letairis perform expect result regulatory action fda decrease letairis sale harm business cayston take patient specific inhalation device deliver drug lung patient ongoing distribution cayston entirely reliant manufacturer device example manufacturer encounter issue regulatory agency relate device unable supply sufficient quantity device addition manufacturer able provide adequate warranty support device distribute patient respect distribution drug device patient reliant capability specialty pharmacy example distribution channel drug device complicated require coordination reimbursement approval process associate drug device similarly complex device manufacturer unable obtain reimbursement approval receive approval lowerthanexpecte price sale cayston adversely affect previously describe issue limit sale cayston adversely affect financial result success depend significant degree ability defend patent intellectual property right domestically internationally able obtain effective patent protect technology use competitor patent company require stop pay use require technology patent proprietary right important business success depend significant degree ability obtain patent license patent right preserve trade secret defend infringement effort invalidate patent operate infringe intellectual property properly draft enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology number foreign patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent patent application confidential period time patent issue result know competitor file patent application technology cover pende application invent file application direct technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete product addition competitor file patent application cover technology participate litigation interference proceeding determine right patent litigation interference proceeding unpredictable expensive ultimately successful result operation adversely affect event patent cover ranolazine compound active ingredient ranexa instead discover sustainedrelease formulation ranolazine achieve therapeutic plasma level patent obtain formulation characteristic plasma level achieve patent cover active ingredient ambisome addition patent filing china certain asian country cover form adefovir dipivoxil active ingredient hepsera asia major market therapie hbv indication hepsera develop obtain patent certain product year marketing approval obtain product patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension supplementary protection certificate country generic manufacturer seek continue seek fda approval market generic version product abbreviate new drug application anda application form typically manufacturer seek approval generic drug description anda litigation legal proceeding begin risk factor entitle litigation generic manufacturer reduce continue reduce earning unsuccessful lawsuit claim patent narrow invalidated generic version product launch prior patent expiry begin success depend large ability operate infringe patent proprietary right party infringe valid patent party prevent commercialize product require obtain license party able obtain alternative technology require license reasonable term fail obtain license alternative technology unable develop commercialize product example aware patent relate operation leap restrict distribution program design support letairis aware patent patent application own party claim cover use sofosbuvir description litigation sofosbuvir risk factor entitle party successful establish exclusive right sofosbuvir expect revenue earning sale sofosbuvir adversely affect beginning furthermore rely unpatented trade secret improvement unpatente internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor agreement provide confidential information develop known individual course relationship keep confidential disclose party specify circumstance case employee agreement provide invention individual employ exclusive property certain party comply confidentiality agreement adequate remedy breach trade secret know independently discover competitor rd agreement invention jointly own corporate partner case exclusive property party certain circumstance difficult determine own particular invention dispute arise invention trade secret confidential information know independently discover competitor enter dispute ownership invention business result operation adversely affect party successful establish exclusive right sofosbuvir expect revenue earning sale sofosbuvir adversely affect patent claim sofosbuvir chemical entity metabolite existence patent necessarily guarantee right practice patent technology commercialize patent product party obtain right patent allegedly prevent attempt prevent commercialize sofosbuvir example aware patent patent application own party allege party cover use sofosbuvir party successfully obtain valid enforceable patent successfully prove infringement patent sofosbuvir prevent sell sofosbuvir able obtain license patent license available commercially reasonable term party successful establish exclusive right sofosbuvir expect revenue earning sale sofosbuvir adversely affect contract arbitration jeremy clark march jeremy clark employee pharmasset inventor patent patent file demand arbitration lawsuit pharmasset dr raymond schinazi mr clark initially file lawsuit pharmasset dr schinazi district court northern district alabama february seek void assignment provision employment agreement assert ownership patent patent claim metabolite sofosbuvir rg december court order stay litigation pende outcome arbitration proceeding require mr clark employment agreement instead proceed arbitration mr clark file additional lawsuit september june court subsequently dismiss september mr clark file motion seek reconsideration court december order court deny december mr clark file motion appoint special prosecutor february court issue order require mr clark enter arbitration risk dismissal case mr clark file demand arbitration march arbitration panel hold hear april june arbitration panel issue decision favor pharmasset gilead dr schinazi august gilead dr schinazi file motion district court northern district alabama seek court confirm arbitration decision mr clark file motion seek vacate arbitration decision court rule motion arbitration f hoffmanla roche ltd hoffmanla roche inc collectively roche gilead successor pharmasset party october collaboration agreement roche agreement grant roche right develop psi cytidine analog prodrug treatment hcv infection collaborative research effort agreement end december roche later ask pharmasset consider roche contributed inventorship sofosbuvir pharmasset comply confidentiality provision collaboration agreement pharmasset advise carefully consider issue raise roche believe issue merit consider issue reach conclusion march roche initiate arbitration pharmasset predecessor gilead pharmasset llc collaboration agreement arbitration demand roche assert exclusive license sofosbuvir pursuant collaboration agreement sofosbuvir prodrug uridine monophosphate analog allegedly prodrug psi cytidine analog roche claim exclusive right sofosbuvir exclusive license patent cover sofosbuvir infringe patent selling offer sale product contain sofosbuvir gilead gilead pharmasset llc file response roche arbitration demand april interference proceeding litigation idenix pharmaceuticals inc february receive notice patent trademark office uspto declare interference idenix interference patent patent idenix pharmaceuticals inc idenix pende patent application interference administrative proceeding uspto design determine invent subject matter claim party patent cover metabolite sofosbuvir rg prodrug cytidine nucleoside analog pharmasset license roche idenix attempt patent class compound include metabolite purpose idenix interference determine invent compound entitle patent claim compound march uspto patent trial appeal board board determine idenix entitle benefit early application filing date patent application include application lead idenixs patent patent patent teach compound dispute board determine entitle filing date early application file patent application compound dispute senior party idenix interference january board determine pharmasset idenix invent compound dispute accordingly gilead prevail decision board hold idenix fail prove conceive compound dispute specifically idenix fail prove idenix inventor identify structure method make use dispute compound board go conclude idenix fail work diligently make testing compound dispute relevant time period idenix appeal board decision district court district delaware board decision reverse appeal court determine idenix entitle patent claim determine infringe claim require obtain license pay royalty idenix commercialize sofosbuvir rg united states decision district court appeal party court appeal federal circuit cafcwe believe claim idenix application involve idenix interference similar foreign patent claim compound metabolite invalid result file impeachment action federal court canada invalidate idenix canadian patent canadian patent correspond patent idenix patent application subject idenix interference idenix assert canadian patent correspond patent patent idenix interference invalid file similar legal action norway oslo district court seek invalidate idenix correspond norwegian patent september idenix file invalidation action norwegian proceeding norwegian patent patent correspond patent patent trial hold november court issue decision august idenix file request invalidation chinese patent office chinese patent cn zl correspond patent patent file legal action federal court australia seek invalidate idenixs australian patent correspond patent april idenix assert commercialization sofosbuvir infringe australian patent correspond patent bring similar action country future idenix award patent compound european patent office japan china event patent issue expect challenge proceeding si milar invoke canada norway australia courts hear proceeding determine idenix entitle patent claim determine infringe claim require obtain license pay royalty idenix commercialize sofosbuvir rg country december receive gilead request uspto declare interference second idenix interference pende patent application patent patent include claim direct method treat hcv nucleoside compound similar involved idenix interference second idenix interference determine invent claim method treat hcv declaration second idenix interference uspto initially designate gilead junior party base patent application filing date appear face patent february uspto issue order cause idenix second idenix interference order require idenix explain judgment enter second idenix interference favor gilead base outcome idenix interference order indicate claim patent involve second idenix interference unpatentable gilead prevail idenix interference idenix allow claim benefit filing date early file patent application believe board determination idenix interference idenix entitle benefit early application filing date include file date patent equally applicable second idenix interference correct board conclude gilead senior party second idenix interference consistent determination idenix interference light board conclusion idenix interference application lead patent teach claim compound possible board determination second idenix interference eliminate need board address invent claim method treat hcv board consider invent claim method treat hcv ultimately conclude gilead claim patent revoke board determine idenix invent entitle patent claim determine proceeding infringe claim require obtain license pay royalty idenix commercialize sofosbuvir rg determination board appeal party federal court december idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversit montpellier ii sue district court district delaware allege commercialization sofosbuvir infringe patent interference exist patent patent patent believe claim patent invalid sole right commercialize sofosbuvir court disagree view determine patent infringe require obtain license pay royalty idenix commercialize sofosbuvir decision district court appeal party cafc december idenix udsg sue district court district massachusetts allege commercialization sofosbuvir infringe patent nos patent believe idenixs patent invalid infringe commercialization sofosbuvir sole right commercialize sofosbuvir court disagree view determine patent infringe require obtain license pay royalty idenix commercialize sofosbuvir decision district court appeal party cafc expansive patent portfolio cover nsa inhibitor treatment hcv follow recent disclosure structure idenixs nsa inhibitor samatasvir know idx evaluate compound light pende claim patent application litigation merck co inc august merck co inc merck contact request pay royalty sale sofosbuvir license patent patent patent patent coown isis pharmaceuticals inc believe merck patent invalid infringe commercialization sofosbuvir sole right commercialize sofosbuvir accordingly august file lawsuit district court northern district california seek declaratory judgment merck patent invalid infringe merck patent nos patent cover compound include relate sofosbuvir patent prosecution merck amend patent application attempt cover compound relate sofosbuvir ultimately extract royalty payment sofosbuvir commercialization exclude market court determine merck patent valid infringe claim require obtain license pay royalty merck commercialize sofosbuvir party appeal decision district court cafc litigation abbvie inc abbvie abbvie recently obtain patent nos patent purport claim use combination ldvsof treatment hcv publish pende patent application direct use combination treatment hcv specifically combination ledipasvir sofosbuvir certain application file abbvie recently issue patent reason believe abbvie patent invalid accordingly december file lawsuit district court district delaware seek declaratory judgment abbvie patent invalid unenforceable relief believe abbott laboratories inc abbvie conspire eliminate competition hcv market falsely represent pto gilead invent method treat hcv combination ldvsof february abbvie respond lawsuit filing lawsuit district court district delaware allege ldvsof product infringe patent expect abbvie patent block delay commercialization combination product court determine abbvie patent valid infringe claim require obtain license pay royalties abbvie commercialize sofosbuvir combination product party appeal decision district court cafc manufacturing problem include thirdparty manufacturer corporate partner cause inventory shortage delay product shipment regulatory approval adversely affect result operation order generate revenue product able produce sufficient quantity product satisfy demand product result complex manufacturing process manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation product manufacture facility thirdparty manufacturer corporate partner depend party perform manufacturing activity effectively timely basis majority solid dose product addition roche party responsible manufacturing tamiflu thirdparty manufacturer corporate partner subject current good manufacturing practice gmp extensive regulation govern manufacturing process stability testing record keep quality standard define fda ema similar regulation effect country thirdparty manufacturer corporate partner independent entity subject unique operational financial risk control thirdparty manufacturer corporate partner fail perform require impair ability deliver product timely basis receive royalty cause delay clinical trial application regulatory approval extent risk materialize affect performance obligation financial result adversely affect addition thirdparty manufacturer corporate partner able produce product limit number facility limited manufacturing capacity certain product example unexpected delay qualify new external site expand cayston manufacturing san dimas unable supply cayston fulfill project demand february september suspend access patient new prescription cayston subject certain exception specific medical need exist result inability manufacture sufficient cayston meet demand revenue receive sale cayston reduce manufacturing operation subject routine inspection regulatory agency example april fda conduct inspection foster city facility issue form inspectional observation note deficiency documentation validation certain quality testing procedure method result observation fda deliver complete response letter notify unable approve nda elvitegravir cobicistat standalone agent midoctober fda complete sofosbuvir preapproval inspection foster city facility follow inspection fda issue additional form inspectional observation cite deficiency relate testing reconciliation stability sample test protocol test shipping sample procedure calibrate test equipment recently complete file response observation fda unable remedy deficiency cite fda inspection currently market product time regulatory approval product development adversely affect risk regulatory agency country marketing application pende undertake similar additional review apply heighten standard review delay regulatory approval product country approval product candidate include idelalisib ldvsof delay production market product interrupt anticipate revenue stock price adversely affect able obtain material supply necessary conduct clinical trial manufacture sell product limit ability generate revenue need access certain supply product conduct clinical trial manufacture product light global economic downturn increase difficulty purchase certain raw material manufacturing process unable purchase sufficient quantity material find suitable alternate material timely manner development effort product candidate delay ability manufacture product limit limit ability generate revenue supplier key component material name nda file fda ema regulatory authority product candidate seek marketing approval significant delay occur qualification new supplier require manufacturer qualified regulatory authority manufacturer continue expend time money effort area production quality control ensure compliance gmp manufacturer subject regular periodic inspection regulatory authority follow initial approval result inspection regulatory authority determine equipment facility laboratory process comply applicable regulation condition product approval regulatory authority suspend manufacturing operation manufacture operation single supplier product suspend unable generate sufficient quantity commercial clinical supply product meet market demand turn decrease revenue harm business addition delivery material supplier interrupt reason unable ship certain product commercial supply supply product development clinical trial addition product material utilize operation facility example manufacture certain drug product intermediate utilize ambisome exclusively facility san dimas california event disaster include earthquake equipment failure difficulty unable replace manufacturing capacity timely manner unable manufacture ambisome meet market need addition depend single supplier highquality cholesterol active pharmaceutical ingredient manufacture ambisome rely single source active pharmaceutical ingredient letairis astellas llc markets lexiscan united states responsible commercial manufacture supply product united states dependent single supplier active pharmaceutical ingredient lexiscan problem single supplier depend negatively impact development commercialization effort significant portion raw material intermediate manufacture hiv product sovaldi stribild compleraeviplera atripla truvada viread emtriva tybost supply chinesebased company result international trade dispute china united states action chinese government limit prevent chinese company supply material adversely affect ability manufacture supply hiv product meet market need material adverse effect operating result litigation generic manufacturer reduce continue reduce earning unsuccessful lawsuit claim patent narrow invalidated generic version product launch prior patent expiry approval process product fda grant new chemical entity nce exclusivity period manufacturer application approval generic version product approve generic manufacturer challenge patent protect product grant nce exclusivity year prior end nce exclusivity period generic manufacturer seek continue seek fda approval similar identical drug anda application form typically manufacturer seek approval generic drug receive notice generic manufacturer submit andas manufacture generic version atripla truvada viread emtriva ranexa tamiflu united states atripla truvada viread canada april teva pharmaceutical teva reach agreement settle ongoing patent litigation concern patent protect tenofovir disoproxil fumarate atripla truvada viread product agreement teva allow launch generic version viread december august lupin limited lupin reach agreement settle patent litigation concern patent protect ranexa agreement lupin allow launch generic version ranexa february february teva reach agreement principle settle ongoing patent litigation concern emtricitabine patent protect atripla truvada term settlement agreement confidential settlement agreement file federal trade commission department justice require law august teva file impeachment action federal court canada seek invalidation canadian patent associate viread september hearing consolidated request order prohibition connection tevas and filing tevas generic version viread truvada atripla take place december court issue request order prohibit canadian minister health issuing notice compliance tevas generic version viread truvada atripla product expiry patent july teva appeal decision decision court ultimately resolve validity challenge raise teva impeachment action teva successful invalidating patent teva able launch generic version viread truvada atripla product prior expiry patent trial impeachment action schedule january anticipate trial relate lupin anda request permission generic version truvada viread anda file cipla ltd request permission generic version emtriva viread place fourth quarter predict ultimate outcome action spend significant resource enforce defend patent unsuccessful lawsuit original claim patent narrow invalidated patent protection atripla truvada viread emtriva ranexa tamiflu united states atripla truvada viread canada substantially shorten patent cover product invalidate fda canadian minister health approve request manufacture generic version products united states canada respectively prior expiration date patent sale generic version product early patent expiration significant negative effect revenue result operation face credit risk southern european customer adversely affect result operation european product sale governmentowne support customer southern europe specifically greece italy portugal spain historically continue subject significant payment delay government funding reimbursement practice result continue result day sale outstanding significantly high country average length time account receivable remain outstanding december account receivable country total approximately million million past great day million past great day follow thousand december greater great day past day past spain portugal italy greece total historically receivable balance certain publiclyowne hospital accumulate period time subsequently settle large lump sum payment pattern experience pharmaceutical company sell directly hospital significant change occur reimbursement practice european government government funding unavailable able collect amount customer result operation adversely affect collect million past account receivable customer base spain portugal include million proceed onetime factoring arrangement sell receivables spain greek government settle substantially outstanding receivables subject bond settlement zerocoupon bond trade discount face value march greek government restructure sovereign debt impact holder greek bond result record million loss revenue gross margin reduce import country product available low price price product base local market economic competition differ country country sale country relatively high price reduce product import country low price market case pharmaceutical product sell steeply discount price develop world reexporte european country resold high price happen product particularly truvada viread agree available substantially reduce price country participate gilead access program atripla merck distribute substantially reduce price hiv infect patient develop country agreement revenue adversely affect addition establish partnership indian generic manufacturer distribute highquality lowcost generic version tenofovir disoproxil fumarate develop world country include india expand agreement include right stribild tybost vitekta enter collaboration certain indian generic manufacturer produce distribute generic emtricitabine develop world include single tablet regimen contain emtricitabine fixeddose combination emtricitabine co formulate hiv medicine generic version medication license reexporte united states europe market outside country revenue adversely affect addition purchase product country sell price relatively low resale country sell price relatively high adversely impact revenue gross margin cause sale fluctuate quarter quarter example european union require permit product purchase country sell country purchase product country sell price relatively low resale country sell price relatively high affect inventory level hold wholesaler cause relative sale level country fluctuate quarter quarter reflect actual consumer demand give quarter quarterly fluctuation impact earning adversely affect stock price harm business expensive litigation government investigation reduce continue reduce earning involve number litigation investigation disputerelate matter require expend substantial internal financial resource expect matter continue require high level internal financial resource foreseeable future matter reduce continue reduce earning description litigation sofosbuvir litigation generic manufacturers department justice investigation legal proceeding begin outcome lawsuit lawsuit brought investigation investigation initiate inherently uncertain adverse development outcome result significant expense monetary damage penalty injunctive relief significantly reduce earning cash flow harm business country require grant compulsory license product patent enforce number develop country government official interested group suggest pharmaceutical company drug hiv infection available low cost alternatively government develop country require grant compulsory license allow competitor manufacture sell version product reduce product sale example past certain office government brazil express concern affordability hiv product declare consider issue compulsory license permit manufacture patent product hiv infection include viread addition concern cost availability tamiflu relate potential avian flu pandemic hn influenza generate international discussion compulsory licensing tamiflu patent example canadian government consider allow canadian manufacturer manufacture export active ingredient tamiflu eligible develop develop country canada access medicine regime furthermore roche issue voluntary license permit thirdparty manufacturing tamiflu example roche grant sublicense shanghai pharmaceutical group co ltd china sublicense india hetero drug limited india certain develop country compulsory license issue permit generic manufacturing override tamiflu patent roche issue additional voluntary license permit thirdparty manufacturing tamiflu development reduce royalty receive roche sale tamiflu require grant compulsory license product reduce earning cash flow harm business addition certain country permit enforcement patent thirdparty manufacturer able sell generic version product country example july brazilian patent authority reject patent application tenofovir disoproxil fumarate active pharmaceutical ingredient viread high level appeal available brazilian patent authority currently patent brazil brazilian government purchase supply tenofovir disoproxil fumarate generic manufacturer sale generic version product significantly reduce sale adversely affect result operation particularly generic version product import territory exist commercial sale change royalty revenue disproportionately affect pretax income earning share gross margin portion revenue derive royalty revenue recognize collaboration agreement party royalty revenue impact pretax income earning share gross margin disproportionately contribution revenue increase decrease royalty revenue material significantly impact operating result example roche tamiflu sale unpredictable variability strong relationship seasonal influenza global pandemic planning effort period royalty revenue tamiflu increase disproportionate increase pretax income earning share gross margin similarly period royalty tamiflu decrease disproportionate decrease pretax income earning share gross margin face significant liability result product cover insurance successful claim materially reduce earning testing manufacturing marketing use commercial product product candidate development involve substantial risk product liability claim claim directly consumer healthcare provider pharmaceutical company recent year coverage availability costeffective product liability insurance decrease unable maintain sufficient coverage product liability arise addition cost defend lawsuit pay damage product liability claim exceed coverage unable maintain adequate coverage claim exceed coverage financial condition ability clinically test product candidate market product adversely impact addition negative publicity associate claim regardless merit decrease future demand product impair financial condition business disruption natural manmade disaster harm future revenue worldwide operation subject business interruption stem natural manmade disaster selfinsure corporate headquarters fremont location house majority rd activity san dima oceanside manufacture facility locate california seismically active region carry earthquake insurance significant recovery time require resume operation financial condition operating result materially adversely affect event major earthquake change effective income tax rate reduce earning factor favorable unfavorable effect income tax rate factor include limited interpretation exist tax law change tax law rate portion nontax deductible pharmaceutical excise tax accounting stock option sharebase payment merger acquisition ability manufacture product cork ireland facility amortization certain acquisition relate intangible receive tax benefit expiration federal research tax credit future level rd spending change accounting standard change mix earning tax jurisdiction operate change overall level pretax earning resolution federal state foreign income tax audits impact income tax provision result mention factor significant negative impact net income income tax return audit federal state foreign tax authority currently examination internal revenue service tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction resolution exposure report period material impact result operation period fail attract retain highly qualified personnel unable successfully develop new product candidate conduct clinical trial commercialize product candidate future success depend large continue ability attract retain highly qualified scientific technical management personnel personnel expertise clinical testing governmental regulation commercialization face competition personnel company university public private research institution government entity organization competition qualified personnel biopharmaceutical field intense limited pool qualified potential employee recruit able attract retain quality personnel acceptable term unsuccessful recruitment retention effort business harm item b unresolved staff comment applicable item property corporate headquarters locate foster city california house administrative manufacturing rd activity rd facility oceanside fremont california seattle washington branford connecticut alberta canada manufacturing facilities san dimas california cork ireland global commercial operation include office europe seven asia south america north america believe exist property include own lease site good condition suitable conduct business believe capital resource sufficient purchase lease construct additional facility require meet expect longterm growth need item legal proceeding litigation sofosbuvir january acquire pharmasset inc pharmasset acquisition acquire sofosbuvir know gs nucleotide analog act inhibit replication hcv december receive food drug administration fda approval sofosbuvir brandname sovaldi receive number contractual intellectual property claim sofosbuvir carefully consider claim prior follow acquisition believe merit patent claim sofosbuvir chemical entity metabolite existence patent necessarily guarantee right practice patent technology commercialize patent product party obtain right patent allegedly prevent attempt prevent commercialize sofosbuvir example aware patent patent application own party allege party cover use sofosbuvir party successfully obtain valid enforceable patent successfully prove infringement patent sofosbuvir prevent sell sofosbuvir able obtain license patent license available commercially reasonable term party successful establish exclusive right sofosbuvir expect revenue earning sale sofosbuvir adversely affect contract arbitration jeremy clark march jeremy clark employee pharmasset inventor patent patent file demand arbitration lawsuit pharmasset dr raymond schinazi mr clark initially file lawsuit pharmasset dr schinazi district court northern district alabama february seek void assignment provision employment agreement assert ownership patent patent claim metabolite sofosbuvir rg december court order stay litigation pende outcome arbitration proceeding require mr clark employment agreement instead proceed arbitration mr clark file additional lawsuit september june court subsequently dismiss september mr clark file motion seek reconsideration court december order court deny december mr clark file motion appoint special prosecutor february court issue order require mr clark enter arbitration risk dismissal case mr clark file demand arbitration march arbitration panel hold hear april june arbitration panel issue decision favor pharmasset gilead dr schinazi august gilead dr schinazi file motion district court northern district alabama seek court confirm arbitration decision mr clark file motion seek vacate arbitration decision court rule motion arbitration f hoffmanla roche ltd hoffmanla roche inc collectively roche gilead successor pharmasset party october collaboration agreement roche agreement grant roche right develop psi cytidine analog prodrug treatment hcv infection collaborative research effort agreement end december roche later ask pharmasset consider roche contributed inventorship sofosbuvir pharmasset comply confidentiality provision collaboration agreement pharmasset advise carefully consider issue raise roche believe issue merit consider issue reach conclusion march roche initiate arbitration pharmasset predecessor gilead pharmasset llc collaboration agreement arbitration demand roche assert exclusive license sofosbuvir pursuant collaboration agreement sofosbuvir prodrug uridine monophosphate analog allegedly prodrug psi cytidine analog roche claim exclusive right sofosbuvir exclusive license patent cover sofosbuvir infringe patent selling offer sale product contain sofosbuvir gilead gilead pharmasset llc file response roche arbitration demand april interference proceeding litigation idenix pharmaceuticals inc february receive notice patent trademark office uspto declare interference idenix interference patent patent idenix pharmaceuticals inc idenix pende patent application interference administrative proceeding uspto design determine invent subject matter claim party patent cover metabolite sofosbuvir rg prodrug cytidine nucleoside analog pharmasset license roche idenix attempt patent class compound include metabolite purpose idenix interference determine invent compound entitle patent claim compound march uspto patent trial appeal board board determine idenix entitle benefit early application filing date patent application include application lead idenixs patent patent patent teach compound dispute board determine entitle filing date early application file patent application compound dispute senior party idenix interference january board determine pharmasset idenix invent compound dispute accordingly gilead prevail decision board hold idenix fail prove conceive compound dispute specifically idenix fail prove idenix inventor identify structure method make use dispute compound board go conclude idenix fail work diligently make testing compound dispute relevant time period idenix appeal board decision district court district delaware board decision reverse appeal court determine idenix entitle patent claim determine infringe claim require obtain license pay royalty idenix commercialize sofosbuvir rg united states decision district court appeal party court appeal federal circuit cafcwe believe claim idenix application involve idenix interference similar foreign patent claim compound metabolite invalid result file impeachment action federal court canada invalidate idenix canadian patent canadian patent correspond patent idenix patent application subject idenix interference idenix assert canadian patent correspond patent patent idenix interference invalid file similar legal action norway oslo district court seek invalidate idenix correspond norwegian patent september idenix file invalidation action norwegian proceeding norwegian patent patent correspond patent patent trial hold november court issue decision august idenix file request invalidation chinese patent office chinese patent cn zl correspond patent patent file legal action federal court australia seek invalidate idenixs australian patent correspond patent april idenix assert commercialization sofosbuvir infringe australian patent correspond patent bring similar action country future idenix award patent compound european patent office japan china event patent issue expect challenge proceeding similar invoke canada norway australia courts hear proceeding determine idenix entitle patent claim determine infringe claim require obtain license pay royalty idenix commercialize sofosbuvir rg country december receive gilead request uspto declare interference second idenix interference pende patent application patent patent include claim direct method treat hcv nucleoside compound similar involved idenix interference second idenix interference determine invent claim method treat hcv declaration second idenix interference uspto initially designate gilead junior party base patent application filing date appear face patent february uspto issue order cause idenix second idenix interference order require idenix explain judgment enter second idenix interference favor gilead base outcome idenix interference order indicate claim patent involve second idenix interference unpatentable gilead prevail idenix interference idenix allow claim benefit filing date early file patent application believe board determination idenix interference idenix entitle benefit early application filing date include file date patent equally applicable second idenix interference correct board conclude gilead senior party second idenix interference consistent determination idenix interference light board conclusion idenix interference application lead patent teach claim compound possible board determination second idenix interference eliminate need board address invent claim method treat hcv board consider invent claim method treat hcv ultimately conclude gilead claim patent revoke board determine idenix invent entitle patent claim determine proceeding infringe claim require obtain license pay royalty idenix commercialize sofosbuvir rg determination board appeal party federal court december idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversit montpellier ii sue district court district delaware allege commercialization sofosbuvir infringe patent interference exist patent patent patent believe claim patent invalid sole right commercialize sofosbuvir court disagree view determine patent infringe require obtain license pay royalty idenix commercialize sofosbuvir decision district court appeal party cafc december idenix udsg sue district court district massachusetts allege commercialization sofosbuvir infringe patent nos patent believe idenixs patent invalid infringe commercialization sofosbuvir sole right commercialize sofosbuvir court disagree view determine patent infringe require obtain license pay royalty idenix commercialize sofosbuvir decision district court appeal party cafc expansive patent portfolio cover nsa inhibitor treatment hcv follow recent disclosure structure idenixs nsa inhibitor samatasvir know idx evaluate compound light pende claim patent application litigation merck co inc august merck co inc merck contact request pay royalty sale sofosbuvir license patent patent patent patent coown isis pharmaceuticals inc believe merck patent invalid infringe commercialization sofosbuvir sole right commercialize sofosbuvir accordingly august file lawsuit district court northern district california seek declaratory judgment merck patent invalid infringe merck patent nos patent cover compound include relate sofosbuvir patent prosecution merck amend patent application attempt cover compound relate sofosbuvir ultimately extract royalty payment sofosbuvir commercialization exclude market court determine merck patent valid infringe claim require obtain license pay royalty merck commercialize sofosbuvir party appeal decision district court cafc litigation abbvie inc abbvie abbvie recently obtain patent nos patent purport claim use combination ldvsof treatment hcv publish pende patent application direct use combination treatment hcv specifically combination ledipasvir sofosbuvir certain application file abbvie recently issue patent reason believe abbvie patent invalid accordingly december file lawsuit district court district delaware seek declaratory judgment abbvie patent invalid unenforceable relief believe abbott laboratories inc abbvie conspire eliminate competition hcv market falsely represent pto gilead invent method treat hcv combination ldvsof february abbvie respond lawsuit filing lawsuit district court district delaware allege ldvsof product infringe patent expect abbvie patent block delay commercialization combination product court determine abbvie patent valid infringe claim require obtain license pay royalties abbvie commercialize sofosbuvir combination product party appeal decision district court cafc litigation generic manufacturer approval process product fda grant new chemical entity nce exclusivity period manufacturer application approval generic version product approve generic manufacturer challenge patent protect product grant nce exclusivity year prior end nce exclusivity period generic manufacturer seek continue seek fda approval similar identical drug anda application form typically manufacturer seek approval generic drug tenofovir disoproxil fumarate emtricitabine fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz november receive notice teva pharmaceutical teva submit abbreviate new drug application anda fda request permission manufacture market generic version truvada notice teva allege patent associate emtricitabine own emory university license exclusively invalid unenforceable andor infringe teva manufacture use sale generic fixeddose combination emtricitabine tenofovir disoproxil fumarate december file lawsuit district court southern district new york teva infringement emtricitabine patent march receive notice teva submit anda fda request permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz notice teva challenge emtricitabine patent file lawsuit district court southern district new york teva infringement emtricitabine patent lawsuit consolidated lawsuit file december january receive notice teva submit anda fda request permission manufacture market generic version viread notice teva challenge tenofovir disoproxil fumarate patent protect viread january receive notice teva amend anda relate generic version atripla truvada product notice relate teva anda generic version atripla teva challenge patent relate tenofovir disoproxil fumarate additional patent relate emtricitabine patent relate efavirenz notice relate teva anda generic version truvada teva challenge patent relate tenofovir disoproxil fumarate additional patent relate emtricitabine march file lawsuit teva infringement viread patent additional emtricitabine patent march bristolmyers squibb company merck file lawsuit teva infringement patent relate efavirenz file lawsuit requisite day period provide hatch waxman act stay prevent fda approval teva andas month district court decision adverse patent month stay teva anda expire july april teva reach agreement settle ongoing patent litigation concern patent protect tenofovir disoproxil fumarate atripla truvada viread agreement teva allow launch generic version viread december settlement agreement file federal trade commission department justice require law october court dismissal case pursuant settlement agreement party final trial lawsuit teva relate patent protect emtricitabine atripla truvada hold october february teva reach agreement principle settle ongoing patent litigation concern emtricitabine patent protect atripla truvada term settlement agreement confidential settlement agreement file federal trade commission department justice require law november receive notice teva submit abbreviate new drug submission and canadian minister health request permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate notice teva allege patent associate truvada invalid unenforceable andor infringe teva manufacture use sale generic version truvada january file lawsuit teva federal court canada seek order prohibition approval and december receive notice teva submit and canadian minister health request permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz notice teva allege patent associate atripla merck patent associate atripla invalid unenforceable andor infringe teva manufacture use sale generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz february file lawsuit teva federal court canada seek order prohibition approval and august receive notice teva submit and canadian minister health request permission manufacture market generic version viread notice teva allege patent associate tenofovir disoproxil fumarate invalid unenforceable andor infringe teva manufacture use sale generic version viread truvada atripla september file lawsuit teva federal court canada seek order prohibition approval and august teva file impeachment action federal court canada seek invalidation canadian patent associate viread currently defend impeachment action request order prohibition connection tevas and filing tevas generic version viread truvada atripla consolidated hearing consolidated request order prohibition take place september december court issue request order prohibit canadian ministry health issue notice compliance tevas generic version viread truvada atripla product expiry patent july teva appeal decision decision ultimately resolve validity challenge raise teva impeachment action teva successful invalidating patent teva able launch generic version viread truvada atripla product prior expiry patent trial impeachment action schedule january july receive notice lupin limited lupin submit anda fda request permission manufacture market generic version truvada notice lupin allege patent associate emtricitabine patent associate tenofovir disoproxil fumarate invalid unenforceable andor infringe lupin manufacture use sale generic version fixeddose combination emtricitabine tenofovir disoproxil fumarate august file lawsuit lupin district court southern district new york infringement patent anticipate trial case fourth quarter party appeal decision district court cafc lupin successful invalidate patent lupin able launch generic version truvada product prior expiry patent july receive notice cipla ltd cipla submit anda fda request permission manufacture market generic version emtriva generic version viread notice cipla allege patent associate emtricitabine invalid unenforceable andor infringe cipla manufacture use sale generic version emtricitabine patent associate tenofovir disoproxil fumarate invalid unenforceable andor infringe cipla manufacture use sale generic version tenofovir disoproxil fumarate august file lawsuit cipla district court southern district new york infringement patent anticipate trial case fourth quarter party appeal decision district court cafc cipla successful invalidate patent cipla able launch generic version viread andor emtriva product prior expiry patent october receive notice lupin submit anda fda request permission manufacture market generic version viread notice lupin allege patent associate tenofovir disoproxil fumarate invalid unenforceable andor infringe lupin manufacture use sale generic version tenofovir disoproxil fumarate october file lawsuit lupin district court southern district new york infringement patent anticipate trial case fourth quarter party appeal decision district court cafc lupin successful invalidate patent lupin able launch generic version viread product prior expiry patent ranolazine june receive notice lupin submit anda fda request permission manufacture market generic version sustain release ranolazine notice lupin allege patent associate ranexa invalid unenforceable andor infringe lupin manufacture use sale generic version ranexa july file lawsuit lupin district court district new jersey infringement patent ranexa trial take place april august party reach agreement settle patent litigation prior issuance court decision agreement lupin allow launch generic version ranexa february settlement agreement file federal trade commission department justice require law tamiflu february receive notice natco pharma ltd natco submit anda fda request permission manufacture market generic version tamiflu notice natco allege patent associate oseltamivir phosphate invalid unenforceable andor infringe natco manufacture use sale generic version tamiflu march f hoffmannla roche ltd roche file lawsuit natco district court district new jersey infringement patent associate tamiflu december court issue rule favor gilead roche patent invalid reason state natco notice letter natco appeal decision cafc hear natcos appeal take place january court issue decision appeal natco successful appeal case remand district court district new jersey trial merit predict ultimate outcome action spend significant resource enforce defend patent unsuccessful lawsuit claim patent narrow invalidated patent protection atripla truvada viread emtriva tamiflu united states atripla truvada viread canada substantially shorten patent cover product invalidate fda canadian minister health approve request manufacture generic version products united states canada respectively prior expiration date patent sale generic version product early patent expiration significant negative effect revenue result operation department justice investigation june receive subpoena attorney office northern district california request document relate manufacture relate quality distribution practice complera atripla truvada viread emtriva hepsera letairis cooperating continue cooperate governmental inquiry matter party legal action arise ordinary course business believe legal action material adverse impact consolidate business financial position result operation item safety disclosure applicable ii item market registrant common equity relate stockholder matter issuer purchase equity security common stock trade nasdaq global select market symbol gild follow table set forth high low intraday sale price share common stock nasdaq global select market period indicate price represent quotation dealer adjustment retail markup markdown commission represent price actual transaction high low quarter second quarter quarter fourth quarter quarter second quarter quarter fourth quarter february share common stock outstanding hold approximately stockholder record include share hold broker bank nominee pay cash dividend common stock inception expect retain earning primarily use operation expansion business anticipate pay cash dividend near future performance graph follow graph compare total stockholder return past year index standard poor stock index label sp index nasdaq biotechnology index label nbi index total return index assume reinvestment dividend pay company include index calculate december year composite member sp index nbi index intend use indice comparator stock performance purpose follow graph go forward composite member sp index require applicable regulation use index comparator believe nbi index relevant comparator compose peer company linesofbusiness similar stockholder return show graph necessarily indicative future performance endorse prediction future stockholder return comparison cumulative total return investment past year section soliciting material deem file sec incorporate reference filing securities act exchange act date hereof irrespective general incorporation language filing show cumulative return investment assume investment common stock nbi index sp index december issuer purchase equity security december repurchase billion common stock january threeyear billion stock repurchase program expire september spend total million repurchase retire approximately million share common stock average purchase price share item note stockholder equity consolidated financial statement include annual report information stock repurchase program table summarize stock repurchase activity month end december thousands share amount total number maximum fair share purchase value share publicly purchase total number average price announce share purchase pay share program program october october november november december december total january announce board authorize threeyear billion stock repurchase program expire september difference total number share purchase total number share purchase publicly announce program share common stock withhold employee restrict stock award order satisfy applicable tax withholding obligation item select financial datum gilead sciences inc select consolidated financial datum thousand share datum year end december consolidated statement income datum total revenue total cost expense income operation provision income taxis net income attributable gilead net income share attributable gilead common stockholdersbasic share share calculationbasic net income share attributable gilead common stockholdersdilute share share calculationdilute december consolidated balance sheet datum cash cash equivalent marketable security work capital total asset longterm obligation convertible senior note senior unsecured note credit facility retain earning total stockholder equity record million million stockbase compensation research development rd expense sell general administrative expense respectively relate acquisition pharmasset inc pharmasset record million impairment charge rd expense relate certain inprocess research development iprd asset acquire cgi pharmaceuticals inc record million impairment charge rd expense relate certain iprd asset acquire cv therapeutics inc cv therapeutic certain prior period amount reclassify conform current presentation complete acquisition pharmasset recognize consideration transfer billion primarily record intangible asset finance transaction approximately billion cash hand billion bank debt issue january billion senior unsecured note issue december complete acquisition cv therapeutic recognize consideration transfer billion primarily record intangible asset repay billion principal balance convertible senior note repay million fiveyear revolve credit facility credit agreement fiveyear revolve credit agreement borrow million fiveyear revolve credit agreement issue billion principal senior unsecured note register offering issue billion principal convertible senior note private placement item management discussion analysis financial condition result operation follow management discussion analysis financial condition result operation mda intend help reader understand result operation financial condition mda provide supplement read conjunction audit consolidated financial statement accompany note consolidated financial statement disclosure include annual report include disclosure item risk factor consolidate financial statement prepare accordance generally accept accounting principle present dollar management overview gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery experimental drug candidate strive transform simplify care people lifethreatene illness world gilead primary area focus include human immunodeficiency virus hiv liver disease hepatitis b virus hbv infection hepatitis c virus hcv infection oncologyinflammation cardiovascular respiratory condition headquarter foster city california operations north south america europe asiapacific continue add exist portfolio product internal discovery clinical development program product acquisition inlicense strategy product portfolio comprise stribild compleraeviplera atripla truvada viread emtriva tybost sovaldi hepsera vitekta letairis ranexa cayston ambisome vistide business highlight continue advance product pipeline therapeutic area significant progress particularly phase study oncology liver disease hiv combination exist internal research program acquisition partnership allow continue bring innovative therapy individual live unmet medical need summary key accomplishment expand single tablet regimen str product european launch stribild country receive food drug administration fda european medicines agency ema approval compleraeviplera use certain adult patient switch stable antiretroviral regimen receive ema approval oncedaily tybost pharmacokinetic enhancer boost blood level certain hiv medicine receive ema approval vitekta integrase inhibitor treatment hiv infection adult know mutation associate resistance elvitegravir advanced clinical development tenofovir alafenamide taf oncedaily single tablet regimen treatment hiv infection phase clinical trial receive approval fda health canada december sovaldi sofosbuvir daily oral regimen treatment hcv component combination antiviral treatment regimen receive approval ema sovaldi january announce positive interim result phase clinical study ion ion ion evaluate oncedaily fixeddose combination ledipasvirsofosbuvir ldvsof ribavirin rbv treatment genotype hcv infection file new drug application nda fixeddose combination ldvsof february submit nda fda approval idelalisib treatment patient indolent nonhodgkin lymphoma inhl chronic lymphocytic leukemia cll file approval idelalisib treatment inhl cll ema october january fda accept nda inhl set target review date september prescription drug user fee act pdufa february fda previously grant breakthrough therapy designation idelalisib cll accept nda set target review date august pdufa complete acquisition ym biosciences inc ym acquire momelotinib orally administer oncedaily candidate hematologic cancer advance clinical development momelotinib phase clinical trial outlook continue focus key operating objective include continue progression product pipeline continue uptake commercial product research development rd perspective continue invest ongoing clinical study support exist product pipeline new drug candidate expect forward number latestage clinical study new product candidate plan file marketing application therapeutic area commercial perspective begin buildout commercial organization support launch sovaldi united states canada december january receive approval ema sovaldi countries european union sovaldi represent significant shift treatment paradigm certain hcv patient world plan buildout expansion international commercial infrastructure particularly europe asia support sovaldi launch increase marketing sale effort relate anticipated launch oncology product idelalisib continue monitor condition macroeconomic environment affect ability achieve goal change reimbursement payor landscape legislation delay impact funding aid drug assistance program adap united states worsen economic condition certain key market particularly europe patent expiration competitive product launch generic competitor government pricing pressure internationally potential volatility foreign currency exchange rate adjust business process appropriate attempt mitigate risk business expect product pipeline investment expand commercial infrastructure enable execute operating objective financial highlight deliver strong financial performance continue invest product pipeline total revenue grow billion total product sale grow billion compare drive primarily increase antiviral product sale rd expense increase billion compare progression clinical study particularly phase study oncology liver disease hiv sell general administrative sga expense increase billion compare ongoing growth expansion business include commercial expansion relate launch sovaldi net income attributable gilead billion diluted share compare billion diluted share increase total revenue partially offset increase rd sga expense generate billion operating cash flow pay billion warrant relate note settle august repay billion debt net proceed convertible note hedge utilize million acquisition ym net cash acquire result operation total revenue total revenue include product sale royalty revenue contract revenue total revenue increase billion compare increase billion compare billion product sale represent total revenue total revenue royalty revenue represent total revenue product sale total product sale billion increase total product sale billion drive primarily continue uptake str product primarily stribild compleraeviplera cardiovascular product sale consist letairis ranexa increase million compare million total product sale billion increase total product sale billion drive primarily continue growth sale antiviral product include atripla truvada compleraeviplera product sale united states increase billion compare billion drive sale growth str product specifically stribild complera launch new product sovaldi fourth quarter note strong wholesaler subwholesaler purchase anticipation price increase effective january estimate fourth quarter sale exceed demand approximately million million period base observation quarter result inventory drawdown quarter approximately product sale generate outside united states result face exposure adverse movement foreign currency exchange rate primarily euro foreign currency exchange forward contract hedge percentage foreign currency exposure foreign currency exchange net hedge unfavorable impact million revenue compare unfavorable impact million revenue compare product sale europe increase billion compare billion drive primarily high underlying demand antiviral product specifically eviplera partially offset decrease average net selling price product sale europe increase billion compare billion drive primarily high underlying demand antiviral franchise antiviral product sale europe total billion increase compare billion drive primarily sale atripla truvada foreign currency exchange net hedge unfavorable impact million european product sale compare unfavorable impact million european product sale compare light fiscal debt crisis experience country european union government announce implement measure manage healthcare expenditure date pay rebate country outside united states payment foreign government represent significant portion government rebate chargeback percentage total product sale foreign location continue experience pricing pressure increase discount require product delay reimbursement negatively impact future product sale result operation expect total product sale grow realize year impact sale sovaldi continue uptake commercial product primarily single tablet regimen believe growth temper pricing pressure certain european territory impact generic efavirenz available canada europe potential volatility foreign currency exchange rate change macroeconomic environment government rebate chargeback government rebate chargeback deduct gross product sale increase billion billion increase billion represent total gross product sale total gross product sale march healthcare reform legislation adopt united states require rebate discount product reimburse pay public payer medicaid entity eligible purchase discount product result legislation impact economic downturn total rebate chargeback increase experienced change payer mix specifically believe certain patient previously cover private insurance move public reimbursement program result expect government rebate chargeback percentage total gross product sale continue increase follow table summarize period period change product sale thousand percentage change change antiviral product atripla truvada viread compleraeviplera stribild sovaldi hepsera emtriva total antiviral product letairis ranexa ambisome product total product sale antiviral product antiviral product sale increase compare compare atripla increase atripla sale drive primarily increase average net selling price atripla sale drive primarily sale volume growth united states atripla sale account total antiviral product sale respectively efavirenz component atripla gross margin zero comprise billion billion billion atripla sale respectively generic version bristolmyers squibb company sustiva efavirenz component atripla available canada europe available united states result expect increase competitive pricing pressure future atripla sale truvada decrease truvada sale decrease sale volume partially offset increase average net selling price truvada sale drive primarily sale volume growth united states truvada sale account total antiviral product sale respectively future sale truvada impact patient switch different str regimen compleraeviplera increase compleraeviplera sale drive primarily sale volume growth europe united states compleraeviplera sale increase primarily sale volume growth united states complera approve united states august eviplera approve european union november estimate complera number mostprescribe regimen treatment nave hiv patient united states number mostprescribe regimen treatment nave hiv patients europe big market united kingdom france germany italy spain stribild increase sale stribild drive primarily sale volume growth united states stribild approve united states august europe estimate stribild number mostprescribe regimen treatment nave hiv patient united states sovaldi december fda approve sovaldi treatment hcv sovaldi sale total million estimate approximately half relate initial inventory stocking wholesaler subwholesaler cardiovascular product cardiovascular product include letairis ranexa increase primarily sale volume growth royalty revenue follow table summarize period period change royalty revenue thousand percentage change change royalty revenue royalty revenue increase compare high royalty revenue f hoffmannla roche ltd roche result increase number patient treat influenza tamiflu royalty revenue increase compare drive primarily high royalty revenues glaxosmithkline inc japan tobacco inc astella llc partially offset low tamiflu royalty roche tamiflu royalty roche contribute million million million total royalty revenue respectively recognize royalty tamiflu sale roche quarter follow quarter correspond sale occur cost good sell product gross margin follow table summarize period period change product sale cost good sell product gross margin thousand percentage change change total product sale cost good sell product gross margin product gross margin consistent product gross margin product gross margin fourth quarter include million amortization expense relate transition inprocess research development iprd asset indefinitelive finitelive intangible asset fda approval commercial launch sovaldi expect recognize year impact amortization approximately million related sovaldi research development expense follow table summarize period period change rd expense thousand percentage change change research development track total rd expense product candidate therapeutic area development phase manage rd expense identify rd activity anticipate perform give period prioritize effort base scientific datum probability successful development market potential available human capital resource consideration continually review rd pipeline status development necessary reallocate resource rd product portfolio believe good support future growth business rd expense summarize consist primarily clinical study perform contract research organization cro material supply license fee milestone payment collaboration arrangement personnel cost include salary benefit stockbase compensation overhead allocation consist support facilitiesrelate cost follow table provide breakout rd expense major cost type thousand percentage clinical study outside service personnel infrastructure expense facility cost inprocess research development impairment charge total rd expense increase million compare primarily million increase clinical study million increase personnel infrastructure expense support continue progression clinical study particularly phase study oncology liver disease hiv increase partially offset million decrease stockbase compensation expense acceleration vest stock option relate acquisition pharmasset inc pharmasset january clinical study outside service increase million compare progression expansion phase study particularly liver disease oncology additionally personnel expense increase million high headcount support product pipeline study progression record million impairment charge relate certain iprd asset acquire cgi pharmaceuticals inc impairment charge result change anticipate market share relate spleen tyrosine kinase syk compound expect rd expense increase primarily continue investment advance product pipeline drive primarily progression clinical study oncology liver disease hiv sell general administrative expense follow table summarize period period change sga expense thousand percentage change change sell general administrative sga expense relate sale marketing finance human resource legal administrative activity expense primarily comprise facility overhead cost outside marketing advertising legal expense general administrative cost sga expense increase million compare increase primarily million increase headcountrelate expense support ongoing growth business legal expense pharmaceutical excise tax result healthcare reform increase partially offset million decrease stockbase compensation acceleration vest stock option relate acquisition pharmasset january sequentially sga expense fourth quarter increase million compare quarter primarily increase marketing activity relate launch sovaldi sga expense increase million compare increase primarily million increase cost associate growth business include personnel headcountrelate expense million increase stockbase compensation expense primarily result acquisition pharmasset increase million pharmaceutical excise tax result healthcare reform increase partially offset reduction bad debt provision million include gain million relate sale account receivables balance spain second quarter expect sga expense increase support continue buildout expansion commercial infrastructure europe asia support sovaldi launches increase sale marketing effort relate anticipated launch oncology product idelalisib increase pharmaceutical excise tax estimate portion pharmaceutical excise tax approximately million compare approximately million approximately million interest expense interest expense decrease million compare million decrease primarily repayment note conversion convertible senior note note note repayment revolve credit facility interest expense increase million compare million increase primarily additional debt issue connection acquisition pharmasset include billion senior unsecured note issue december billion bank debt issue january income expense net income expense net net expense million compare net expense million net income million change income expense net primarily million loss greek bond relate greece restructure sovereign debt quarter provision income taxis provision income tax billion billion million respectively effective tax rate differ federal statutory rate primarily retroactive extension federal research tax credit january federal research tax credit certain operating earning nonus subsidiary consider indefinitely reinveste partially offset state taxis portion non tax deductible pharmaceutical excise tax amortization expense relate pharmasset acquisition contingent consideration expense relate certain acquisition receive tax benefit provide income taxis undistribute earning foreign operation intend indefinitely reinveste foreign subsidiary effective tax rate differ federal statutory rate primarily tax credit certain operating earning nonus subsidiary consider indefinitely reinveste partially offset state taxis stockbase compensation expense relate pharmasset acquisition contingent consideration expense relate certain acquisition receive tax benefit effective tax rate differ federal statutory rate primarily tax credit certain operating earning nonus subsidiary consider indefinitely reinveste partially offset state taxis nontax deductible pharmaceutical excise tax future effective tax rate impact factor include amortization certain acquisitionrelate intangible receive tax benefit acquisition ym biosciences inc complete acquisition ym biosciences inc ym base canada total consideration transfer million february time ym whollyowne subsidiary gilead ym drug development company primarily focus advance momelotinib know cyt orally administer oncedaily candidate hematologic cancer fair value acquire asset assume liability include primarily iprd million goodwill million defer tax asset million unrecognized tax benefit defer tax liability million cash acquire million pro forma result operation acquisition ym present acquisition material consolidated result operation note intangible asset goodwill description iprd acquire pharmasset inc january complete acquisition pharmasset publiclyheld clinicalstage pharmaceutical company commit discover develop commercialize novel drug treat viral infection pharmasset primary focus development oral therapeutic treatment hcv infection pharmasset lead compound sofosbuvir know gs nucleotide analog december approve fda health canada sovaldi oncedaily oral regimen treatment hcv patient genotype infection include hepatocellular carcinoma meeting milan criterion await liver transplantation hcvhiv coinfection january european commission grant marketing authorization sovaldi countries european union acquisition pharmasset allow advance effort develop alloral regimen treatment hcv acquire outstanding share common stock pharmasset share cash tender offer subsequent merger term agreement plan merger enter november aggregate cash payment acquire outstanding share common stock billion finance transaction approximately billion cash hand billion senior unsecured note issue december billion bank debt issue january pharmasset acquisition account business combination result operation pharmasset include consolidated statement income january date acquire approximately outstanding share common stock pharmasset cash consideration transfer result obtain effective control pharmasset acquisition complete january time pharmasset whollyowne subsidiary gilead integrate operation track earning result product candidate therapeutic area maintain separate earning result acquire pharmasset business follow table summarize component cash pay acquire pharmasset thousand total consideration transfer stockbase compensation expense total cash pay billion cash payment consist billion cash payment outstanding common stockholder million cash payment option holder pharmasset stock option plan billion cash payment outstanding common stockholder million cash payment vested option holder pharmasset stock option plan account consideration transfer remain million cash payment account stockbase compensation expense result accelerate vest pharmasset employee option immediately prior acquisition follow table summarize acquisition date fair value asset acquire liability assume consideration transfer thousand identifiable intangible asset cash cash equivalent asset acquire liability assume net total identifiable net asset goodwill total consideration transfer identifiable intangible asset acquire intangible asset primarily comprise sofosbuvir iprd compound estimate fair value billion date acquisition fair value determine probabilityweighte income approach discount expect future cash flow present value estimate net cash flow discount discount rate base estimate weightedaverage cost capital company profile similar pharmasset rate comparable estimate internal rate return acquisition represent rate market participant use value intangible asset project cash flow base key assumption estimate revenue operate profit relate project consider stage development acquisition date time resource need complete development approval product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop product candidate obtain marketing approval fda regulatory agency risk related viability potential alternative treatment future target market intangible asset relate iprd project consider indefinitelive asset amortize completion abandonment associate rd effort december follow approval fda commercialization sofosbuvir sovaldi reclassify billion purchase iprd project sofosbuvir indefinitelived finitelive intangible asset amortize asset estimate useful life utilize straightline method goodwill million goodwill represent excess consideration transfer fair value asset acquire liability assume attributable synergy expect combine rd operation pharmasset goodwill expect deductible income tax purpose stockbase compensation expense stockbase compensation expense recognize accelerate vest employee option immediately prior acquisition report consolidated statement income follow thousands year end december research development expense sell general administrative expense total stockbase compensation expense cost cost incur connection acquisition include thousands year end december transaction cost eg investment advisory legal accounting fee bridge financing cost restructure cost total cost follow table summarize cost line item consolidate statement income cost recognize thousands year end december research development expense sell general administrative expense interest expense total cost liquidity capital resource believe exist capital resource supplement cash flow generate operating activity adequate satisfy capital need foreseeable future cash cash equivalent marketable security working capital decrease significantly compare complete acquisition pharmasset january follow table summarize cash cash equivalent marketable security work capital cash flow activity end period present thousand december cash cash equivalent marketable security working capital year end december cash provide operating activity invest activity financing activity certain prior period amount reclassify conform current presentation cash cash equivalent marketable security cash cash equivalent marketable security remain relatively flat billion december compare billion december generate billion operating cash flow pay billion warrant relate note settle august repay billion debt net proceed convertible note hedge utilize million acquisition ym net cash acquire cash cash equivalent marketable security total billion december decrease billion december primarily acquisition pharmasset billion january total cash cash equivalent marketable security december approximately billion generate operation foreign jurisdiction intend use foreign operation rely unrepatriate earning source fund domestic business expect sufficient cash flow borrowing capacity united states fund domestic operational strategic need work capital work capital million december decrease million work capital december increase current portion longterm debt accrue liability partially offset increase account receivable inventory cash cash equivalent work capital billion december decrease billion work capital december primarily attributable billion cash pharmasset acquisition increase shortterm debt billion relate current portion bank debt issue finance pharmasset acquisition current portion note cash provide operating activity cash provide operating activity billion primarily related net income billion adjust noncash item million depreciation amortization expense million stockbase compensation expense partially offset million net cash outflow relate change operate asset liability february collect approximately million past account receivable customer base spain cash provide operating activity billion primarily related net income billion adjust noncash item million depreciation amortization expense million stockbase compensation expense million net cash inflow relate change operate asset liabilitie million tax benefit employee stock plan cash provide operating activity billion primarily related net income billion adjust noncash item million depreciation amortization expense million net cash inflow relate change operate asset liability million stockbase compensation expense cash provide investing activity cash investing activity million consist primarily million acquisition ym net cash acquire million capital expenditure primarily relate construction progress associate new facility headquarters support ongoing growth business partially offset million net proceed sale marketable security cash investing activity billion consist primarily billion acquisition pharmasset net stockbase compensation expense cash acquire million net purchase marketable security million capital expenditure relate primarily purchase office building million million increase construction progress associate new facility headquarters support ongoing growth business cash provide investing activity billion consist billion net proceed relate sale marketable security connection acquisition pharmasset partially offset million acquisition arresto biosciences inc calistoga pharmaceuticals inc million capital expenditure cash provide financing activity cash financing activity billion consist primarily billion repay debt financing include maturity note conversion note note billion warrant relate note settle august million repurchase common stock stock repurchase program cash outflow partially offset proceed billion relate convertible note hedges cash provide financing activity million drive primarily net proceed billion issuance bank debt conjunction pharmasset acquisition proceed million issuance common stock employee stock plan million proceed receive related convertible note hedge cash proceed partially offset billion repay debt financing year million repurchase common stock stock repurchase programs cash provide financing activity billion drive primarily issuance billion senior unsecured note billion raise december partially fund pharmasset acquisition net issuance cost million proceed issuance common stock employee stock plan cash proceed partially offset billion repurchase common stock stock repurchase program million repay convertible senior note debt credit facility bank debt january conjunction acquisition pharmasset enter fiveyear billion revolve credit facility credit agreement year revolve credit agreement million shortterm revolve credit facility credit agreement shortterm revolve credit agreement billion term loan facility term loan credit agreement borrow million fiveyear revolve credit agreement million shortterm revolve credit agreement billion term loan credit agreement close acquisition fully repay billion outstanding debt term loan credit agreement shortterm revolve credit agreement time agreement terminate repay million fiveyear revolve credit agreement fiveyear revolve credit agreement contain customary representation warranty affirmative negative financial maintenance covenant event default loan bear interest eurodollar rate plus applicable margin ii base rate plus applicable margin define credit agreement reduce commitment prepay loan time premium penalty require comply certain covenant credit agreement note indenture december compliance covenant fiveyear revolve credit agreement inclusive million swing line loan subfacility million letter credit subfacility december million letter credit outstanding fiveyear revolve credit agreement fiveyear revolve credit agreement terminate amount owe agreement shall payable january maturity convertible senior note portion note convert remainder note mature repay aggregate principal balance million pay million cash relate conversion spread note represent conversion value excess principal receive million cash convertible note hedge relate note warrant relate note expire august pay billion settle warrant average market price common stock exceed warrant exercise price convertible senior note senior unsecured note portion note note convert repay billion principal balance primarily comprise note pay billion cash relate conversion spread note represent conversion value excess principal receive billion cash convertible note hedge relate note note mature settle related warrant stock price currently exceed conversion warrant exercise price expect base stock price filing form pay approximately billion settle aggregate principal note related warrant follow summary borrowing financing arrangement thousand percentage interest december type borrowing description issue date date rate convertible senior note april convertible senior note july convertible senior note july senior unsecured april note march april senior unsecured december note december december senior unsecured december note december december senior unsecured december note december december senior unsecured december note december december credit facility fiveyear revolver january january variable total debt net current portion total longterm debt net believe exist capital resource supplement cash flow generate operation adequate satisfy capital need foreseeable future consider finance opportunity well position growth term potential financing opportunity factor affect liquidity financial condition future capital requirement depend factor include limited follow commercial performance current future product progress scope rd effort include preclinical study clinical trial cost timing outcome regulatory review expansion sale marketing capability administrative expense possibility acquire additional manufacturing capability office facility possibility acquire company new product cost associate settlement conversion convertible senior note relate warrant establishment additional collaborative relationship company cost associate defense settlement adverse result litigation government investigation future require additional funding form proceed equity debt financing fund require guarantee available favorable term critical accounting policy estimate judgment discussion analysis financial condition result operation base consolidated financial statement prepare accordance generally accept accounting principle preparation financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis evaluate estimate include related revenue recognition allowance doubtful account valuation intangible asset contingent consideration liability result business combination tax provision base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate believe follow critical accounting policy reflect significant judgment estimate preparation consolidated financial statement revenue recognition product sale recognize revenue product sale persuasive evidence arrangement exist delivery customer occur price fix determinable collectability reasonably assure record estimate reduction revenue government rebate medicaid reimbursement customer incentive cash discount prompt payment distributor fee expect return expire product estimate deduct gross product sale time revenue recognize reduction gross product sale government rebate significantly impact report net product sale base certain estimate require complex significant judgment management estimate assess period update reflect current information actual experience accrue government rebate allowance government chargeback estimate reduction revenue governmentmanage medicaid program certain qualify federal state foreign government program reimbursement portion retail price prescription fill cover program reduction settle invoice directly chargeback wholesaler qualified program purchase product wholesaler low contractual government price wholesaler charge difference acquisition cost low contractual government price pay rebate country outside united states date payment foreign government represent significant portion total government rebate estimate government rebate invoice directly record accrue government rebate consolidated balance sheet estimate government rebate charge wholesaler record allowance account receivable consolidated accrue government rebate total million december million december consolidated allowance government chargeback total million december million december record account receivable government program united states rebate allowance estimate base product sell contractual term historical utilization rate estimate population channel inventory datum obtain major wholesaler accordance inventory management agreement consideration new information change program regulation guideline impact actual rebate andor expectation future utilization rate program accrue government rebate total million december million december allowance government chargeback total million december million december record account receivable government rebate chargeback total billion billion represent total gross product sale deduct gross product sale government rebate chargeback total billion represent total gross product sale deduct gross product sale believe methodology use estimate sale allowance government price reduction reasonable appropriate give current fact circumstance actual result future period differ significantly provision affordable care act aca effective extension medicaid drug rebate program patient medicaid manage care insurance plan rebate previously require estimating rebate implementation aca complex delay actual claim datum provide medicaid program amount record reduction increase product sale relate prior period million million million respectively increase product sale million approximately million relate estimate claim rest relate estimate prior year claim result change estimate medicaid manage care rebate base current information available actual government rebate chargeback claim prior period vary estimate follow table summarize aggregate activity government rebate allowance accrue government rebate account thousand balance deduct balance beginning reductionincrease end accrue government rebate allowance government chargeback year product sale accrual year year end december activity relate sale activity relate sale prior total year end december activity relate sale activity relate sale prior total allowance doubtful account maintain allowance doubtful account estimate loss result inability customer require payment allowance base analysis factor include limited contractual payment term historical payment pattern customer individual customer circumstance analysis day sale outstanding geographic region review local economic environment potential impact government funding reimbursement practice financial condition customer economic environment operate deteriorate result inability payment additional allowance require believe allowance doubtful account adequate significant deterioration factor materially change expectation result increase allowance doubtful account december allowance doubtful account million million respectively valuation intangible asset conjunction business combination record intangible asset primarily relate iprd project total intangible asset billion december billion december pharmasset acquisition acquire intangible asset primarily comprise sofosbuvir iprd compound estimate fair value billion date acquisition december follow approval fda commercialization sofosbuvir sovaldi reclassify billion purchase iprd project indefinitelive finite live intangible asset amortize asset estimate useful life utilize straightline method identifiable intangible asset measure respective fair value acquisition date model value intangible asset require use significant estimate assumption include limited estimate revenue operate profit relate product product candidate probability success unapproved product candidate consider stage development time resource need complete development approval product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop product candidate obtain fda regulatory approval risk relate viability potential alternative treatment future target market believe fair value record intangible asset acquire connection business combination base reasonable estimate assumption give fact circumstance relate valuation date intangible asset relate iprd project consider indefinitelive completion abandonment associate rd effort development complete generally occur regulatory approval market product obtain associate asset deem finitelived amortize base respective estimate useful life point time period asset consider indefinitelive amortize test impairment annual basis annual test aware event change indicate likely fair value iprd project respective carrying amount fair value indefinitelive intangible asset dependent assumption expect timing probability achieve specify milestone change project revenue change discount rate significant judgment employ determine assumption change assumption significant impact result operation give period intangible asset finite useful life amortize estimate useful life primarily straightline basis intangible asset finite useful life review impairment fact circumstance suggest carry value asset recoverable valuation contingent consideration liability result business combination conjunction business combination record contingent consideration liability payable achievement specify development regulatory approval salesbase milestone event contingent consideration liability measure respective fair value acquisition date model value contingent consideration liability require use significant estimate assumption include limited estimate revenue operate profit relate product product candidate probability success unapproved product candidate consider stage development time resource need complete development approval product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop product candidate obtain fda regulatory approval risk relate viability potential alternative treatment future target market revalue contingent consideration obligation quarter follow acquisition record increase decrease fair value rd expense consolidated statement income increase decrease fair value contingent consideration liability result update assumption expect timing probability achieve specify milestone change project revenue change discount rate significant judgment employ determine assumption acquisition date subsequent period update assumption significant impact result operation give period actual result differ estimate total contingent consideration liabilitie million december million december tax provision estimate income tax provision include defer tax asset liability base significant management judgment evaluate realization portion defer tax asset quarterly basis record valuation allowance reduce defer tax asset amount likely realize consider future taxable income ongoing tax planning strategy historical financial performance assess need valuation allowance expect realize defer tax asset previously record valuation allowance reduce valuation allowance period determination factor favorable unfavorable effect income tax rate factor include limited interpretation exist tax law change tax law rate portion nontax deductible pharmaceutical excise tax accounting stock option sharebase payment merger acquisition ability manufacture product cork ireland facility amortization certain acquisition relate intangible receive tax benefit expiration federal research tax credit future level rd spending change accounting standard change mix earning tax jurisdiction operate change overall level pretax earning resolution federal state foreign income tax audits impact income tax provision result mention factor significant negative impact net income record liability relate uncertain tax position accordance guidance clarifie accounting uncertainty income taxis recognize enterprise financial statement prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return believe uncertain tax position currently pende material adverse effect consolidated financial statement adverse resolution uncertain tax position period material impact result operation period december total federal state foreign unrecognized tax benefit million million respectively total unrecognized tax benefit million million december respectively recognize reduce effective tax rate period recognition december believe reasonably possible unrecognized tax benefit decrease approximately million month expect clarification irs tax authority uncertain tax position respect remain unrecognized tax benefit currently unable reasonable estimate period cash settlement respective tax authority file federal state foreign income tax return jurisdiction unite states abroad federal income tax purpose statute limitation open onwards certain acquire entity statute limitation open year inception utilization net operating loss credit carry prior year california income tax purpose statute limitation open onwards income tax return audit federal state foreign tax authority currently examination irs tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction periodically evaluate exposure associate tax filing position balance sheet arrangement balance sheet arrangement define item aii regulation sk contractual obligation contractual obligation consist debt obligation operating lease capital commitment purchase obligation active pharmaceutical ingredient inventoryrelate item clinical trial contract follow table summarize significant enforceable legally bind obligation future commitment obligation relate contract likely continue regardless fact certain obligation cancelable december thousands payment period contractual obligation total year year year year debt operating lease obligation capital commitment purchase obligation clinical trial total debt obligation include convertible senior note senior unsecured note fiveyear revolve credit agreement incur future interest payment base fix rate note note respectively senior unsecured note december december april december december respectively fiveyear revolve credit agreement incur interest base variable interest rate portion interest expense relate variable interest total million december firm capital project commitment approximately million primarily relate facility improvement project december firm purchase commitment relate active pharmaceutical ingredient certain inventoryrelate item amount include minimum purchase requirement actual purchase expect significantly exceed amount addition commit potential future milestone payment party license collaboration development arrangement payment agreement generally payable achievement certain developmental regulatory andor commercial milestone achievement milestone probable reasonably estimable contingency record consolidated balance sheet include table december clinical study clinical trial phase significant clinical trial expenditure cro material contract cro cancelable historically cancel contract amount reflect commitment base exist contract reflect future modification termination exist contract anticipate potential new contract total gross unrecognized tax benefit liability million december believe reasonably possible unrecognized tax benefit decrease approximately million month expect clarification irs tax authority uncertain tax position respect remain unrecognized tax benefit currently unable reasonable estimate period cash settlement respective tax authority unrecognize tax benefit include current longterm income taxis payable longterm defer tax asset consolidate balance sheet include table recent accounting pronouncement february financial accounting standard board fasb issue update exist standard liability update provide guidance recognition measurement disclosure obligation result joint liability arrangement obligation total fix reporting date entity require measure obligation sum reporting entity agree pay basis arrangement coobligor additional report entity expect pay behalf coobligor entity require disclose nature significant information obligation guidance effective begin quarter believe adoption update material impact consolidate financial statement july fasb issue update relate presentation unrecognize tax benefit net operating loss carryforward similar tax loss tax credit carryforward exist unrecognized tax benefit portion unrecognized tax benefit present financial statement reduction defer tax asset net operating loss carryforward similar tax loss tax credit carryforward follow extent net operating loss carryforward similar tax loss tax credit carryforward available reporting date tax law applicable jurisdiction settle additional income taxis result disallowance tax position tax law applicable jurisdiction require entity use entity intend use defer tax asset purpose unrecognized tax benefit present financial statement liability combine defer tax asset guidance effective begin quarter believe adoption update material impact consolidate financial statement item quantitative qualitative disclosure market risk expose market risk result change foreign currency exchange rate interest rate credit risk reduce certain risk enter type foreign currency interest rate derivative hedging transaction follow investment guideline monitor outstanding receivables risk management program foreign currency exchange risk operation include manufacture sale activity united states canada ireland sale activity country outside united states include europe asia pacific result financial result significantly affect factor change foreign currency exchange rate weak economic condition foreign market distribute product operating result expose change foreign currency exchange rate dollar foreign currency significant euro dollar strengthen currency relative value sale respective foreign currency decrease conversely dollar weaken currency relative amount sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business approximately product sale denominate foreign currency partially mitigate impact change currency exchange rate net cash flow foreign currency denominate sale enter foreign currency exchange forward option contract hedge certain monetary asset liability denominate foreign currency reduce eliminate exposure currency fluctuation date transaction record date cash collect pay general market risk contract offset correspond gain loss transaction hedge december open foreign currency forward contract notional amount billion billion respectively hypothetical adverse movement foreign currency exchange rate compare dollar relative exchange rate december resulted reduction fair value contract approximately million date realize negatively affect earning remain life contract hypothetical movement foreign currency exchange rate compare dollar relative exchange rate december resulted reduction fair value contract approximately million date realize negatively affect earning remain life contract analysis consider impact hypothetical change foreign currency exchange rate anticipated transaction foreign currency sensitive instrument design offset interest rate risk portfolio availableforsale marketable security fix variable rate liability create exposure interest rate risk respect investment portfolio adhere investment policy require limit amount invest security base credit rating maturity industry group investment type issuer security issue government goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return follow table summarize expect maturity average interest rate interestgenerate asset fix interestbeare liability december thousands percentage expect maturity total fair value december total asset available forsale debt security average interest rate liabilitie debt average interest rate december issue senior unsecured note december register offering note pay interest fix annual rate range march issue senior unsecured note april register offering note pay interest fix annual rate july issue convertible senior note note note private placement pursuant rule securities act amend note note issue par bear interest rate respectively convert share common stock subject certain circumstance connection acquisition pharmasset enter credit agreement subject variable interest rate portion interest expense relate variable interest total million credit risk subject credit risk portfolio cash equivalent marketable security investment policy limit amount invest security credit rating maturity industry group investment type issuer security issue government expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return subject credit risk account receivable relate product sale majority trade account receivable arise product sale united states europe second quarter receive payment million past account receivable customer base spain include proceed onetime factoring arrangement sell receivables carry value million net allowance doubtful account receive proceed million record gain million result primarily reversal relate allowance doubtful account gain record offset sga expense consolidate statement income subsequent transaction continue involvement transfer receivables derecognize time sale december account receivable southern europe specifically greece italy portugal spain total approximately million million great day past million great day past december account receivable southern europe specifically greece italy portugal spain total approximately million million great day past million great day past date experience significant loss respect collection account receivable believe allowance doubtful account adequate december item financial statement supplementary datum financial statement require item set forth begin annual report incorporate reference item change disagreement accountant account financial disclosure applicable item control procedure evaluation disclosure control procedure evaluation december carry supervision participation management include chief executive officer chief financial officer effectiveness disclosure control procedure define rule ae securities exchange act amended exchange act control procedure company design ensure information require disclose company report file submit exchange act record process summarize report time period specify securities exchange commission rule form information accumulate communicate company management include chief executive officer chief financial officer appropriate allow timely decision require disclosure base evaluation chief executive officer chief financial officer conclude disclosure control procedure effective december b management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule af exchange act internal control system design provide reasonable assurance preparation fair presentation financial statement external purpose accordance generally accept accounting principle internal control system matter design inherent limitation provide reasonable assurance objective internal control system meet supervision participation management include chief executive officer chief financial officer conduct evaluation effectiveness internal control financial reporting base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission framework coso criterion base evaluation conclude internal control financial reporting effective december independent register public accounting firm ernst young llp audit consolidated financial statement include annual report issue report internal control financial reporting december report audit internal control financial reporting appear c change internal control financial reporting management include chief executive officer chief financial officer evaluate change internal control financial reporting occur quarter end december conclude change quarter materially affect reasonably likely materially affect internal control financial reporting report independent register public accounting firm board director stockholder gilead sciences inc audit gilead sciences inc internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission framework coso criterion gilead sciences inc management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle company internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion gilead sciences inc maintain material respect effective internal control financial reporting december base coso criterion audit accordance standard public company accounting oversight board united states consolidated financial statement gilead sciences inc report date february express unqualified opinion thereon ernst young llp redwood city california february item b information applicable iii item director executive officer corporate governance information require item concern director executive officer incorporate reference section definitive proxy statement file securities exchange commission pursuant regulation connection annual meeting stockholder proxy statement heading nominee board committee meeting executive officer section beneficial ownership reporting compliance write code ethic apply director employee include executive officer include limitation principal executive officer principal financial officer principal accounting officer controller person perform similar function code ethic available website httpwwwgileadcom investor section corporate governance change waiver code ethic disclose website intend satisfy disclosure requirement item form k amendment waiver provision code ethic disclose information website item executive compensation information require item incorporate reference section proxy statement heading executive compensation compensation committee interlock insider participation compensation committee report compensation nonemployee board member item security ownership certain beneficial owner management relate stockholder matter information require item incorporate reference section proxy statement heading security ownership certain beneficial owner management security authorize issuance equity compensation plan item certain relationship relate transaction director independence information require item incorporate reference section proxy statement heading nominee certain relationship relate party transaction item principal accountant fee service information require item incorporate reference section proxy statement head principal accountant fee service iv item exhibit financial statement schedule follow document file annual report index list consolidate financial statement report independent register public accounting firm audit consolidated financial statement consolidate balance sheet consolidate statement income consolidate statement comprehensive income consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement schedule ii include report schedule omit require require information include financial statement note thereto exhibit follow exhibit file herewith incorporate reference item exhibit exhibit footnote exhibit number description document agreement plan merger registrant apex merger sub inc cv therapeutics inc date march agreement plan merger registrant merger sub pharmasset inc date november arrangement agreement registrant nova scotia limited ym biosciences inc date december restate certificate incorporation registrant amendment certificate incorporation registrant amend restate bylaw registrant amend restate reference exhibit exhibit indenture relate convertible senior note note registrant wells fargo bank national association trustee include form convertible senior note date april indenture relate convertible senior note note registrant wells fargo bank national association trustee include form convertible senior note date july indenture relate convertible senior note note registrant wells fargo bank national association trustee include form convertible senior note date july indenture relate senior note date march registrant wells fargo national association trustee supplemental indenture relate senior note date march registrant wells fargo national association trustee include form senior note second supplemental indenture relate senior note date december registrant wells fargo national association trustee include form note form note form note form note confirmation otc convertible note hedge relate note date april amend restate april registrant bank america na confirmation otc warrant transaction date april amend restate april registrant bank america na warrants expire confirmation otc convertible note hedge relate note date july registrant goldman sachs co confirmation otc convertible note hedge relate note date july registrant jpmorgan chase bank national association confirmation otc convertible note hedge relate note date july registrant goldman sachs co confirmation otc convertible note hedge relate note date july registrant jpmorgan chase bank national association confirmation otc warrant transaction date july registrant goldman sach co warrant expire confirmation otc warrant transaction date july registrant jpmorgan chase bank national association warrants expire confirmation otc warrant transaction date july registrant goldman sach co warrant expire confirmation otc warrant transaction date july registrant jpmorgan chase bank national association warrants expire confirmation otc additional convertible note hedge relate note date august registrant goldman sachs co confirmation otc additional convertible note hedge relate note date august registrant jpmorgan chase bank national association confirmation otc additional convertible note hedge relate note date august registrant goldman sachs co confirmation otc additional convertible note hedge relate note date august registrant jpmorgan chase bank national association confirmation otc additional warrant transaction date august registrant goldman sach co warrant expire confirmation otc additional warrant transaction date august registrant jpmorgan chase bank national association warrants expire confirmation otc additional warrant transaction date august registrant goldman sach co warrant expire confirmation otc additional warrant transaction date august registrant jpmorgan chase bank national association warrants expiring amendment confirmation otc convertible note hedge relate note date august registrant goldman sachs co amendment confirmation otc convertible note hedge relate note date august registrant jpmorgan chase bank national association amendment confirmation otc convertible note hedge relate note date august registrant goldman sachs co amendment confirmation otc convertible note hedge relate note date august registrant jpmorgan chase bank national association amendment confirmation otc additional convertible note hedge relate note date august registrant goldman sachs co amendment confirmation otc additional convertible note hedge relate note date august registrant jpmorgan chase bank national association amendment confirmation otc additional convertible note hedge relate note date august registrant goldman sachs co amendment confirmation otc additional convertible note hedge relate note date august registrant jpmorgan chase bank national association year revolve credit facility credit agreement registrant gilead biopharmaceutics ireland corporation borrowers bank america na administrative agent swing line lender lc issuer certain lender party thereto barclays capital syndication agent goldman sachs bank usa jpmorgan chase bank na royal bank canada wells fargo bank na codocumentation agent date january parent guaranty agreement year revolve credit facility date january registrant gilead sciences inc equity incentive plan amend form employee stock option agreement equity incentive plan grant prior february form employee stock option agreement equity incentive plan grant february april form employee stock option agreement equity incentive plan grant commencing form employee stock option agreement equity incentive plan grant commence february form employee stock option agreement equity incentive plan subsequent year grant form nonemployee director stock option agreement equity incentive plan grant prior form nonemployee director option agreement equity incentive plan initial grant form nonemployee director option agreement equity incentive plan annual grant form nonemployee director option agreement equity incentive plan annual grant commencing form nonemployee director option agreement equity incentive plan annual grant form nonemployee director option agreement nonus equity incentive plan annual grant form restrict stock unit issuance agreement equity incentive plan annual grant nonemployee director form restrict stock award agreement equity incentive plan annual grant certain nonemployee director prior form restrict stock unit issuance agreement equity incentive plan annual grant nonemployee director commence form restrict stock unit issuance agreement nonus equity incentive plan annual grant non employee director commence form performance share award agreement equity incentive plan grant certain executive officer form performance share award agreement equity incentive plan grant certain executive officer form performance share award agreement equity incentive plan grant certain executive officer form performance share award agreement equity incentive plan grant certain executive officer form performance share award agreement equity incentive plan tsr goal form performance share award agreement equity incentive plan revenue goal form restrict stock unit issuance agreement equity incentive plan grant certain executive officer prior form restrict stock unit issuance agreement equity incentive plan grant certain executive officer commence form restrict stock unit issuance agreement equity incentive plan servicebase vest certain executive officer commence november form restrict stock unit issuance agreement equity incentive plan servicebase vest certain executive officer commence gilead sciences inc employee stock purchase plan amend restate gilead sciences inc international employee stock purchase plan amend restate gilead sciences inc defer compensation planbasic plan document gilead sciences inc defer compensation planadoption agreement addendum gilead sciences inc defer compensation plan gilead sciences inc defer compensation plan amend restate october gilead sciences inc severance plan amend january gilead sciences inc corporate bonus plan amend restate gilead sciences inc code section bonus plan base salary name executive officer offer letter date april registrant robin washington form indemnity agreement enter registrant director executive officer form employee proprietary information invention agreement enter registrant certain officer key employee form employee proprietary information invention agreement enter registrant certain officer key employee revise september amend restate collaboration agreement registrant gilead holding llc bristolmyers squibb company er squibb son llc bristolmyers squibb gilead sciences llc date september commercialization agreement gilead sciences limited bristolmyers squibb company date december amendment agreement date october registrant institute organic chemistry biochemistry iocb rega stichting vzw rega follow exhibit license agreement date december registrant iocb rega license agreement license agreement date october registrant iocb rega october license agreement license agreement date december registrant iocb rega december license agreement amendment agreement registrant iocbrega date december amend license agreement december license agreement sixth amendment agreement license agreement iocbrega registrant date august amend october license agreement december license agreement seventh amendment agreement license agreement iocbrega registrant date july amend october license agreement december license agreement development license agreement registrant f hoffmannla roche ltd hoffmannla roche inc date september amendment supplement date november development licensing agreement registrant f hoffmannla roche ltd hoffmanla roche inc date september second amendment date december development licensing agreement registrant f hoffmannla roche ltd hoffmanla roche inc date september amendment date october development licensing agreement registrant f hoffmannla roche ltd hoffmanla roche inc date september exclusive license agreement registrant successor triangle pharmaceuticals inc glaxo group limited wellcome foundation limited glaxo wellcome inc emory university date royalty sale agreement registrant emory university investor trust custodial service ireland limit solely capacity trustee royalty pharma date july amend restate license agreement registrant emory university investor trust custodial service ireland limit solely capacity trustee royalty pharma date july license agreement japan tobacco inc registrant date march amendment license agreement japan tobacco inc registrant date second amendment license agreement japan tobacco inc registrant date amendment license agreement japan tobacco inc registrant date july fourth amendment license agreement japan tobacco inc registrant date july fifth amendment license agreement japan tobacco inc registrant date october license agreement registrant successor myogen inc abbott deutschland holding gmbh date october license agreement registrant successor myogen inc glaxo group limit date march license agreement registrant successor cv therapeutics inc roche palo alto llc successor interest merger syntex usa inc date march amendment license agreement registrant successor cv therapeutics inc roche palo alto llc successor interest merger syntex usa inc date july amendment license agreement registrant successor cv therapeutics inc roche palo alto llc successor interest merger syntex usa inc date november amendment license agreement registrant successor cv therapeutics inc roche palo alto llc successor interest merger syntex usa inc date june amendment license agreement registrant successor cv therapeutics inc roche palo alto llc successor interest merger syntex usa inc date december license collaboration agreement registrant gilead sciences limited janssen rd ireland tibotec pharmaceutical date july second amendment license collaboration agreement registrant gilead sciences limited janssen rd ireland tibotec pharmaceutical date july amend restate second amendment license collaboration agreement registrant gilead sciences limited janssen rd ireland tibotec pharmaceutical date february master clinical commercial supply agreement gilead world market limited registrant patheon inc date january restate amend toll manufacturing agreement gilead sciences limited registrant takeda gmbh nycome gmbh altana pharma oranienburg gmbh date november emtricitabine manufacturing supply agreement gilead sciences limit evonik degussa gmbh know degussa ag date june amendment emtricitabine manufacture supply agreement gilead sciences limit evonik degussa gmbh know degussa ag date april purchase sale agreement joint escrow instruction electronics imaging inc registrant date july amendment date october purchase sale agreement joint escrow instruction electronics imaging inc registrant date july subsidiary registrant consent independent register public accounting firm power attorney reference signature certification chief executive officer require rule aa rule da securities exchange act amend certification chief financial officer require rule aa rule da securities exchange act amend certification chief executive officer chief financial officer require rule ab rule db section chapter title united states code usc follow material registrant annual report year end december format extensible business report language xbrl include consolidated balance sheet december ii consolidated statement income year end december iii consolidated statement comprehensive income year end december iv consolidate statement stockholder equity year end december v consolidate statement cash flow year end december vi note consolidated financial statement file exhibit registrant current report form k file march incorporate reference file exhibit registrant current report form k file november incorporate reference file exhibit ym biosciences inc report form k file december incorporate reference file exhibit registrant current report form k file incorporate reference file exhibit registrant current report form k file incorporate reference file exhibit registrant current report form k file april incorporate reference file exhibit registrant current report form k file august incorporate reference file exhibit registrant current report form k file april incorporate reference file exhibit registrant current report form k file december incorporate reference file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant quarterly report form q quarter end september incorporate reference file exhibit registrant current report form k file january incorporate reference file exhibit registrant current report form ka file february incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant quarterly report form q quarter end march incorporate reference file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant quarterly report form q quarter end march incorporate reference file exhibit registrant quarterly report form q quarter end march incorporate reference file exhibit registrant current report form k file december incorporate reference file exhibit registrant quarterly report form q quarter end march incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference information include registrant current report form k file february incorporate reference file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant registration statement form amend incorporate reference file exhibit registrant quarterly report form q quarter end september incorporate reference file exhibit registrant annual report fiscal year end march incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant quarterly report form q quarter end september incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit triangle pharmaceuticals inc quarterly report form qa file november incorporate reference file exhibit registrant quarterly report form q quarter end september incorporate reference file exhibit registrant quarterly report form q quarter end march incorporate reference file exhibit registrant quarterly report form q quarter end september incorporate reference file exhibit myogen inc registration statement form amend originally file august incorporate reference file exhibit myogen inc quarterly report form q file incorporate reference file exhibit cv therapeutics inc registration statement form amend originally file april incorporate reference file exhibit cv therapeutics inc quarterly report form q quarter end june incorporate reference file exhibit registrant quarterly report form q quarter end september incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant quarterly report form q quarter end september incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference agreement plan merger merger agreement contain representation warranty registrant apex merger sub inc cv therapeutics inc solely specific date representation warranty solely purpose merger agreement subject important qualification limitation agree registrant apex merger sub inc cv therapeutics inc representation warranty accurate complete specify date subject standard materiality provide merger agreement purpose allocate risk registrant apex merger sub inc cv therapeutics inc establish matter fact agreement plan merger pharmasset merger agreement contain representation warranty registrant merger sub pharmasset inc solely specific date representation warranty solely purpose pharmasset merger agreement subject important qualification limitation agree registrant merger sub pharmasset inc representation warranty accurate complete specify date subject standard materiality provide pharmasset merger agreement purpose allocate risk registrant merger sub pharmasset inc establish matter fact management contract compensatory plan arrangement certification accompanie form q relate deem file security exchange commission incorporate reference file registrant security act amend securities exchange act amend date form q irrespective general incorporation language contain filing xbrl information file herewith certain confidential portion exhibit omit mean mark portion asterisk mark exhibit file separately secretary securities exchange commission mark pursuant registrant application request confidential treatment rule b securities exchange act amend gilead sciences inc consolidated financial statement year end december content report independent register public accounting firm audit consolidated financial statement consolidate balance sheet consolidate statement income consolidate statement comprehensive income consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement report independent register public accounting firm board director stockholder gilead sciences inc audit accompany consolidated balance sheet gilead sciences inc december relate consolidated statement income comprehensive income stockholder equity cash flow year period end december audits include financial statement schedule list index item financial statement schedule responsibility company management responsibility express opinion financial statement schedule base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statement refer present fairly material respect consolidate financial position gilead sciences inc december consolidate result operation cash flow year period end december conformity generally accept accounting principle opinion relate financial statement schedule consider relation basic financial statement take present fairly material respect information set forth audit accordance standard public company accounting oversight board united states gilead sciences inc internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission framework coso criterion report date february express unqualified opinion thereon ernst young llp redwood city california february gilead sciences inc consolidated balance sheet thousand share amount december asset current asset cash cash equivalent shortterm marketable security account receivable net allowance december december inventory defer tax asset prepay taxis prepaid expense current asset total current asset property plant equipment net longterm portion prepay royalty longterm defer tax asset longterm marketable security intangible asset net goodwill longterm asset total asset liability stockholder equity current liability account payable accrue government rebate accrue compensation employee benefit income taxis payable accrue liability defer revenue current portion longterm debt obligation net total current liability longterm defer revenue longterm debt net longterm income taxis payable longterm defer tax liability longterm obligation commitment contingency note equity component currently redeemable convertible note note stockholder equity prefer stock par value share share authorize outstanding common stock par value share share authorize december december share issue outstanding december december additional paidin capital accumulate comprehensive loss retain earning total gilead stockholder equity noncontrolle interest total stockholder equity total liability stockholder equity common stock share additional paidin capital period present reflect twoforone stock split form stock dividend take effect january accompany note gilead sciences inc consolidated statement income thousand share amount year end december revenue product sale royalty revenue contract revenue total revenue cost expense cost good sell research development expense sell general administrative expense total cost expense income operation interest expense income expense net income provision income taxis provision income taxis net income net loss attributable noncontrolle interest net income attributable gilead net income share attributable gilead common stockholdersbasic share share calculationbasic net income share attributable gilead common stockholdersdilute share share calculationdilute accompany note gilead sciences inc consolidated statement comprehensive income thousand year end december net income comprehensive income loss net foreign currency translation gain loss net tax availableforsale security net unrealize gain loss net tax impact reclassification net income net tax impact net change cash flow hedge net unrealized gain loss net tax impact reclassification net income net tax impact net change comprehensive income loss comprehensive income comprehensive loss attributable noncontrolle interest comprehensive income attributable gilead accompany note gilead sciences inc consolidated statement stockholder equity thousand gilead stockholder equity common stock accumulate additional total paidin comprehensive retain noncontrolle stockholder share capital income loss earning interest equity balance december distribution noncontrolle interest net income loss comprehensive income issuance employee stock purchase plan issuance equity incentive plans tax benefit employee stock plan stockbase compensation repurchase common stock convertible note settlement convertible notes hedge settlement balance december contribution noncontrolle interest net income loss comprehensive loss issuance employee stock purchase plan issuance equity incentive plan tax benefit employee stock plan stockbase compensation repurchase common stock convertible note settlement convertible notes hedge settlement reclassification equity component currently redeemable convertible note balance december contribution noncontrolle interest net income loss comprehensive loss issuance employee stock purchase plan issuance equity incentive plan tax benefit employee stock plan stockbase compensation repurchase common stock warrant settlement convertible note settlement convertible notes hedge settlement reclassification equity component currently redeemable convertible note balance december common stock share additional paidin capital period present reflect twoforone stock split form stock dividend take effect january accompany note gilead sciences inc consolidated statement cash flow thousands year end december operating activity net income adjustment reconcile net income net cash provide operating activity depreciation expense amortization expense stockbase compensation expense inprocess research development impairment charge excess tax benefit stockbase compensation tax benefit employee stock plan defer income taxis change fair value contingent consideration change operate asset liability account receivable net inventory prepaid expense asset account payable income taxis payable accrue liability defer revenue net cash provide operating activity invest activity purchase marketable security proceed sale marketable security proceed maturitie marketable security purchase investment acquisition net cash acquire capital expenditure net cash provide investing activity financing activity proceed debt finance net issuance cost proceed convertible note hedge proceed issuance common stock repurchase common stock repayment debt financing payment settle warrant repayment longterm obligation excess tax benefit stockbase compensation contribution distribution noncontrolle interest net cash provide financing activity effect exchange rate change cash net change cash cash equivalent cash cash equivalent begin period cash cash equivalent end period supplemental disclosure cash flow information interest pay net amount capitalize income taxis pay accompany note gilead sciences inc note consolidated financial statement organization summary significant accounting policy overview gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery experimental drug candidate strive transform simplify care people lifethreatene illness world gilead primary area focus include human immunodeficiency virus hiv liver disease hepatitis b virus hbv infection hepatitis c virus hcv infection oncologyinflammation cardiovascular respiratory condition continue add exist portfolio product internal discovery clinical development program product acquisition licensing strategy product portfolio comprise stribild compleraeviplera atripla truvada viread emtriva tybost sovaldi hepsera vitekta letairis ranexa cayston ambisome vistide international commercial sale operation marketing subsidiary north south america europe asiapacific addition sell distribute certain product corporate partner royaltypaye collaborative agreement basis presentation accompany consolidated financial statement include account gilead whollyowne subsidiary joint ventures bristolmyers squibb company bms primary beneficiary record noncontrolle interest consolidated financial statement reflect bms interest joint venture intercompany transaction eliminate consolidated financial statement include result company acquire date acquisition applicable reporting period january complete twoforone stock split form stock dividend stockholders record january declare december accordingly share share amount period present consolidated financial statement note adjust retroactively reflect stock split additionally certain prior period amount consolidated financial statement relate note reclassify conform current presentation significant accounting policy estimate judgment preparation consolidated financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis management evaluate significant accounting policy estimate base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate estimate assess period update reflect current information actual experience revenue recognition product sale recognize revenue product sale persuasive evidence arrangement exist delivery customer occur price fix determinable collectability reasonably assure recognition revenue product sale provision government rebate medicaid reimbursement customer incentive cash discount prompt payment distributor fee expect return expire product appropriate item deduct gross product sale government rebate chargeback estimate reduction revenue governmentmanage medicaid program certain qualify federal state foreign government program estimate consideration contractual term historical utilization rate available new information change program regulation guideline impact actual rebate expectation future utilization rate program product sale channel inventory datum obtain major wholesaler accordance inventory management agreement government rebate invoice directly record accrue government rebate consolidated balance sheet qualified program purchase product wholesaler low contractual government price wholesaler charge difference acquisition cost low contractual government price record allowance account receivable cash discount estimate cash discount base contractual term historical utilization rate available expectation future utilization rate distributor fee inventory management agreement significant wholesaler pay wholesaler fee primarily compliance certain contractually determine covenant maintenance agree inventory level distributor fee base contractually determine fix percentage sale product return provide customer general right product return typically permit return product damage defective receive customer case product sell united states certain country outside united states product expire accept return product expire month expire year expiration date estimate expect return expire product base primarily ongoing analysis historical return pattern royalty revenues royalty revenue sale product generally recognize receive generally quarter follow quarter correspond sale occur royalty revenue sale lexiscan ambisome astella llc astella pharma inc respectively recognize month follow month correspond sale occur contract revenue revenue nonrefundable upfront license fee milestone payment development collaboration obligation supply product recognize performance occur obligation complete accordance specific term obligation arrangement revenue recognize obligation fulfil ratably development manufacturing period revenue associate substantive atrisk milestone recognize base achievement milestone set forth respective agreement advance payment receive excess amount earn classified defer revenue consolidated balance sheet shipping handle cost shipping handling cost incur inventory purchase product shipment record cost good sell consolidated statement income research development expense research development rd expense consist primarily personnel cost include salary benefit stockbase compensation clinical study perform contract research organization cro material supply license fee milestone payment collaboration arrangement overhead allocation consist support facilitiesrelate cost charge rd cost include clinical study cost expense incur clinical study cost significant component rd expense clinical study perform thirdparty cro monitor level performance significant contract include extent patient enrollment activity communication cro accrue cost clinical study perform cro service period specify contract adjust estimate require base ongoing review level effort cost actually incur cro material cro contract terminable write notice generally liable actual service complete cro certain noncancelable expense incur point termination amount pay advance relate uncompleted service refund contract terminate advertising expense expense cost advertising include promotional expense incur advertising expense million million million stockbased compensation utilize share base compensation form type equitybase award include restrict stock unit rsus performance unit stock option compensation expense recognize consolidated statement income base estimate fair value grant date estimate fair value rsus base closing price common stock performance unit award base monte carlo valuation methodology stock price date grant stock option award base blackschole option valuation model cash cash equivalent consider highly liquid investment insignificant interest rate risk original maturity month purchase date cash equivalent eligible instrument investment policy include cash equivalent include commercial paper money market fund overnight repurchase agreement repos major bank authorize dealer bank obligation marketable nonmarketable security determine appropriate classification marketable security consist primarily debt security variable rate demand obligation time purchase reevaluate designation balance sheet date marketable security consider availableforsale carry estimate fair value report cash equivalent shortterm marketable security longterm marketable security unrealize gain loss availableforsale security exclude net income report accumulate comprehensive income loss separate component stockholder equity income expense net include interest dividend amortization purchase premium discount realize gain loss sale security otherthantemporary decline fair value security cost security sell base specific identification method regularly review investment otherthantemporary decline fair value review include consideration cause impairment include creditworthiness security issuer number security unrealize loss position severity duration unrealize loss intent sell security likely require sell security recovery amortize cost basis determine decline fair value investment accounting basis decline otherthantemporary reduce carry value security hold record loss decline result enter collaboration time time hold investment nonpublic company record nonmarketable security cost longterm asset amount otherthantemporary impairment regularly review security indicator impairment investment nonmarketable security material period present concentration risk subject credit risk portfolio cash equivalent marketable security investment policy limit amount invest security credit rating maturity industry group investment type issuer security issue government expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return subject credit risk account receivable relate product sale majority trade account receivable arise product sale united states europe receive payment million past account receivable customer base spain include proceed onetime factoring arrangement sell receivables carry value million net allowance doubtful account receive proceed million record gain million result primarily reversal relate allowance doubtful account gain record offset sell general administrative sga expense consolidate statement income subsequent transaction continue involvement transfer receivables derecognize time sale december account receivable southern europe specifically greece italy portugal spain total approximately million million great day past million great day past date experience significant loss respect collection account receivable believe allowance doubtful account adequate december certain raw material component utilize operation obtain single supplier certain raw material utilize operation facility supplier key component raw material name new drug application nda file food drug administration fda product significant delay occur qualification new supplier require delivery material supplier interrupt reason unable ship commercial product supply product candidate clinical trial account receivable trade account receivable record net allowance wholesaler chargeback relate government rebate program cash discount prompt payment sale return doubtful account estimate wholesaler chargeback government rebate cash discount sale return base contractual term historical trend expectation utilization rate program estimate allowance doubtful account determine base exist contractual payment term historical payment pattern customer individual customer circumstance analysis day sale outstanding geographic region review local economic environment potential impact government funding reimbursement practice historically amount uncollectible account receivable write insignificant consistent management expectation inventory inventory record low cost market cost determine firstin firstout basis periodically review composition inventory order identify obsolete slowmoving unsaleable item unsaleable item observe alternate use inventory record writedown net realizable value period impairment recognize future commercialization consider probable future economic benefit expect realize base management judgment capitalize prelaunch inventory cost prior regulatory approval number factor take consideration include current status regulatory approval process potential impediment approval process safety efficacy anticipate research development initiative impact indication compound viability commercialization marketplace trend december prelaunch inventory consolidate balance sheet significant property plant equipment property plant equipment state cost accumulate depreciation amortization depreciation amortization recognize straight line method repair maintenance cost expense incur estimate useful life year follow description estimate useful life building improvement laboratory manufacturing equipment office computer equipment leasehold improvement short useful life lease term office computer equipment include capitalize software unamortize capitalize software cost consolidate balance sheet million december million december leasehold improvement capitalize lease equipment amortize short lease term asset useful life amortization capitalize lease equipment include depreciation expense capitalize interest construction inprogress include property plant equipment interest capitalize significant goodwill intangible asset goodwill represent excess consideration transfer estimate fair value asset acquire liability assume business combination intangible asset indefinite useful life relate purchase inprocess research development iprd project measure respective fair value acquisition date amortize goodwill intangible asset indefinite useful live intangible asset relate iprd project consider indefinitelive completion abandonment associate rd effort development complete generally occur regulatory approval market product obtain associate asset deem finitelived amortize base respective estimate useful life point time test goodwill indefinitelive intangible asset impairment annual basis annual test aware event change indicate likely fair value asset carry amount intangible asset finite useful life amortize estimate useful life primarily straightline basis review impairment fact circumstance suggest carry value asset recoverable impairment longlive asset carry value longlive asset review regular basis existence fact circumstance internally externally suggest impairment specific potential indicator impairment include significant decrease fair value asset significant change extent manner asset significant physical change asset significant adverse change legal factor business climate affect value asset adverse action assessment fda regulator accumulation cost significantly excess originally expect acquire construct asset operate cash flow loss combine history operate cash flow loss projection forecast demonstrate continue loss associate income produce asset indication impairment test recoverability compare estimate undiscounted future cash flow expect result use asset asset group eventual disposition carry asset asset group excess carrying value asset asset group estimate fair value recognize impairment loss valuation contingent consideration result business combination connection certain acquisition require pay future consideration contingent achievement specify development regulatory approval salesbase milestone event record contingent consideration result business combination fair value acquisition date quarter revalue obligation record increase decrease fair value rd expense consolidated statement income time relate product candidate receive marketing approval increase decrease fair value contingent consideration liability result update assumption expect timing probability achieve specify milestone change project revenue change discount rate significant judgment employ determine assumption acquisition date subsequent period update assumption significant impact result operation give period actual result differ estimate foreign currency translation transaction gain loss hedge contract nonus entity operation record functional currency entity result operation nonus dollar functional currency entity translate dollar average currency rate asset liability translate currency rate period end foreign currency translation adjustment record component comprehensive income loss stockholder equity foreign currency transaction gain loss record income expense net consolidated statement income net foreign currency transaction loss total million million million hedge portion foreign currency exposure related outstanding monetary asset liability forecast product sale foreign currency exchange forward option contract general market risk relate contract offset correspond gain loss hedge transaction credit risk associate contract drive change interest currency exchange rate result vary time work major bank closely monitor current market condition seek limit risk counterpartie contract unable perform seek limit risk loss enter contract permit net settlement maturity overall risk loss event counterparty default limit unrecognized gain outstanding contract ie contract positive fair value date default enter derivative contract trading purpose hedge net investment foreign subsidiary fair value financial instrument apply fair value account financial asset liability nonfinancial asset liability recognize disclose fair value financial statement recur basis define fair value price receive sell asset pay transfer liability orderly transaction market participant measurement date determine fair value measurement asset liability require record fair value consider principal advantageous market transact marketbase risk measurement assumption market participant use price asset liability risk inherent valuation technique transfer restriction credit risk determine fair value financial nonfinancial asset liability fair value hierarchy establish level input measure fair value follow level input include quote price active market identical asset liability level input include observable input level input quote price similar asset liability quote price identical similar asset liability market active input observable corroborate observable market datum substantially term asset liability marketable security review trading activity pricing measurement date sufficient quote price identical security available use market pricing observable market input similar security obtain thirdparty datum provider input represent quote price similar asset active market derive observable market datum level input include unobservable input support little market activity significant fair value underlie asset liability level asset liability include fair value measurement determine pricing model discount cash flow methodology similar valuation technique significant management judgment estimation derivative financial instrument recognize derivative instrument asset liabilitie fair value consolidate balance sheet change fair value derivative record period current earning accumulate comprehensive income loss depend derivative designate hedge transaction type hedge transaction classify cash flow instrument category cash flow hedge item hold issue derivative instrument trade speculative purpose assess inception ongoing basis derivative hedging transaction highly effective offset change cash flow fair value hedge item assess hedge ineffectiveness quarterly basis record gain loss relate ineffective portion current earning extent significant determine forecast transaction long probable occur discontinue hedge accounting affect portion hedge instrument relate unrealized gain loss contract recognize current earning income taxis income tax provision compute liability method defer tax asset liability determine base difference financial statement tax basis asset liability enact tax rate effect year difference expect reverse significant estimate require determine provision income taxis estimate base interpretation exist tax law regulation factor favorable unfavorable effect income tax rate factor include limited interpretation exist tax law change tax law rate portion nontax deductible pharmaceutical excise tax accounting stock option sharebase payment merger acquisition ability manufacture product cork ireland facility amortization certain acquisition relate intangible receive tax benefit expiration federal research tax credit future level rd spending change accounting standard change mix earning tax jurisdiction operate change overall level pretax earning resolution federal state foreign income tax audits impact income tax provision result mention factor significant negative impact consolidate net income record liability relate uncertain tax position accordance guidance clarifie accounting uncertainty income taxis recognize enterprise financial statement prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return believe uncertain tax position currently pende material adverse effect consolidated financial statement adverse resolution uncertain tax position period material impact result operation period recent accounting pronouncement february financial accounting standard board fasb issue update exist standard liability update provide guidance recognition measurement disclosure obligation result joint liability arrangement obligation total fix reporting date entity require measure obligation sum reporting entity agree pay basis arrangement coobligor additional report entity expect pay behalf coobligor entity require disclose nature significant information obligation guidance effective begin quarter believe adoption update material impact consolidate financial statement july fasb issue update relate presentation unrecognize tax benefit net operating loss carryforward similar tax loss tax credit carryforward exist unrecognized tax benefit portion unrecognized tax benefit present financial statement reduction defer tax asset net operating loss carryforward similar tax loss tax credit carryforward follow extent net operating loss carryforward similar tax loss tax credit carryforward available reporting date tax law applicable jurisdiction settle additional income taxis result disallowance tax position tax law applicable jurisdiction require entity use entity intend use defer tax asset purpose unrecognized tax benefit present financial statement liability combine defer tax asset guidance effective begin quarter believe adoption update material impact consolidate financial statement fair value measurement financial instrument consist principally cash cash equivalent marketable security account receivable foreign currency exchange forward contract account payable shortterm longterm debt cash cash equivalent marketable security foreign currency exchange contract hedge account receivable forecast sale report respective fair value consolidate balance sheet shortterm longterm debt report amortize cost consolidated balance sheet remain financial instrument report consolidated balance sheet amount approximate current fair value fair value convertible senior note senior unsecured note determine level input base quote market value follow table summarize carry value fair value convertible senior note senior unsecured note thousand december december type borrowing description carry value fair value carry value fair value convertible senior note convertible senior note convertible senior note senior unsecured april note senior unsecured december note senior unsecured december note senior unsecured december note senior unsecured december note follow table summarize asset liability record fair value respective fair value classification level input fair value hierarchy thousand december december level level level total level level level total asset debt security treasury security money market fund government agency security municipal debt security corporate debt security residential mortgage assetbacke security total debt security defer compensation plan derivative liability contingent consideration defer compensation plan derivative maintain deferred compensation plan director key employee defer compensation income tax purpose amount defer participant deposit rabbi trust periodically adjust reflect earning loss base participant investment election select group investment fund consist money market fund mutual fund note defer compensation plan information level input estimate fair value government relate debt corporate debt residential mortgage assetbacked security take consideration valuation obtain thirdparty pricing service pricing service utilize industry standard valuation model include income marketbase approach significant input observable directly indirectly estimate fair value input include report trade brokerdealer quote similar security issuer credit spread benchmark security prepaymentdefault projection base historical datum observable input substantially foreign currency derivative contract maturity primarily month time horizon counterpartie minimum credit rating equivalent standard poor moody investors service inc fitch inc estimate fair value contract take consideration valuation obtain thirdparty valuation service utilize incomebase industry standard valuation model significant input observable directly indirectly input include foreign currency rate london interbank offer rate libor swap rate input applicable commonly quote interval level input december asset liability measure level input contingent consideration liability hold auction rate security greek government bond measure fair value level input policy recognize transfer level classification actual date event change circumstance cause transfer follow table provide rollforward change fair value asset measure level input thousand year end december fair value beginning period total realize unrealized gain loss include income expense net comprehensive income loss net sale marketable security fair value end period auction rate security sell remain portfolio auction rate security result sale receive total proceed million result million loss recognize income expense net consolidated statement income underlie asset auction rate security consist student loan auction rate security typically measure level input failure auction lack market activity liquidity experience begin require security measure level input fair value auction rate security determine discount cash flow model consider project cash flow issue trust underlie collateral expect yield project cash flow estimate base underlying loan principal bond outstanding payout formula weightedaverage life cash flow project consider collateral composition security relate historical project prepayment greek government bond greek government restructure sovereign debt impact holder greek bond result record million loss relate debt restructure income expense net consolidated statement income exchange greek governmentissue bond new security liquidate quarter estimate fair value greek zerocoupon bond level input current lack market activity liquidity discount rate fair value model bond base credit default swap rate contingent consideration liability connection certain acquisition require pay future consideration contingent achievement specify development regulatory approval salesbase milestone event estimate fair value contingent consideration liability acquisition date report period probabilityweighte income approach reflect probability time future payment fair value measurement base significant level input anticipate timeline probability achieve development regulatory approval salesbase milestone event project revenue result probabilityweighte cash flow discount creditrisk adjust interest rate report period revalue obligation perform review assumption list record increase decrease fair value contingent consideration obligation rd expense consolidated statement income time relate product candidate receive marketing approval absence significant change key assumption quarterly determination fair value contingent consideration obligation primarily reflect passage time significant judgment employ determine level input fair value measurement acquisition date subsequent period update assumption significant impact result operation give period actual result differ estimate example significant increase probability achieve milestone project revenue result significantly high fair value measurement significant decrease estimate probability achieve milestone project revenue result significantly low fair value measurement significant increase discount rate anticipate timeline result significantly low fair value measurement significant decrease discount rate anticipate timeline result significantly high fair value measurement potential contingent consideration payment require achievement development regulatory approval base milestone relate cgi pharmaceuticals inc calistoga pharmaceuticals inc calistoga acquisition range payment milestone achieve estimate maximum million undiscounted accrue million december million december remainder contingent consideration liability accrual december relate potential future payment result acquisition arresto biosciences inc arresto royalty obligation future sale specify salesbased milestone achieve follow table provide rollforward contingent consideration liability record accrue liability longterm obligation consolidate balance sheet thousand year end december balance beginning period addition new acquisition net change valuation balance end period availableforsale security estimate fair value availableforsale security generally base price obtain commercial pricing service follow table summary availableforsale debt security record cash cash equivalent marketable security consolidate balance sheet thousand december december gross gross gross gross amortize unrealize unrealized estimate amortize unrealize unrealized estimate cost gain loss fair value cost gain loss fair value debt security treasury security money market fund government agency security municipal debt security corporate debt security residential mortgage assetbacke security total follow table summarize classification availableforsale debt security consolidate balance sheet thousand december december cash cash equivalent shortterm marketable security longterm marketable security total cash cash equivalent table exclude cash million december million december follow table summarize portfolio availableforsale debt security contractual maturity thousand december amortize cost fair value year great year year great year year great year total follow table summarize gross realize gain loss relate sale marketable security thousand year end december gross realize gain sale gross realize loss sale cost security sell determine base specific identification method follow table summarize availableforsale debt security continuous unrealized loss position deem otherthan temporarily impair thousand month month great total gross gross gross unrealize estimate unrealized estimate unrealized estimate loss fair value loss fair value loss fair value december debt security treasury security government agency security municipal debt security corporate debt security residential mortgage asset back security total december debt security treasury security government agency security municipal debt security corporate debt security residential mortgage asset back security total hold total security december securities december unrealize loss position base review security believe otherthantemporary impairment security december intend sell security believe likely require sell security recovery amortize cost basis derivative financial instrument operate foreign country expose market risk associate foreign currency exchange rate fluctuation dollar foreign currency significant euro order manage risk hedge portion foreign currency exposure related outstanding monetary asset liability forecast product sale foreign currency exchange forward option contract general market risk relate contract offset correspond gain loss hedge transaction credit risk associate contract drive change interest currency exchange rate result vary time work major bank closely monitor current market condition seek limit risk counterpartie contract unable perform seek limit risk loss enter contract permit net settlement maturity overall risk loss event counterparty default limit unrecognized gain outstanding contract ie contract positive fair value date default enter derivative contract trading purpose hedge exposure foreign currency exchange rate fluctuation certain monetary asset liability foreign subsidiary denominate nonfunctional currency derivative instrument use hedge exposure designate hedge result change fair value record income expense net consolidated statement income hedge exposure foreign currency exchange rate fluctuation forecast product sale denominate nonfunctional currency derivative instrument use hedge exposure designate cash flow hedge maturity date month execute hedge contract quarterly assess prospective hedge effectiveness regression analysis calculate change cash flow result hedge instrument monthly basis assess retrospective hedge effectiveness dollar offset approach exclude time value effectiveness testing recognize change time value hedge income expense net effective component hedge record unrealized gain loss hedge instrument accumulate comprehensive income oci stockholder equity hedge forecast transaction occur hedge dedesignate unrealized gain loss reclassify product sale majority gain loss relate hedged forecast transaction report accumulate oci december reclassify product sale month cash flow effect derivative contract year end december include net cash provide operating activity consolidate statement cash flow notional amount foreign currency exchange contract outstanding billion december billion december derivative contract allow right offset asset liability present amount gross basis international swap dealers association inc master agreement respective counterpartie foreign currency exchange contract subject applicable requirement allow net settle transaction currency single net payable party follow table summarize location fair value derivative instrument consolidate balance sheet thousand december asset derivative liability derivative classification fair value classification fair value derivative designate hedge foreign currency exchange contract current asset accrue liability foreign currency exchange contract longterm asset longterm obligation total derivative designate hedge derivative designate hedge foreign currency exchange contract current asset accrue liability total derivative designate hedge total derivative december asset derivative liability derivative classification fair value classification fair value derivative designate hedge foreign currency exchange contract current asset accrue liability foreign currency exchange contract longterm asset longterm obligation total derivative designate hedge derivative designate hedge foreign currency exchange contract current asset accrue liability total derivative designate hedge total derivative follow table summarize effect foreign currency exchange contract consolidate statement income thousands year end december derivative designate hedge gain loss recognize oci effective portion gain loss reclassify accumulated oci product sale effective portion gain loss recognize income expense net ineffective portion amount exclude effectiveness testing derivative designate hedge gain loss recognize income expense net time time discontinue cash flow hedge result record relate amount income expense net consolidated statement income material amount record income expense net year end december result discontinuance cash flow hedge december hold type financial instrument derivative contract relate foreign currency exchange contract follow table summarize potential effect offset derivative type financial instrument consolidated balance sheet thousand december offset derivative assetsliabilitie gross amount offset consolidated balance sheet amount assetsliabilitie gross amount present derivative recognize gross amount offset consolidated financial cash collateral net description assetsliabilitie consolidate balance sheet balance sheet instrument receivedpledge legal offset derivative asset derivative liability december offset derivative assetsliabilitie gross amount offset consolidated balance sheet gross amount amount assetsliabilitie derivative recognize gross amount offset present consolidated financial cash collateral net description assetsliabilitie consolidate balance sheet balance sheet instrument receivedpledge legal offset derivative asset derivative liability acquisition ym biosciences inc complete acquisition ym biosciences inc ym base canada total consideration transfer million february time ym whollyowne subsidiary gilead ym drug development company primarily focus advance momelotinib know cyt orally administer oncedaily candidate hematologic cancer fair value acquire asset assume liability include primarily iprd million goodwill million defer tax asset million unrecognized tax benefit defer tax liability million cash acquire million pro forma result operation acquisition ym present acquisition material consolidated result operation note intangible asset goodwill description iprd acquire pharmasset inc january complete acquisition pharmasset publiclyheld clinicalstage pharmaceutical company commit discover develop commercialize novel drug treat viral infection pharmasset primary focus development oral therapeutic treatment hcv infection pharmasset lead compound sofosbuvir refer gs nucleotide analog december approve fda health canada sovaldi oncedaily oral regimen treatment hcv patient genotype infection include hepatocellular carcinoma meeting milan criterion await liver transplantation hcvhic coinfection january european commission grant marketing authorization sovaldi countries european union acquisition pharmasset allow advance effort develop alloral regimen treatment hcv acquire outstanding share common stock pharmasset share cash tender offer subsequent merger term agreement plan merger enter november aggregate cash payment acquire outstanding share common stock billion finance transaction approximately billion cash hand billion senior unsecured note issue december billion bank debt issue january pharmasset acquisition account business combination result operation pharmasset include consolidated statement income january date acquire approximately outstanding share common stock pharmasset cash consideration transfer result obtain effective control pharmasset acquisition complete january time pharmasset whollyowne subsidiary gilead integrate operation track earning result product candidate therapeutic area maintain separate earning result acquire pharmasset business follow table summarize component cash pay acquire pharmasset thousand total consideration transfer stockbase compensation expense total cash pay billion cash payment consist billion cash payment outstanding common stockholder million cash payment option holder pharmasset stock option plan billion cash payment outstanding common stockholder million cash payment vested option holder pharmasset stock option plan account consideration transfer remain million cash payment account stockbase compensation expense result accelerate vest pharmasset employee option immediately prior acquisition follow table summarize acquisition date fair value asset acquire liability assume consideration transfer thousand identifiable intangible asset cash cash equivalent asset acquire liability assume net total identifiable net asset goodwill total consideration transfer identifiable intangible asset acquire intangible asset primarily comprise sofosbuvir iprd compound estimate fair value billion date acquisition fair value asset determine probabilityweighte income approach discount expect future cash flow present value estimate net cash flow discount discount rate base estimate weightedaverage cost capital company profile similar pharmasset rate comparable estimate internal rate return acquisition represent rate market participant use value intangible asset project cash flow sofosbuvir base key assumption estimate revenue operate profit relate project consider stage development acquisition date time resource need complete development approval product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop product candidate obtain marketing approval fda regulatory agency risk related viability potential alternative treatment future target market intangible asset relate iprd project consider indefinitelive asset completion abandonment associate rd effort december billion purchase iprd project sofosbuvir complete reclassify finitelived intangible asset amortize asset estimate useful life utilize straightline method goodwill million goodwill represent excess consideration transfer fair value asset acquire liability assume attributable synergy expect combine rd operation pharmasset goodwill expect deductible income tax purpose stockbase compensation expense stockbase compensation expense recognize accelerate vest employee option immediately prior acquisition report consolidated statement income follow thousands year end december research development expense sell general administrative expense total stockbase compensation expense cost cost incur connection acquisition include thousands year end december transaction cost eg investment advisory legal accounting fee bridge financing cost restructure cost total cost follow table summarize cost line item consolidate statement income cost recognize thousands year end december research development expense sell general administrative expense interest expense total cost pro forma information follow unaudited pro forma information present combine result operation gilead pharmasset acquisition pharmasset complete january adjustment effect pro forma event directly attributable acquisition unaudite pro forma result reflect operating efficiency potential cost saving result consolidation operation gilead pharmasset accordingly unaudite pro forma result present informational purpose necessarily indicative actual result operation combine company acquisition occur begin period present indicative future result operation thousands year end december total revenue net income attributable gilead unaudited pro forma consolidated result include nonrecurre pro forma adjustment assume acquisition occur january stock base compensation expense million incur include net income attributable gilead year end december cost million incur year end december include net income attributable gilead year end december calistoga pharmaceuticals inc february enter agreement acquire calistoga million plus potential payment million base achievement certain milestone transaction close april time calistoga whollyowne subsidiary calistoga privatelyheld biotechnology company base seattle washington focus development medicine treat cancer inflammatory disease acquisition provide portfolio proprietary compound selectively target isoform phosphoinositide kinase pik lead product candidate idelalisib refer gs firstinclass specific inhibitor pik delta isoform pik delta preferentially express leukocyte involve variety inflammatory autoimmune disease hematological cancer acquisition account business combination calistoga result operation april include consolidated statement income significant acquisitiondate fair value total consideration transfer acquire calistoga million consist cash pay prior closing million contingent consideration million follow table summarize fair value asset acquire liability assume april thousand iprd net liability assume total identifiable asset goodwill total consideration transfer iprd intangible asset associate iprd project relate idelalisib product candidate management determine estimate acquisitiondate fair value intangible asset relate iprd million estimate fair value determine income approach discount expect future cash flow present value estimate fair value present value discount rate consider estimate weightedaverage cost capital company profile substantially similar calistoga acquirer estimate weightedaverage cost capital believe appropriate give unique characteristic acquisition include competitive bidding process rate comparable estimate internal rate return acquisition represent rate market participant use value intangible asset project cash flow iprd project base key assumption estimate revenue operate profit relate project consider stage development acquisition date time resource need complete development approval product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop product candidate obtain marketing approval fda regulatory agency risk related viability potential alternative treatment future target market intangible asset relate iprd project consider indefinitelive completion abandonment associate rd effort goodwill excess consideration transfer fair value assign asset acquire liability assume million represent goodwill result calistoga acquisition management believe goodwill mainly represent synergy expect combine rd operation acquire calistoga assemble workforce intangible asset qualify separate recognition consider calistoga acquisition material business combination disclose pro forma result operation require material business combination arresto biosciences inc december enter agreement acquire arresto million plus potential future payment base achievement certain sale target transaction close january time arresto whollyowne subsidiary arresto privatelyheld developmentstage biotechnology company base palo alto california focus develop antibody potential treatment fibrotic disease cancer lead product acquisition arresto simtuzumab refer gs humanize monoclonal antibody mab target human lysyl oxidaselike loxl protein addition ongoing phase study simtuzumab patient advance solid tumor time acquisition phase study initiate evaluate simtuzumab patient idiopathic pulmonary fibrosis acquisition account business combination arresto result operation january include consolidated statement income significant acquisitiondate fair value total consideration transfer acquire arresto million consist cash pay prior closing million contingent consideration million follow table summarize fair value asset acquire liability assume january thousand iprd defer tax asset defer tax liability net liability assume total identifiable net asset goodwill total consideration transfer iprd intangible asset associate iprd project relate simtuzumab product candidate management determine estimate acquisitiondate fair value intangible asset relate iprd million estimate fair value determine income approach discount expect future cash flow present value estimate fair value present value discount rate base estimate weightedaverage cost capital company profile substantially similar arresto comparable estimate internal rate return acquisition represent rate market participant use value intangible asset project cash flow iprd project base key assumption estimate revenue operate profit relate project consider stage development acquisition date time resource need complete development approval product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop product candidate obtain marketing approval fda regulatory agency risk related viability potential alternative treatment future target market intangible asset relate iprd project consider indefinitelive completion abandonment associate rd effort goodwill excess consideration transfer fair value assign asset acquire liability assume million represent goodwill result arresto acquisition management believe goodwill mainly represent synergy expect combine rd operation acquire arresto assemble workforce intangible asset qualify separate recognition consider arresto acquisition material business combination disclose pro forma result operation require material business combination inventory inventory summarize follow thousand december raw material work process finish good total joint venture form gilead bms note collaborative arrangement include consolidated financial statement hold efavirenz active pharmaceutical ingredient inventory efavirenz inventory purchase bms bms estimate net selling price efavirenz total billion december billion december property plant equipment property plant equipment summarize follow thousand december property plant equipment net building improvement include leasehold improvement laboratory manufacturing equipment office computer equipment capitalize lease equipment construction progress subtotal accumulate depreciation amortization include relate capitalize lease equipment subtotal land total complete construction new laboratory facility headquarters support ongoing growth business total cost complete facility million intangible asset goodwill intangible asset follow table summarize carry intangible asset thousand december indefinitelive intangible asset finitelive intangible asset total intangible asset indefinitelive intangible asset december indefinitelive intangible asset consist primarily purchase iprd know commercially sovaldi sofosbuvir acquisition pharmasset fda approval commercial launch sovaldi december reclassify iprd relate sovaldi finite live intangible asset complete acquisition ym total million fair value acquire asset assume liability ym attribute million iprd relate momelotinib consolidated balance sheet follow table summarize indefinitelive intangible asset thousand december indefinitelive intangible asset sovaldi sofosbuvir indefinitelive intangible asset momelotinib cyt indefinitelive intangible asset foreign currency translation adjustment total finitelive intangible asset follow table summarize finitelive intangible asset thousand december december gross carry accumulate gross carry accumulate amortization amortization intangible asset sofosbuvir intangible asset ranexa intangible asset lexiscan total fda approval commercial launch sovaldi december reclassify iprd relate sovaldi finitelive intangible asset amortization expense relate finitelived intangible asset include primarily cost good sell consolidated statement income total million million million weightedaverage amortization period finitelive intangible asset approximately year december estimate future amortization expense associate intangible asset succeed fiscal year follow thousands fiscal year total goodwill complete acquisition ym attribute million goodwill consolidated balance sheet follow table summarize change carry goodwill thousand balance december goodwill result acquisition ym foreign currency translation adjustment balance december collaborative arrangement time time result enter strategic collaboration hold investment nonpublic company review interest investee company consolidation andor appropriate disclosure base applicable guidance variable interest entity vie require consolidate entity contractual term arrangement essentially provide control entity majority voting interest assess primary beneficiary vie base power direct activity vie significantly impact vie economic performance obligation absorb loss right receive benefit vie potentially significant vie december determine certain investee company vie respect joint venture bms primary beneficiary consolidate investee bristolmyers squibb company north america enter collaboration arrangement bms develop commercialize single tablet regimen truvada bms sustiva efavirenz united states combination approve use united states sell brand atripla bms structure collaboration joint venture operate limited liability company name bristolmyers squibb gilead sciences llc consolidate bms grant royaltyfree sublicense joint venture use respective company own technology return grant license joint venture use intellectual property result collaboration bms amend joint venture collaboration agreement allow joint venture sell atripla canada economic interest joint venture hold bms include share revenue outofpocket expense base portion net selling price atripla attributable efavirenz truvada net selling price truvada change time relative net selling price efavirenz bms respective economic interest joint venture vary annually bms share marketing sale effort start limited number activity jointly manage party long coordinate detail promotional activity united states party reduce joint promotional effort launch complera august stribild august party continue collaborate activity manufacture regulatory compliance pharmacovigilance daily operation joint venture govern primary joint committee form bms gilead responsible accounting financial reporting tax reporting manufacturing product distribution joint venture party provide respective bulk active pharmaceutical ingredient joint venture approximate market value agreement continue terminate mutual agreement party addition party terminate party participation collaboration day launch generic version party single agent product double agent product terminate party right continue sell atripla continue party obligate pay terminate party certain royalty threeyear period follow effective date termination december joint venture hold efavirenz active pharmaceutical ingredient purchase bms bms estimate net selling price efavirenz market amount include inventory consolidate balance sheet december total asset hold joint venture billion consist primarily cash cash equivalent million account receivable million inventory billion total liability billion consist primarily account payable million accrue expense million december total asset hold joint venture billion consist primarily cash cash equivalent million account receivable million inventory billion total liability billion consist primarily account payable billion accrue expense million asset liability amount reflect impact intercompany elimination include consolidated balance sheet consolidate joint venture legal structure joint venture limit recourse creditor general credit asset similarly asset hold joint venture settle obligation joint venture certain prior period amount reclassify conform current presentation europe gilead sciences limit whollyowne subsidiary ireland bms enter collaboration agreement bms set forth term condition bms commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory party form limited liability company consolidate manufacture atripla distribution european territory efavirenz purchase bms bms estimate net selling price efavirenz european territory responsible manufacturing product distribution inventory management warehouse local subsidiary primary responsibility order fulfillment collection receivables customer relation handle sale return territory bms promote atripla general party share revenue outofpocket expense proportion net selling price component atripla truvada efavirenz start limited number activity jointly manage party long coordinate detail promotional activity region responsible accounting financial reporting tax reporting collaboration december efavirenz purchase bms bms estimate net selling price efavirenz european territory include inventory consolidate balance sheet party form limited liability company hold marketing authorization atripla europe primary responsibility regulatory activity major market country party agree independently continue use commercially reasonable effort promote atripla agreement terminate expiration lasttoexpire patent afford market exclusivity atripla component european territory addition party terminate agreement reason termination effective calendar quarter notice termination nonterminate party right continue sell atripla continue party obligate pay terminate party certain royalty threeyear period follow effective date termination event continue party decide sell atripla effective date termination date atripla withdraw country date party assume distribution atripla whichever early japan tobacco inc japan tobacco inc japan tobacco grant exclusive right develop commercialize elvitegravir novel hiv integrase inhibitor country world exclude japan japan tobacco retain right agreement responsible seek regulatory approval territory require use diligent effort commercialize elvitegravir treatment hiv infection november european commission grant marketing authorization elvitegravir know commercially vitekta component stribild bear cost expense associate commercialization effort term agreement incur upfront license fee million include rd expense future alternative use technology record million rd expense relate milestone incur result dose patient phase clinical study record million rd expense relate milestone pay related dose patient phase clinical study october submit nda fda approval stribild december submit marketing authorization application ema marketing approval stribild time record million rd expense relate milestone incur connection filing obligate additional payment achievement milestone total million pay royalty base net sale territory market product august capitalize million related milestone incur connection fda approval stribild capitalize million related milestone incur connection ema approval stribild milestone amortize useful patent life vitekta approximately year expiring agreement obligation pay royalty japan tobacco terminate productbyproduct basis patent provide exclusivity product expire later tenth anniversary commercial launch product terminate agreement reason case license grant japan tobacco terminate party terminate agreement response material breach party janssen rd ireland enter license collaboration agreement janssen rd ireland janssen tibotec pharmaceutical develop commercialize fixeddose combination truvada janssen nonnucleoside reverse transcriptase inhibitor rilpivirine combination approve united states european union sell brand complera united states eviplera european union agreement janssen grant exclusive license compleraeviplera worldwide exclude certain middle income develop world country japan party restrict combine drug product drug accordance term agreement record million approximately million reimbursable research development cost incur janssen development rilpivirine december responsible manufacturing compleraeviplera lead role registration distribution commercialization product license country janssen exercise right codetail combination product country gilead sell party amend agreement include distribution compleraeviplera rest world right distribute product north america europe latin america mexico australia new zealand janssen right distribute product region include japan russia price product expect sum price truvada price rilpivirine purchase separately cost rilpivirine purchase janssen compleraeviplera approximately market price rilpivirine specified percentage major market party terminate collaboration agreement compleraeviplera withdraw market party materially breach agreement terminate agreement united states canada expiration expire patent tenofovir disoproxil fumarate united states terminate agreement country expiration expire patent tenofovir disoproxil fumarate country european union janssen terminate agreement united states canada expiration expire patent rilpivirine united states terminate agreement country expiration expire patent rilpivirine country european union roche tamiflu enter development license agreement agreement roche develop commercialize therapy treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codevelope roche agreement roche exclusive right obligation manufacture sell tamiflu worldwide subject obligation pay percentage net revenue roche generate tamiflu sale turn subject reduction certain define manufacturing cost enter amendment supplement agreement roche amend agreement provide formation joint manufacturing committee review roche manufacturing capacity tamiflu global plan manufacture tamiflu commercial committee evaluate commercial plan strategy tamiflu united states joint supervisory committee evaluate roche overall commercial plan tamiflu global basis case consist representative roche amend agreement option provide specialized sale force supplement roche marketing effort united states tamiflu exercise date agreement roche obligation pay royalty terminate countrybycountry basis patent provide exclusivity tamiflu country expire roche terminate agreement reason case right tamiflu revert party terminate agreement response material breach party royalty payable net sale tamiflu sell roche remain amend agreement follow million worldwide net sale give calendar year b million worldwide net sale calendar year c worldwide net sale excess million calendar year amend agreement revise provision agreement relate calculation royalty payment give calendar quarter roche pay royalty base actual royalty rate applicable quarter addition amend agreement royalty payable roche long subject cost good sell adjustment provide agreement record tamiflu royalty total million million million ranexa result acquisition cv therapeutic assume right agreement cv therapeutic roche exclusive worldwide license ranexa license agreement pay initial license fee obligate certain payment roche receipt second product approval ranexa follow major market country france germany italy united states united kingdom receive fda approval ranexa treatment chronic angina pay million roche accordance agreement receive marketing authorization european medicine agency ema ranexa treatment chronic angina european union member state pay million roche relate approval capitalize longterm asset consolidated balance sheet amortize useful patent life approximately year expiring enter amendment agreement roche relate ranexa amendment provide exclusive worldwide commercial right ranexa potential indication human term amendment upfront payment roche obligate royalty payment roche worldwide net product sale license product addition obligate additional milestone payment achievement certain regulatory approval debt credit facility financing arrangement follow table summarize carry borrowing financing arrangement thousand interest december type borrowing description issue date date rate convertible senior note april convertible senior note july convertible senior note july senior unsecured april note march april senior unsecured december note december december senior unsecured december note december december senior unsecured december note december december senior unsecured december note december december credit facility fiveyear revolver january january variable total debt net current portion total longterm debt net convertible senior note april issue million note private placement pursuant rule securities act amend portion note convert remainder mature repay aggregate principal balance million million pay million cash million relate conversion spread note represent conversion value excess principal receive million cash million convertible note hedge relate note warrant relate note expire august pay billion settle warrant average market price common stock exceed warrant exercise price note issue par bore interest rate debt issuance cost million record longterm asset amortize interest expense contractual term note initial conversion rate note share principal represent initial conversion price approximately share conversion rate subject customary antidilution adjustment prior maturity note convertible subject adjustment follow circumstance calendar quarter begin september closing price common stock trading day consecutive trading day period previous quarter applicable conversion price share specified distribution holder common stock specify corporate transaction occur month prior maturity applicable note conversion holder receive cash equal less principal note ii conversion value note conversion value exceed principal deliver option cash common stock combination cash common stock conversion value excess principal december note classify current give maturity date conversion criterion discuss meet related unamortized discount million classified equity component currently redeemable convertible note december consolidated balance sheet note convert connection change control require provide premium form increase conversion rate subject state maximum addition event change control holder require purchase portion note purchase price equal principal plus accrue unpaid interest concurrent issuance note purchase convertible note hedge private transaction cost million tax deductible life note sell warrant private transaction acquire million share common stock strike price share receive net proceed million sale warrant convertible note hedge warrant intend reduce potential economic dilution future conversion note effectively increase conversion price share note net cost million convertible note hedge warrant transaction record stockholder equity consolidated balance sheet addition contract classify stockholder equity index common stock account derivative convertible note hedge cover subject customary antidilution adjustment million share common stock strike price initially correspond initial conversion price note subject adjustment similar applicable conversion price relate note market value share common stock time conversion note strike price applicable convertible note hedge entitle receive counterpartie transaction share common stock extent correspond election respect relate convertible note cash combination cash share common stock option excess market value common stock strike price convertible note hedge convertible note hedge terminate maturity note note remain outstanding conversion million share common stock underlie warrant subject customary antidilution adjustment warrant strike price share exercisable expiration date market value common stock time exercise applicable warrant exceed strike price require net settle cash share common stock option counterpartie value warrant excess warrant strike price contemporaneously close sale note portion net proceed note issuance proceed warrant transaction repurchase share common stock current accounting guidance bifurcated conversion option note debt instrument classified conversion option equity accrete result debt discount interest expense contractual term note follow table summarize information equity liability component note thousand carry value net carrying unamortized discount equity component liability component liability component december december december convertible senior note recognize million million million interest expense relate contractual coupon rate amortization debt discount issuance cost note effective interest rate liability component note convertible senior note july issue billion note billion note private placement pursuant rule securities act amend portion note note convert repay billion principal balance primarily comprise note pay billion cash relate conversion spread note represent conversion value excess principal receive billion cash convertible note hedge relate note note note issue par bear interest rate respectively debt issuance cost million record longterm asset amortize interest expense contractual term note note aggregate principal note note sell reflect exercise initial purchaser option purchase additional note cover overallotment initial conversion rate note share principal represent initial conversion price approximately share initial conversion rate note share principal represent initial conversion price approximately share conversion rate subject customary antidilution adjustment note note convert prior april april respectively follow circumstance calendar quarter commence september closing price common stock trading day consecutive period consecutive trading day end trading day precede calendar quarter great applicable conversion price applicable trading day business day period measurement period consecutive trading day trading day period trading price principal note product report sale price common stock applicable conversion rate trading day occurrence specify corporate transaction distribution certain stock right cash amount asset shareholder occurrence change control april case note april case note holder convert note time regardless forego circumstance generally conversion holder receive cash equal less principal note ii conversion value note measure indenture govern relevant note conversion value exceed principal deliver option cash common stock combination cash common stock conversion value excess principal december note classify current give maturity date note classify current give conversion criterion discuss meet result relate unamortized discount million classified equity component currently redeemable convertible note consolidated balance sheet note note convert connection change control require provide premium form increase conversion rate subject state maximum addition event change control holder require purchase portion note purchase price equal principal plus accrue unpaid interest december ifconverte value note note exceed principal amount note million billion respectively concurrent issuance note note purchase convertible note hedge private transaction cost million tax deductible life note sell warrant private transaction acquire million share common stock receive net proceed million sale warrant convertible note hedge warrant intend reduce potential economic dilution future conversion note note effectively increase conversion price share note share note net cost million convertible note hedge warrant transaction record stockholder equity consolidated balance sheet addition contract classify stockholder equity index common stock account derivative convertible note hedge cover subject customary antidilution adjustment million share common stock strike price initially correspond initial conversion price note note subject adjustment similar applicable conversion price relate note market value share common stock time conversion note note strike price applicable convertible note hedge entitle receive counterpartie transaction share common stock extent correspond election respect relate convertible note cash combination cash share common stock option excess market value common stock strike price convertible note hedge convertible note hedge terminate maturity note note note note remain outstanding conversion million share common stock underlie warrant subject customary antidilution adjustment warrant strike price share warrant expire share warrant expire exercisable respective expiration date market value common stock time exercise applicable warrant exceed respective strike price require net settle cash share common stock option respective counterpartie value warrant excess warrant strike price net proceed issuance convertible note repurchase share common stock repay exist indebtedness current accounting guidance bifurcated conversion option note note debt instrument classified conversion option equity accrete result debt discount interest expense contractual term note note follow table summarize information equity liability component note note thousand carry value net carrying unamortized discount equity component liability component liability component december december december convertible senior note convertible senior note total convertible senior note recognize million million million interest expense relate contractual coupon rate amortization debt discount issuance cost note note effective interest rate liability component note note respectively april senior unsecured note march issue april note register offering aggregate principal billion april note mature april pay interest fix annual rate debt issuance cost incur connection issuance debt total approximately million amortize interest expense contractual term april note recognize million million million interest expense relate contractual coupon rate amortization debt discount issuance cost april note april note redeem option time time time redemption price equal great principal note redeem ii sum determine independent investment banker present value remain schedule payment principal interest note redeem exclusive interest accrue date redemption discount redemption date semiannual basis treasury rate plus basis point plus case accrue unpaid interest note redeem date redemption time january redeem note principal note redeem plus accrue unpaid interest date redemption addition event occurrence change control downgrade rating april note investment grade rating standard poor rating service moody investors service inc holder require purchase portion note price equal principal plus accrue unpaid interest net proceed general corporate purpose include repayment exist indebtedness repurchase common stock december senior unsecured note december issue december note december note december note december note december note register offer million million billion billion respectively aggregate principal billion note mature december pay interest fix annual rate respectively debt issuance cost incur connection issuance debt total approximately million amortize interest expense contractual term respective note recognize million million million interest expense relate contractual coupon rate amortization debt discount issuance cost december note note redeem option time time time redemption price equal great principal note redeem ii sum determine independent investment banker present value remain schedule payment principal interest note redeem exclusive interest accrue date redemption discount redemption date semiannual basis treasury rate plus basis point case december note december note basis point case december note december notes plus case accrue unpaid interest note redeem date redemption time date month prior maturity date december note redeem note principal note redeem plus accrue unpaid interest date redemption time date month prior maturity date december note redeem note principal note redeem plus accrue unpaid interest date redemption event occurrence change control downgrade rating series note investment grade rating standard poor rating service moody investors service inc holder series note require purchase portion note series price equal aggregate principal note repurchase plus accrue unpaid interest net proceed fund acquisition pharmasset complete january note credit facility january conjunction acquisition pharmasset enter fiveyear billion revolve credit facility credit agreement year revolve credit agreement million shortterm revolve credit facility credit agreement shortterm revolve credit agreement billion term loan facility term loan credit agreement borrow million fiveyear revolve credit agreement million shortterm revolve credit agreement billion term loan credit agreement close acquisition fully repay outstanding debt term loan credit agreement shortterm revolve credit agreement time agreement terminate repay million fiveyear revolve credit agreement fiveyear revolve credit agreement contain customary representation warranty affirmative negative financial maintenance covenant event default loan bear interest eurodollar rate plus applicable margin ii base rate plus applicable margin define credit agreement reduce commitment prepay loan time premium penalty require comply certain covenant credit agreement note indenture december compliance covenant fiveyear revolve credit agreement inclusive million swing line loan subfacility million letter credit subfacility december million letter credit outstanding fiveyear revolve credit agreement fiveyear revolve credit agreement terminate amount owe agreement shall payable january contractual maturity finance obligation base contractual date aggregate maturity finance obligation subsequent december follow thousand maturity date total commitment contingency lease arrangement enter longterm noncancelable operating lease equipment facility lease facility foster city fremont palo alto san dimas california branford connecticut seattle washington dublin cork areas ireland london area united kingdom operate lease sale marketing administrative facilities europe canada asiapacific lease expire date lease contain option renew certain facility lease contain rent escalation clause significant lease relate facility seattle washington expire year term lease provide consecutive right extend term lease contain annual percent rent escalation clause lease require pay additional amount operating expense maintenance lease corporate aircraft vary term renewal option expiration lease term lease expense operating lease approximately million million million aggregate noncancelable future minimum rental payment operating lease follow thousand total legal proceeding department justice investigation june receive subpoena attorney office northern district california request document relate manufacture relate quality distribution practice atripla emtriva hepsera letairis truvada viread complera cooperating continue cooperate governmental inquiry estimate possible loss range loss determine litigation generic manufacturer approval process product fda grant new chemical entity nce exclusivity period manufacturer application approval generic version product approve generic manufacturer challenge patent protect product grant nce exclusivity year prior end nce exclusivity period generic manufacturer seek continue seek fda approval similar identical drug abbreviate new drug application anda application form typically manufacturer seek approval generic drug receive notice generic manufacturer submit andas manufacture generic version atripla truvada viread emtriva ranexa tamiflu united states atripla truvada viread canada april teva pharmaceutical teva reach agreement settle ongoing patent litigation concern patent protect tenofovir disoproxil fumarate atripla truvada viread product agreement teva allow launch generic version viread december august lupin limited lupin reach agreement settle patent litigation concern patent protect ranexa agreement lupin allow launch generic version ranexa february february teva reach agreement principle settle ongoing patent litigation concern emtricitabine patent protect atripla truvada term settlement agreement confidential settlement agreement file federal trade commission department justice require law august teva file impeachment action federal court canada seek invalidation canadian patent associate viread september hearing consolidated request order prohibition connection tevas and filing tevas generic version viread truvada atripla take place december court issue request order prohibit canadian ministry health issue notice compliance tevas generic version viread truvada atripla product expiry patent july teva appeal decision decision court ultimately resolve validity challenge raise teva impeachment action teva successful invalidating patent teva able launch generic version viread truvada atripla product prior expiry patent trial impeachment action schedule january anticipate trial relate lupin anda request permission generic version truvada viread cipla anda request permission generic version emtriva viread place fourth quarter predict ultimate outcome action spend significant resource enforce defend patent unsuccessful lawsuit original claim patent narrow invalidated patent protection atripla truvada viread emtriva ranexa tamiflu united states atripla truvada viread canada substantially shorten patent cover product invalidate fda canadian minister health approve request manufacture generic version products united states canada respectively prior expiration date patent sale generic version product early patent expiration significant negative effect revenue result operation litigation relate sofosbuvir january acquire pharmasset acquisition acquire sofosbuvir nucleotide analog act inhibit replication hcv december receive fda approval sofosbuvir brandname sovaldi receive number contractual intellectual property claim sofosbuvir carefully consider claim prior follow acquisition believe merit contract arbitration jeremy clark march jeremy clark employee pharmasset inventor patent patent file demand arbitration lawsuit pharmasset dr raymond schinazi mr clark initially file lawsuit pharmasset dr schinazi district court northern district alabama february seek void assignment provision employment agreement assert ownership patent patent claim metabolite sofosbuvir rg december court order stay litigation pende outcome arbitration proceeding require mr clark employment agreement instead proceed arbitration mr clark file additional lawsuit september june court subsequently dismiss september mr clark file motion seek reconsideration court december order court deny december mr clark file motion appoint special prosecutor february court issue order require mr clark enter arbitration risk dismissal case mr clark file demand arbitration march arbitration panel hold hear april june arbitration panel issue decision favor pharmasset gilead dr schinazi august gilead dr schinazi file motion district court northern district alabama seek court confirm arbitration decision mr clark file motion seek vacate arbitration decision court rule motion arbitration f hoffmanla roche ltd hoffmanla roche inc collectively roche gilead successor pharmasset party october collaboration agreement roche agreement grant roche right develop psi cytidine analog prodrug treatment hcv infection collaborative research effort agreement end december roche later ask pharmasset consider roche contributed inventorship sofosbuvir pharmasset comply confidentiality provision collaboration agreement pharmasset advise carefully consider issue raise roche believe issue merit consider issue reach conclusion march roche initiate arbitration pharmasset predecessor gilead pharmasset llc collaboration agreement arbitration demand roche assert exclusive license sofosbuvir pursuant collaboration agreement sofosbuvir prodrug uridine monophosphate analog allegedly prodrug psi cytidine analog roche claim exclusive right sofosbuvir exclusive license patent cover sofosbuvir infringe patent selling offer sale product contain sofosbuvir gilead gilead pharmasset llc file response roche arbitration demand april interference proceeding litigation idenix pharmaceuticals inc february receive notice patent trademark office uspto declare interference idenix interference patent patent idenix pharmaceuticals inc idenix pende patent application interference administrative proceeding uspto design determine invent subject matter claim party patent cover metabolite sofosbuvir rg prodrug cytidine nucleoside analog pharmasset license roche idenix attempt patent class compound include metabolite purpose idenix interference determine invent compound entitle patent claim compound march uspto patent trial appeal board board determine idenix entitle benefit early application filing date patent application include application lead idenixs patent patent patent teach compound dispute board determine entitle filing date early application file patent application compound dispute senior party idenix interference january board determine pharmasset idenix invent compound dispute accordingly gilead prevail decision board hold idenix fail prove conceive compound dispute specifically idenix fail prove idenix inventor identify structure method make use dispute compound board go conclude idenix fail work diligently make testing compound dispute relevant time period idenix appeal board decision district court district delaware board decision reverse appeal court determine idenix entitle patent claim determine infringe claim require obtain license pay royalty idenix commercialize sofosbuvir rg united states decision district court appeal party court appeal federal circuit cafcwe believe claim idenix application involve idenix interference similar foreign patent claim compound metabolite invalid result file impeachment action federal court canada invalidate idenix canadian patent canadian patent correspond patent idenix patent application subject idenix interference idenix assert canadian patent correspond patent patent idenix interference invalid file similar legal action norway oslo district court seek invalidate idenix correspond norwegian patent september idenix file invalidation action norwegian proceeding norwegian patent patent correspond patent patent trial hold november court issue decision august idenix file request invalidation chinese patent office chinese patent cn zl correspond patent patent file legal action federal court australia seek invalidate idenixs australian patent correspond patent april idenix assert commercialization sofosbuvir infringe australian patent correspond patent bring similar action country future idenix award patent compound european patent office japan china event patent issue expect challenge proceeding similar invoke canada norway australia courts hear proceeding determine idenix entitle patent claim determine infringe claim require obtain license pay royalty idenix commercialize sofosbuvir rg country december receive gilead request uspto declare interference second idenix interference pende patent application patent patent include claim direct method treat hcv nucleoside compound similar involved idenix interference second idenix interference determine invent claim method treat hcv declaration second idenix interference uspto initially designate gilead junior party base patent application filing date appear face patent february uspto issue order cause idenix second idenix interference order require idenix explain judgment enter second idenix interference favor gilead base outcome idenix interference order indicate claim patent involve second idenix interference unpatentable gilead prevail idenix interference idenix allow claim benefit filing date early file patent application believe board determination idenix interference idenix entitle benefit early application filing date include file date patent equally applicable second idenix interference correct board conclude gilead senior party second idenix interference consistent determination idenix interference light board conclusion idenix interference application lead patent teach claim compound possible board determination second idenix interference eliminate need board address invent claim method treat hcv board consider invent claim method treat hcv ultimately conclude gilead claim patent revoke board determine idenix invent entitle patent claim determine proceeding infringe claim require obtain license pay royalty idenix commercialize sofosbuvir rg determination board appeal party federal court december idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversit montpellier ii sue district court district delaware allege commercialization sofosbuvir infringe patent interference exist patent patent patent believe claim patent invalid sole right commercialize sofosbuvir court disagree view determine patent infringe require obtain license pay royalty idenix commercialize sofosbuvir decision district court appeal party cafc december idenix udsg sue district court district massachusetts allege commercialization sofosbuvir infringe patent nos patent believe idenixs patent invalid infringe commercialization sofosbuvir sole right commercialize sofosbuvir court disagree view determine patent infringe require obtain license pay royalty idenix commercialize sofosbuvir decision district court appeal party cafc expansive patent portfolio cover nsa inhibitor treatment hcv follow recent disclosure structure idenixs nsa inhibitor samatasvir know idx evaluate compound light pende claim patent application litigation merck co inc august merck co inc merck contact request pay royalty sale sofosbuvir license patent patent patent patent coown isis pharmaceuticals inc believe merck patent invalid infringe commercialization sofosbuvir sole right commercialize sofosbuvir accordingly august file lawsuit district court northern district california seek declaratory judgment merck patent invalid infringe merck patent nos patent cover compound include relate sofosbuvir patent prosecution merck amend patent application attempt cover compound relate sofosbuvir ultimately extract royalty payment sofosbuvir commercialization exclude market court determine merck patent valid infringe claim require obtain license pay royalty merck commercialize sofosbuvir party appeal decision district court cafc litigation abbvie inc abbvie abbvie recently obtain patent nos patent purport claim use combination ldvsof treatment hcv publish pende patent application direct use combination treatment hcv specifically combination ledipasvir sofosbuvir certain application file abbvie recently issue patent reason believe abbvie patent invalid accordingly december file lawsuit district court district delaware seek declaratory judgment abbvie patent invalid unenforceable relief believe abbott laboratories inc abbvie conspire eliminate competition hcv market falsely represent pto gilead invent method treat hcv combination ldvsof february abbvie respond lawsuit filing lawsuit district court district delaware allege ldvsof product infringe patent expect abbvie patent block delay commercialization combination product court determine abbvie patent valid infringe claim require obtain license pay royalties abbvie commercialize sofosbuvir combination product party appeal decision district court cafc predict ultimate outcome action spend significant resource enforce defend patent party successfully obtain valid enforceable patent successfully prove infringement patent sofosbuvir prevent sell sofosbuvir able obtain license patent license available commercially reasonable term party successful establish exclusive right sofosbuvir expect revenue earning sale sofosbuvir adversely affect range loss estimate time matter party legal action arise ordinary course business believe legal action material adverse impact consolidate business financial position result operation commitment normal course business enter firm purchase commitment primarily relate active pharmaceutical ingredient certain inventory relate item december commitment year approximately billion million million million million amount relate active pharmaceutical ingredient represent minimum purchase requirement actual payment purchase relate active pharmaceutical ingredient billion billion billion stockholder equity stock repurchase program board authorize threeyear billion stock repurchase program complete program september january board authorize threeyear billion stock repurchase program initiate purchase program september completion stock repurchase program december repurchase million common stock january stock repurchase program remain authorize stock repurchase plan billion spend total billion repurchase retire million share common stock average purchase price share december repurchase billion common stock january stock repurchase program remain authorize stock repurchase plan billion spend total million repurchase retire million share common stock average purchase price share december repurchase billion common stock january stock repurchase program remain authorize stock repurchase plan billion spend total million repurchase retire million share common stock average purchase price share use par value method accounting stock repurchase par value method common stock charge par value share involve excess cost share acquire par value allocate apic base estimate average sale price issue share excess amount charge retain earning addition repurchase stock repurchase program repurchase share common stock withhold employee restrict stock award satisfy applicable tax withholding obligation follow table summarize reduction common stock apic charge retain earning result stock repurchase thousand year end december reduction common stock apic charge retain earning prefer stock million share authorize preferred stock issuable series board authorize determine designation power preference right series prefer stock outstanding december right plan september terminate right plan accumulate comprehensive income follow table summarize change accumulate oci component net tax thousand unrealize gain unrealize gain foreign loss available loss cash currency item forsale security flow hedge total balance december comprehensive income loss reclassification amount reclassify accumulated comprehensive income net current period comprehensive income loss balance december amount reclassify gain loss cash flow hedge record product sale consolidate statement income amount reclassify unrealized gain loss availableforsale security record income expense net consolidated statement income equity incentive plan stockholder approve adopt gilead sciences inc equity incentive plan plan replace exist equity plan prior plan remain share available future grant prior plan transfer plan additionally award grant prior plan expire terminate exercised share common stock reserve award add pool available share common stock plan plan broad base incentive plan provide grant equitybase award include stock option restrict stock unit restrict stock award performance award employee director consultant plan authorize issue maximum million share fullvalue award restrict stock restrict stock unit performance share performance unit extent settle common stock phantom share term plan plan authorize issuance total million share common stock december total million share remain available future grant plan stock option plan provide option grant designate nonqualifie incentive stock option prior january grant nonqualified incentive stock option stock option grant january nonqualified stock option plan employee stock option grant prior generally vest year stock option grant start generally vest year option exercisable period exceed contractual term year date stock option issue grant price fair market value common stock grant date stock option exercise settle common stock plan previously authorize available pool share connection acquisition arresto assume arresto equity incentive plan arresto plan option issue outstanding arresto plan convert option purchase common stock effective january number convert option purchase common stock significant share available future grant arresto plan follow table summarize activity relate information stock option plan option grant present table exercise price fair value underlie common stock grant date share aggregate intrinsic value thousand weightedaverage weight remain average contractual term aggregate intrinsic share exercise price year value outstanding december grant assume forfeited expire exercise outstanding december exercisable december expect vest net estimate forfeiture december aggregate intrinsic value represent value company close stock price trading day period excess weightedaverage exercise price multiply number option outstanding exercisable total intrinsic value option exercise million million million weightedaverage grant date fair value stock option grant share share share december million unrecognized compensation cost relate stock option expect recognize estimate weightedaverage period year performance award plan grant performancebase restricted stock unit vest achievement specify market performance goal include achieve total shareholder return compare predetermine peer group achieve revenue target actual number common share ultimately issue calculated multiplying number performance unit payout percentage range award generally vest committee subcommittee board determine specify market performance goal achieve approval committee generally obtain year period fair value performance share estimate date grant performance objective define grant depend term award fair value date grant determine base monte carlo valuation methodology stock price date grant addition grant performancebase restrict stock award certain employee plan vest award subject achievement specify individual performance goal typically year period fair value award equal closing price common stock grant date follow table summarize activity relate information performance award thousand share amount weightedaverage grantdate share fair value share outstanding december grant vest forfeited outstanding december weightedaverage grantdate fair value share exclude share relate grant currently grantdate fair value performance objective define weightedaverage grant date fair value performance award grant share share share total fair value performance award vest million million million recognize stockbased compensation expense million million million relate performance award december million unrecognized compensation cost relate performance award expect recognize estimate weightedaverage period year restrict stock unit grant timebase restrict stock unit rsus certain employee annual employee equity compensation review program new hire employee nonemployee members board rsus share awards entitle holder receive freely tradable share common stock vest award grant prior rsus vest ratably annual basis year date grant start january rsus vest year date grant fair value rsu equal closing price common stock grant date follow table summarize rsu activity relate information thousand share amount weightedaverage grantdate share fair value share outstanding december grant assume vested forfeited outstanding december weightedaverage grant date fair value rsus grant share share share total fair value rsus vest million million million december million unrecognized compensation cost relate unvested rsus expect recognize weightedaverage period year employee stock purchase plan employee stock purchase plan amend international employee stock purchase plan espp employee purchase share common stock base percentage compensation subject certain limit purchase price share equal low fair market value common stock offering date purchase date espp offer twoyear lookback feature automatic reset feature provide offer period reset new lowerpriced offering offer price new offering period current offering period espp purchase settle common stock espp previously authorize available pool share million share issue espp million total million share common stock reserve issuance espp million share available issuance espp december december million unrecognized compensation cost relate espp expect recognize estimate weightedaverage period year stockbase compensation follow table summarize stockbase compensation expense include consolidated statement income thousands year end december cost good sell research development expense sell general administrative expense stockbase compensation expense include total cost expense income tax effect stockbase compensation expense net tax capitalize stockbased compensation cost inventory total million million million capitalize stock base compensation cost remain inventory million december million december million december total stockbase compensation year end december include million million rd sga expense respectively relate acceleration unvested stock option connection acquisition pharmasset close quarter stockbase compensation recognize expense requisite service period consolidate statement income grade vest expense attribution approach unvested stock option grant prior january straightline expense attribution approach stock option grant adoption new guidance sharebase payment employee director january stockbase compensation expense relate stock option recognize adoption new guidance base award ultimately expect vest gross expense reduce estimate forfeiture guidance require forfeiture estimate time grant revise necessary subsequent period actual forfeiture differ estimate estimate forfeiture base historical experience prior adoption guidance pro forma information require disclose include forfeiture occur result guidance adopt january recognize tax benefit stockbase compensation apic incremental tax benefit realize tax attribute currently available utilize addition elect account indirect benefit stockbase compensation research tax credit extraterritorial income deduction consolidate statement income apic valuation assumption fair value option grant plan purchase espp estimate grant purchase date blackschole option valuation model blackschole option valuation model develop use estimate fair value trade option vest restriction fully transferable addition option valuation model require input highly subjective assumption include expect stock price volatility expect award life follow assumption calculate estimate fair value award year end december expect volatility stock option espp expect term year stock option espp riskfree interest rate stock option espp expect dividend yield fair value stock option grant calculate single option approach use blend historical volatility imply volatility trade option common stock determine expect volatility expect term stockbase award represent weightedaverage period award expect remain outstanding estimate weightedaverage expect term base historical cancellation historical exercise datum relate stock option contractual term vest term award riskfree interest rate base observe interest rate appropriate term stockbase award dividend yield base history expectation dividend payout net income share attributable gilead common stockholder basic net income share attributable gilead common stockholder calculate base weightedaverage number share common stock outstanding period dilute net income share attributable gilead common stockholder calculate base weightedaverage number share common stock outstanding dilutive security outstanding period potential dilutive share common stock result assume exercise outstanding stock option performance share assume exercise warrant relate convertible senior note note note note note determined treasury stock method principal convertible note settle cash conversion spread relate convertible note include calculation dilute net income share attributable gilead common stockholder common stock result assume settlement conversion spread convertible note dilutive effect average market price common stock period exceed conversion price note note warrant relate convertible note dilutive effect average market price common stock period exceed warrant exercise price note note note note mature result include impact period outstanding net income share calculation common stock result assume settlement conversion spread note note dilutive effect average market price common stock period exceed conversion price note note warrant relate note note settle result include impact period outstanding net income share calculation relate warrant dilutive effect average market price common stock period exceed warrant exercise price note note average market price common stock exceed exercise price warrant relate note warrant dilutive effect net income share period exclude stock option purchase approximately million weightedaverage share common stock outstanding million weightedaverage share million weightedaverage share computation dilute net income share attributable gilead common stockholder effect antidilutive follow table reconciliation numerator denominator calculation basic diluted net income share attributable gilead common stockholder thousand year end december numerator net income attributable gilead denominator weightedaverage share common stock outstanding calculation basic net income share attributable gilead common stockholder effect dilutive security stock option equivalent conversion spread relate note conversion spread relate note conversion spread relate note conversion spread relate note warrant relate convertible note weightedaverage share common stock outstanding calculation dilute net income share attributable gilead common stockholder net income share attributable gilead common stockholdersbasic net income share attributable gilead common stockholdersdilute segment information product sale operate business segment primarily focus discovery development commercialization innovative medicine area unmet medical need product include segment majority product similar economic characteristic include nature product production process type customer distribution method regulatory environment product sale consist follow thousands year end december antiviral product atripla truvada viread compleraeviplera stribild sovaldi hepsera emtriva total antiviral product letairis ranexa ambisome product total product sale follow table summarize total revenue external customer collaboration partner geographic region thousand product sale productrelate contract revenue attribute region base shipto location royalty nonproduct relate contract revenue attribute region base location collaboration partner year end december revenues united states europe countrie total revenue follow table summarize revenue customer individually account total revenue percentage total revenue year end december cardinal health inc mckesson corp amerisourcebergen corp property plant equipment december net book value property plant equipment united states ireland canada million million million respectively comprise approximately total net book value property plant equipment december net book value property plant equipment united states ireland canada million million million respectively comprise approximately total net book value property plant equipment income taxis provision income taxis consist follow thousands year end december federal current deferred state current defer foreign current defer provision income taxis foreign pretax income million million billion cumulative unremitted foreign earning consider indefinitely reinveste foreign subsidiary taxis provide approximately billion december billion december residual tax liability amount remit approximately billion december billion december difference provision income taxis compute apply federal statutory income tax rate income provision income taxis follow thousands year end december income provision income taxis tax federal statutory rate state taxis net federal benefit foreign earning different rate research credit net unbenefitted stock compensation nondeductible pharmaceutical excise tax provision income taxis defer income taxis reflect net tax effect temporary difference carry amount asset liability financial reporting purpose amount income tax purpose significant component defer tax asset liability follow thousand december defer tax asset net operating loss carryforward stockbase compensation reserve accrual currently deductible defer revenue depreciation relate research credit carryforward net total defer tax asset valuation allowance valuation allowance total defer tax asset defer tax liability intangible unremitted foreign earning total defer tax liability net defer tax asset valuation allowance decrease million year end december valuation allowance increase million year end december decrease million year end december conclude base standard set forth fasb accounting standard codification relate income taxis likely realize benefit defer tax asset relate certain state net operating loss credit carryforward december federal net operating loss carryforward approximately million federal net operating loss carryforward start expire utilize federal tax credit carryforward approximately million start expire utilize addition state net operating loss tax credit carryforward approximately billion million respectively state net operating loss tax credit carryforward start expire utilize utilization net operating loss tax credit subject annual limitation ownership change limitation provide internal revenue code amend similar state provision annual limitation result expiration net operating loss credit utilization file federal state foreign income tax return jurisdiction unite states abroad federal income tax purpose statute limitation open onwards certain acquire entity statute limitation open year inception utilization net operating loss credit carry prior year california income tax purpose statute limitation open onwards income tax return audit federal state foreign tax authority currently examination internal revenue service irs tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction periodically evaluate exposure associate tax filing position total federal state foreign unrecognized tax benefit million december million december total unrecognized tax benefit million million december respectively recognize reduce effective tax rate period recognition continue classify interest penalty relate unrecognized tax benefit income tax provision consolidate statement income accrue interest penalty relate unrecognized tax benefit million december million december december believe reasonably possible unrecognized tax benefit decrease approximately million month expect clarification irs tax authority uncertain tax position respect remain unrecognized tax benefit currently unable reasonable estimate period cash settlement respective tax authority follow rollforward total gross unrecognized tax benefit liability year end december thousand december balance beginning period tax position relate current year addition reduction tax position relate prior year addition reduction settlement lapse statute limitation balance end period defer compensation plan united states maintain retirement saving plan eligible employee defer compensation income tax purpose section k internal revenue code gilead plan gilead plan employee contribute eligible annual compensation subject irs plan limit match contribution gilead plan contribute employee contribution annual maximum match certain foreign subsidiary maintain define benefit plan require local regulatory requirement deposit fund plan insurance company party trustee governmentmanage account consistent local regulatory requirement applicable total matching contribution expense gilead plan define benefit plan million million million maintain deferred compensation plan director key employee defer compensation income tax purpose defer compensation plan nonqualifie defer compensation plan subject qualification requirement section internal revenue code compensation defer december subject requirement section internal revenue code plan officer senior level employee contribute annual salary annual bonus commission director contribute annual retainer fee effective nonemployee board member defer rsu award amount defer participant deposit rabbi trust correspond plan asset record longterm asset correspond plan liability record longterm obligation consolidate balance sheet begin nonemployee board member elect receive portion annual cash retainer phantom share give participant right receive equal value specify number share specify period time payable share common stock fractional share pay cash establish plan administrator december phantom share outstanding participant elect distribution date event available plan receive defer compensation payment quarterly result operation unaudite follow amount thousand share amount st quarter nd quarter rd quarter th quarter total revenue gross profit product sale net income net income attributable gilead net income share attributable gilead common stockholdersbasic net income share attributable gilead common stockholdersdilute total revenue gross profit product sale net income net income attributable gilead net income share attributable gilead common stockholdersbasic net income share attributable gilead common stockholdersdilute gilead sciences inc schedule ii valuation qualifying account thousand balance begin additionscharged balance end period expense deduction period year end december account receivable allowance valuation allowance defer tax asset year end december account receivable allowance valuation allowance defer tax asset year end december account receivable allowance valuation allowance defer tax asset allowance doubtful account sale return cash discount government chargeback valuation allowance defer tax asset include million million december respectively relate acquisition